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A b s t r a c t
Reversible phosphoiylation of proteins on serine, threonine and tyrosine residues, is now widely 
accepted to be the principal mechanism for the control of intracellular events in eukaryotic and 
prokaryotic cells. The nodularins are known to be potent inhibitors of serine/threonine protein 
phosphatases, PPlc and PP2Ac, witli sub-nanomolar inhibition constants. They have been 
shown to form covalent adducts with the enzymes and are known to be potent hepatotoxins and 
liver promoters.
Nodularin has the general structure: cyclo [(R)-e^t/7ro-p-methyl-/.yo-Asp-(S)rA'-Adda-(i?)-/50- 
Glu-iV-methyldehydrobutyric acid)], where (S)-X is a variable S-amino acid and Adda is the 
unique p-amino acid, (25',3iS',8S',95)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6- 
dienoic acid.
In order to investigate the mode of inliibition and also to probe the active-site binding 
interactions, we decided to synthesis new analogues of nodularin. Specific inhibitors for eitlier 
PPi or PP2A are not presently available, but would be useful biochemical tools in delineating the 
individual physiological roles of these enzymes.
We decided to syntliesise, the potential inhibitor cyclo [pAla-(2R)-GIu-a-OMe-y-Pro-(2R)-Asp- 
a-OMe-p-(25)-Phe], a stripped-down nodularin macrocycle, and also an analogue which is 
suitable for synthetic elaboration at the “Adda position”.
Using solution phase peptide synthesis (LPPS), four such nodularin analogues (both (25)- and 
(2R)- proline) were synthesised in seventeen steps. The cyclisation between the Phe and Asp 
residues were carried out using DIPEA under conditions of high dilution. NMR studies 
(TOCSY, ROESY) have elucidated the three dimensional structures which have been shown to 
be similar to the natural product, nodularin.
A shorter synthesis of these nodularin analogues was developed using solid phase peptide 
synthesis (SPPS), Two solid phase synthesise of the nodularin macrocycles, cyc/o-[pAla-(2R)- 
Glu-a-OMe-y-Pro-(2R)-Asp-p-(2iS)-Phe]; one in which Fmoc-(2S)-Phe-pAla-(2R)-Glu-a-OMe-y- 
Pro-(2R)-Asp(a-0-Wang Resin)-p-OAllyI is deprotected and tlien cyclised on the resin prior to 
cycUsation were found to be successful. Even though the resin-bound synthesis gave low rields 
for the cycUsation step, compared to tlie situation in solution, it offered advantages in tlie 
construction of the linear /^opentapeptide precursor.
Initial stucUes have shown tliat the nodualrin analogues 130 and 131 are moderate inhibitors 
(IC50 2.8 mmol) of PPI when tested using the malachite green system.
Studies towards the synthesis of incorporating more suitable Adda functionalities, and the 
development of a radiolabelled protein phosphatase assay are currently being investigated wthin  
the group.
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1. Introduction
1.1 General introduction
There are many hundreds of cell proteins containing phosphoserine and 
phosphothreonine residues. Their dephosphorylation is regulated by only four 
major classes of serine/threonine protein phosphatases - PPI; PP2A; PP2B and 
PP2C.^’^  The catalytic subunits of which show broad and overlapping substrate 
specificity in vitro. ^
Studies with inhibitors, such as okadaic acid and microcystin, have shown most of 
the measurable serine/threonine protein phosphatase activity in cell extracts is 
likely to be accounted for by PPI and PP2A. Earlier research showed that these 
two phosphatases have significant regulatory roles in most of the major metabolic 
pathways: for example, glycolysis, glycogen synthesis, fatty acid synthesis, 
cholesterol biosynthesis, protein synthesis and lipolysis. More recent studies with 
phenotypes of genetic mutants in which these enzymes have been deleted have 
implicated PP 1 and PP2A as essential in the regulation of processes as diverse as 
the transport of ions and nutrients into cells, gene transcription and the cell cycle. 
The involvement of PP 1 and PP2A are expressed at micromolar concentrations in 
cells and share a 49% sequence homology with their catalytic core.
1.2 Phosphatases
Hundreds of metabolic pathways are controlled by a simple chemical event - the 
transfer of phosphoryl groups from one entity to another. In nature, these 
reactions are catalysed by two sets of enzymes - phosphatases and kinases."  ^
Phosphatases catalyse the hydrolysis (cleavage) reaction, whilst kinases operate in 
the synthetic direction (phosphorylation). This thesis reviews and compares, 
current knowledge about phosphatases, concentrating on protein phosphorylation 
in particular.^
In t r o d u c t io n  P a g e  i
1.2.1 Categories of Phosphatases
Phosphatases can be classified into two major groups due to their substrate 
specificity and mechanism of action/
1.2.1.1 Substrate Specificity
There are a large variety of substrates for phosphatases ranging from small 
phosphorylated metabolites (such as glucose-6-phosphate), to secondary 
messengers (such as phosphoinositols), up to very large phosphorylated proteins/
There are three major groups of phosphatases:
□ Non-Specific - these enzymes catalyse the hydrolysis of almost any 
phosphate;
□ Phosphoprotein Specific - enzymes which use phosphoproteins or 
phosphopeptides as preferred substrates (protein phosphatases); and
□ Sntall-molecule Specific - enzymes which hydrolyse one (or a group of 
structurally similar) substrate(s), for example, inositol monophosphatase 
(see Fig. 1.1).'
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Figure 1.1: Hierarchy o f  Phosphatases^
1.2.1.2 M echanism  of R eaction
The secondary classification scheme is one according to the enzyme’s mechanism 
of reaction.
For example, some phosphatases use an active site nucleophile as the initial 
phosphoryl group acceptor “Ping-Pong”; others transfer it directly to a water 
molecule (see Scheme 1.1).^
(a) H^O ROM
E + RO-POj^ E^R O -PO j E.Pi E+ Pi
(b) ROM H2O
E + RO-PO3" E«R0 .P03^'=^: ^  E-P03 '^ E.pi E-hpj
Scheme 1.1: Typical Phosphatase Reaction Mechanisms,
(a) Direct tranter to water, normally catalysed by active-site metal ions.
(b) Hydrolysis via a phosphoenzyme intermediate. Serine, cysteine and histidine 
are common nucleophiles used as the initial phosphoryl group acceptor.
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This can be further sub-divided according to the phosphoryl group acceptor 
(cysteine, histidine or serine); and characteristically use a two-metal-ion dyad to 
bind phosphates and catalyse their subsequent hydrolysis, for example inositol 
monophosphatase^
1.3 Protein Phosphatases
Just over forty years ago it was first recognised that the enzymic phosphoiylation 
and dephosphorylation of proteins (sometimes referred to as reversible protein 
phosphorylation) was a very dynamic process involved in the regulation of cellular 
functions/ Prior to this, these proteins were primarily considered as proteins 
which had nutritional functions, such as providing a source of phosphorous for 
growing organisms. There was no understanding of how rapid turnover of 
protein-bound phosphate might occur, nor a knowledge of the mechanisms 
involved in the formation of phosphoproteins.*
Reversible protein phosphorylation is now agreed to be the major mechanism for 
the control of a variety of biological processes, including metabolism, cell 
differentiation and proliferation, gene expression, transport, locomotion, 
development and memory. The activities of proteins controlled by 
phosphorylation are also varied and include enzymes, membrane receptors, 
transport proteins, ion pumps and proteins mediating DNA replication, 
transcription and translation.^
During protein phosphorylation, phosphate moieties are transferred from ATP 
molecules by protein kinases, and are hydrolysed by protein phosphatase (see Fig. 
1.2). In eukaryotic cells, reversible phosphoiylation occurs predominantly on 
serine, threonine and tyrosine residues. Changes in the phosphorylation state of 
proteins are responsible for protein conformation which in turn cause functional 
changes. This process, together with its reversibility and scope for signal 
amplification, probably accounts for the importance of protein phosphorylation in
signal transduction 11
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Figure 1.2: Reversible Phosphorylation
Protein phosphatases (PPases) are structurally and functionally diverse enzymes 
which can be represented by three distinct families:
□ Ser/Thr Phosphatases, ( w h i c h  are also probably all two-metal-ion 
phosphatases);
a  Tyr phosphatases (PTPases), and
□ Dual-Specificity Phosphatases.
The Ser/Thr phosphatases (phosphatases which dephosphorylate phosphoserine 
and phosphothreonine residues in proteins) are discussed in more detail below.
1.4 Ser/Thr Protein Phosphatases
1.4.1 General Classification
To date, over 200 enzymes can be counted in the Ser/Thr protein phosphatase 
class. Since 1983 the most widely adopted classification for Ser/Thr phosphatases, 
is that proposed by Ingebritsen and C o h e n . B e c a u s e  of their overlapping 
specificities, PPases cannot be classified by substrate alone, therefore, the action of 
specific inhibitors and activators is employed. Using these criteria, the
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serine/threonine phosphatases in the cytosol of eukaryotic cells are divided into 
two classes;
□ Type 1 (PPI) - those inhibited by small thermostable acid-resistant proteins 
termed inhibitor 1 (I-l), inhibitor 2 (1-2 or modulator) and DARJPP-32, and 
which preferentially dephosphorylate the (3-subunit of phosphorylase kinase; 
and
□ Type 2 (PP2) inhibitor which are insensitive to inhibitors 1 and 2, and 
preferentially dephosphoiylate the a-subunit of phosphorylase kinase.
Type 2 protein phosphatases are further sub-divided according to their requirement 
for divalent cations; PP2A, like PPI, does not require cations, while PP2B (also 
known as calcineurin) and PP2C show an absolute dependence for Ca^" and Mg“~ 
respectively.^"  ^ The use of okadaic acid 1 (see p. 16), a specific phosphatase 
inhibitor, further facilitates the discrimination between these classes.
Recent studies have shown Ser/Thr phosphatases PPI, PP2A and PP2C possess in 
vitro phosphohistidine activity. Because phosphohistidine is unstable to heating 
at low pH, a treatment which is used to analyse other phospho- amino acids, its 
presence in many cellular proteins may have been missed in characterisation.
1.4.2 Gene Families
Athough widely accepted, the protein phosphatase classification is flawed since it 
does not reflect the actual phylogenetic relationship between the different Ser/Thr 
protein phosphatases. Molecular cloning revealed PP2A was, in fact, much more 
closely related to PPI than PP2C.^^ Moreover, in the past few years many novel 
PPases have been identified which do not fit into the above classifications.^* Many 
of these PPases are closely related to the existing classes, or are intermediates 
between classes.^*
I n t r o d u c t i o n  p a g e ?
Recombinant DNA techniques have elucidated the primary structures of the 
phosphatases/^ The deduced protein sequences show there are two structurally 
distinct gene families; a “major” family which includes PPI, PP2A and PP2B, and a 
“smaller” family with a completely distinct primary structure which includes PP2C. 
The symbol PPP was chosen to designate the “major” family, and PPM (Mg^" 
dependent protein phosphatases) for the “smaller” family/°
PPI and PP2A are similar in size and show 41% overall amino acid sequence 
identity. The extreme N and C termini are the most divergent regions, the identity 
rises to 49% if these regions are excluded/^ PP2B shows 39% identity to both 
PP I and PP2A in the catalytic domain, with two small insertions in this region and 
a long C-terminal extension. The C-terminal extension possesses the calmodulin 
binding domain and regions which bind the regulatory subunit and suppress activity 
in the absence of Ca^ ~ and calmodulin (see Fig. 1.3).^  ^ Within each family, the 
catalytic domains are highly conserved, suggesting similarities in tertiary structure 
and catalytic mechanisms. However, the most considerable structural and 
functional diversity of individual PPases is created as a result of a combination of 
associated regulatory domains and subunits.
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Figure 1.3: Schematic Diagram Showing Domain Structure
The open segments denotes the catalytic domain. PP2A is 49% identical to PPI, 
whereas PP2B shows 39% identity. The catalytic domain o f  PP2B contains two 
.small insertions o f  seven and.six re.sidues re.spectively. The number o f  residues is 
also .shown. PP2Bf  (but not PP2Ba) contains an ummuil polyproline sequence 
(Pro) near its N-terminu.s. The calmodulin binding domain is located in the long 
C-terminal extension, which also contains a region (I) involved in the suppre.s.sion 
o f  activity in the absence o f  Ccr' /calmodulin, and a region (R) which may 
interact with a 19 kDa regulatory .subunit.
1.4.3 Targetting Subunit Hypothesis
Many protein phosphatases (and kinases) have multiple substrates in vivo, which 
enables a diversity o f responses to physiological stimuli/^ However, their broad 
specificities, including in vitro activity towards non-physiological protein 
substrates, suggests the need for mechanisms to restrict these enzymes in vivo. 
Protein phosphatases (and kinases) are regulated by regulatoiy (or “targetting”) 
subunits. This novel class o f proteins, not only acts to restrict the location o f the 
phosphatase (and kinase), but also modifies their catalytic and regulatory
properties 2.V
The targetting subunit (T»„b) is the part o f a protein phosphatase (or kinase) which 
directs the catalytic subunit (C»„i,) to the target locus (Ti„c). The T,„b can be an 
organelle, a membrane, or a component in the soluble fraction o f the cell. The T„,i,
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may function to position the Csub close to a particular substrate, or to sequestrate it 
from other substrates and ligands (e.g. inhibitors). The interaction between a Uub 
and a Csub may also alter the catalytic activity or specificity of the Csub for nearby 
substrates. Furthermore, if the binding equilibrium between Tsub and either Tiœ or 
Csub is regulated, the altered properties of the Csub can be turned on and off 
reversibly.^"’’^ '^
1,4,4 Evolution of Protein Phosphatases
Molecular cloning of phosphatase subunits from different species indicates Ser/Thr 
protein phosphatases are among the most highly conserved proteins in evolution."^ 
This implies that protein phosphatases perform functions which are essential to all 
eukaryotic cells. Yet, Ser/Thr protein phosphatases share no structural homology 
with the Tyr protein phosphatases, suggesting that they evolved along separate 
evolutionary pathways.
Comparison of the catalytic subunits of the Ser/Thr protein phosphatases allows 
the generation of a phylogenetic tree. Such analysis reveals PPL  and PP2Ac are 
41% homologous to each o t h e r . T h e  data also shows these genes have been 
highly conserved through evolution. For example, PPL from fungi, flies and 
humans are greater than 86% identical in their primaiy structure. A similar 
argument can be put forward for PP2A<, which shows 93% identity between flies 
and mammals."^ Thus considerable pressure must have been exerted during 
evolution to conserve the structure of PPL and PP2Ac-~  ^ The conservation of 
PP2Ac further supports an important function for the enzyme viability. This 
structural analysis indicates PP2Bc is clearly more distantly related to PPL and 
PP2Ac, with PP2Cc diverging very early in evolution, or even evolving from a 
different linease.^^
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1.4.5 Protein phosphatase 1 (FF l)
T\pe 1 protein phosphatases (PPl) comprises of widely distributed enz>TOes, 
found in all eukaryotic ceils. A number of different forms of PPl have been 
characterised.^* These forms differ in their substrate specificity which are 
measured in vitro using various phosphoproteins. They all contain an isoform of 
the same catalytic subunit, which has an extremely conserved primary strucmre, 
but differ in the targetting subunits which determine the activity, the substrate 
specificity, and the cellular location of the phosphatase.^* Furthermore, PPK is 
inhibited by proteins, termed inhibitor 1 (I-l), inhibitor 2 (1-2 or modulator) and 
the phosphoprotein DARPP-32. These inhibitors can also be considered as 
regulatory subunits."'^
1.4.5.1 Structure of PPlc
The catalytic subunit of PP l, termed PPL, a 37 IcDa protein, is indistinguishable 
from the different forms of PPl, both in its structural and in its enzymic propenies. 
Hence, the differences in the biochemical properties of the ‘native’ forms must be 
conferred by the non-catalytic components.
There are 10 deduced amino acid sequences available for proteins which could be 
classified as a putative type-1 protein phosphatase. Initially, two isoforms of PPL 
were cloned from a rabbit skeletal muscle, and were termed a  and PPLp was 
later showm to be a cloning artefact."’  ^ However, in rat, cDNA cloning revealed the 
existence of at least four isoforms, termed a , yl, y2 and 5.''" Bacterially expressed 
PPL (cc, p and y isoforms) differ in some aspects (sensitivity to phosphatase, 
binding to regulatory subunits, requirement for Mn^" and specific activity) from 
native PPL.
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1.4.5,2 P P l  H oloenzym e Complexes
The holoenzymes are named according to their apparent subcellular location."^ 
For example, the glycogen-bound PPl holoenzyme (PPIG) is a heterodimer of 
PPL and a glycogen-binding subunit (G-subunit)/'’ PPIG is the major 
phosphatase acting upon phospholamban, a protein involved in Ca"~ uptake into 
the cardiac sarcoplasmic reticulum (SR), and in the regulation of the rate of 
cardiac muscle relaxation/'*
The G-subunit anchors the phosphatase to glycogen and increases its activity 
towards the glycogen-bound substrates: glycogen synthase and glycogen 
phosphorylase/^
The PPl holoenzyme isolated from muscle SR has the same subunit as PPIG. It 
therefore appears that the G-subunit can target glycogen to the SR/^
The PP1 bound to the myosin fraction in smooth muscle was purified as a trimer 
consisting of PPL and polypeptides of 130 kDa and 20 kDa. ' The latter subunits 
are responsible for the enhanced activity towards heavy meromyosin or isolated 
myosin light chains.^’ The myosin-bound form of PPl in skeletal muscle (PPIM) 
was purified as a dimeric enzyme consisting of PPL and a regulatory subunit 
which increased dephosphorylation of the myosin light chain, present in heavy 
meromyosin."*
High levels of PPl activity are also present in the nuclei of eukaryotic c e l l s . P a r t  
of the nuclear PPl is present in a latent form (termed PPIK;), and is composed of 
PPL complexed to an inhibitory (NIPP-1) polypeptide.'*^
A cytosolic form of PPl, termed PPIS, is composed of PPl, complexed to 1-2 (or 
the modulator subunit). It has been suggested PPIS serves as a pool of inactive 
phosphatase, fi'om which the catalytic subunit could be recruited if needed in other 
cellular compartments. 1-2 could then function as a “chaperone” which folds the 
nascent PPL into the required orientation."**
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1.4.5.3 Regulation of PP l
Many complex signals are integrated in the control of cellular PPL*" The activity 
of PPlc in the different holoenzyme complexes is primarily mediated through the 
regulatory subunits/"’ In addition, PPl-regulated enzymes demonstrate a 
characteristic inhibition by the thermostable proteins; I-l; 1-2 and DARPP-32. A 
protein factor, termed deinhibitor, further modulates the actions of these inhibitor 
proteins. PPl activity may also be regulated by the reversible phosphorylation of 
these protein components.*^
□ Inhibitor I  & DARPP-32 - the related polypeptides, I-l and DARPP-32, are 
cytosolic proteins which become strong inhibitors of PPL after phosphorylation on 
Thr-35 of I-l and Thr-34 of DARPP-32 by cyclic AMP- (cAMP-) dependent 
protein kinase (cAMP-PK).'*^ I-l, a 18.7 kDa protein, was discovered together 
with 1-2.'*'' DARPP-32 was initially described as a phosphoprotein of 32 kDa in 
dopamine-innervated brain regions.'*'* Addition of dopamine or cAMP to sites of 
these brain regions increased the phosphorylation of DARPP-32, hence its name - 
dopamme and cAMP regulated phosphoprotein.
□ Inhibitor 2 or ‘^Modulator” -1-2 is a 22.9 kDa protein which has been isolated 
from rabbit skeletal muscle and rat adipose tissue."*^  This protein resembles I-l and 
DARPP-32 in that it has a highly symmetrical structure and a low content of amino 
acids, although there is no homology through cDNA sequencing.'*^
1-2 blocks the activity of PPL  in two distinct ways:
i) by impeding the substrate binding (inhibition); and
ii) by inducing a conformational change of the catalytic subunit (inactivation).
1-2 is also required for the enzymic reactivation of inactive PPL. Due to these 
multiple effects it was proposed to replace the original name, 1-2, with that of 
“ModtdatoP\‘^^
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□ Deinhibitor - Deinhibitor is a thermostable polypeptide, first isolated from dog 
liver and shown to prevent the inactivation of PPL by either I-l or Modulator/* 
The deinhibitor not only reduced inhibition of PPl by I-l, but it also promoted 
dephosphor>iation of I-l by PP-L in the absence of Mn~‘. Thus, the deinhibitor 
may act to antagonise the actions of I-l.
1.4.5.4 Physiological role of PPl
It is clear that PPl is involved in many different cellular processes, as diverse as 
glycogen metabolism, calcium transport, muscle contraction and intracellular 
transport.*^ In some cellular processes the substrates for PPl (e.g. glycogen 
synthase and glycogen phosphorylase) have been identified. For other 
phosphoproteins, the contribution of PPl to their dephosphorylation remains to be 
clarified.*^
Recent evidence from the study of cell cycle mutants has revealed that PP 1 also 
plays an important role in the regulation of mitosis and chromosome segregation/^
1.4.6 Protein Phosphatase 2A (PP2A)
1.4.6.1 Structure of PP2A
PP2A, also termed polycation-stimulated phosphatase, represents a substantial 
portion of Ser/Thr phosphatase activity in many cells. The enzyme has been 
isolated and characterised in several trimeric holoenzyme forms."'  ^ The core 
structure consists of a 36 kDa catalytic subunit (PP2A), complexed to two 
regulatory subunits; a 65 kDa subunit A (or PR65), and a variable regulatory 
subunit of 55 kDa (B or PR55), 54 kDa (B’), 72 kDa (PR72), 74 kDa (B"), or 130 
kDa (PR130).'* hi vivo, PP2A is probably present as a trimer, although, the core 
dimer (PP2Ac:PR65) has been purified fi'om many different tissues. This suggests 
the possibility of subunit rearrangements where the variable subunits are able to 
associate and dissociate from the core dimer (see Fig. 1.4).*^
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The exact function of the regulatory subunits is not yet known, but it is considered 
they influence substrate specificity and/or subcellular localisation/"
m m
iPR130
small-t
PTPA |middie-T;J
Figure 1.4; Different PP2A Holoenzynies
The core dimer o f PP2Ac and the PR65 regidatory subunit (A) with variable 
subunits o f 55 kDa (PR55, or B subunit), 54 kDa (B ' subunit), 72 kDa fPR72j. ~4 
kDa (B ” subunit) or 130 kDa (PR!30). PR55, PR72 and PR 130 refer to cloned 
sequences: the 54 and 74 kDa subimits hcrve not been cloned. In addition, the 
core dimer can interact with PTPA and associates with SV40 and polyoma small-t
and middle-T antigens.
Molecular cloning has revealed the existence of several isoforms of each subunit/' 
Two forms of the catalytic subunit (a, p), two forms of PR65 (a, p), three 
isoforms of PR66 (a, P, y) and two forms of PR72 exist/’ The a  and p isoforms 
of PP2Ac from mammalian tissues show 97% amino acid identity. However, they 
are distinct gene products since they possess unrelated nucleotide sequences.
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1.4.6.2 Regulation of PP2A
□ Tyrosine phosphatase activity - although PP2A was originally purified as a 
Ser/Thr protein phosphatase it can, under certain conditions, dephosphorylate Tyr 
residues/^ The tyrosine phosphatase activity of PP2A towards exogenous 
substrates is increased in the presence of ATP. Furthermore, a 37 kDa protein, 
termed PTPA, was isolated and characterised which, in the presence of ATP and 
Mg^^ activates the Tyr phosphatase activity of PP2A. Whilst the mechanism has 
yet to be established,^^ it is known that the PTPA-induced tyrosine phosphatase 
activity of PP2A is stabilised by small-t or middle-T antigens.
Q Interaction with regulatory subunits - interaction of PP2Ac with the regulatory 
subunits PR65, PR55, PR72 and others, influence its substrate activity. The 
PP2A trimer containing PR72 preferentially dephosphorylates Ser-120 and 
Ser-123 in simian virus 40 (SV40) large-T antigen, whereas dephosphorylation of 
Thr-124 is only efficiently catalysed by the PP2A trimer containing PR55.*^
1.4.6.3 Physiological role of PP2A
PP2A has high activity in vitro towards the regulatory enzymes of 
glycolysis/gluconeogenisis, fatty acid synthesis, amino acid breakdown, lipolysis, 
and catecholamine synthesis suggesting it may be the major phosphatase acting to 
regulate these pathways in vivo.
The tumour promoter okadaic acid 1, microcystin-LR 2 and the related class of 
inhibitors of PP2A and PPl, are proving to be valuable tools in identifying or 
substantiating their physiological roles (see Fig. 1.5). It is possible to specifically 
inhibit PP2A activity in cell-free extracts because PP2A requires lower 
concentrations of okadaic acid (OA) for inhibition than does PPl. The okadaic 
acid class of compounds will be discussed in more detail in Section 1.5.2.1.
In t r o d u c t io n PAge  16
HO
OR2
OR
(R)-GIu
CO2H
N-Mdha 
CH3 O
(R>-AlaNHOMe
HN'ÇH-HN
O CO2H 
Me Asp(S)-Arg (S)-Leu
NH
Figure 1,5: Protein Tumour Promoters; Okadaic Acid (1), and
Microcystin-LR (2)
1.4.7 Protein phosphatase 2B
PP2B, or calcineurin, was first identified as a major calmodulin-binding protein 
from the brain, where it accounts for up to 1% of the total protein.^' PP2B is a 
heterodimer of calcineurin A (60 kDa), and calcineurin B (19 kDa). Calcineurin A 
is the catalytic subunit which also binds to calmodulin. Calcineuiin B is the 
regulatory, Ca“~-binding subunit."*^
The A subunit has four functional domains: (i) catalytic; (ii) B-subunit binding; 
(iii) calmodulin-binding, and (iv) autoinhibitory.
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Functionally distinct, subunit B contains four Ca"~-binding loops, and shows 35% 
homology to calmodulin/^
Three PP2B A-subunits (CNAa, CNA(3 and CNAy) have been encoded by three 
separate genes. The CNAa gene gives rise to two transcripts (a l)  and (a 2), and 
the CNA(3 gene gives rise to three transcripts ((31, (32 and P3).
WTiilst this would appear less complicated for the B-subunit, recent studies have 
shown two genes encode for this subunit.^"
1.4.7.1 R egulation of PP2B
PP2B is dependent upon Ca^ ~ for activity' and is stimulated by calmodulin, but the 
purified enzyme also requires divalent metal cations, such as Mn^", Mg“'  or Ni"".
Partial proteolysis of calcineurin convens it to a form which no longer requires 
Ca" for activity. This is due to destruction of the C-terminus of the catalviic 
subunit, which contains an autoinhibitory domain (see Fig. 1.3, P 8).^  ^ Binding of 
calmodulin to a nearby site and binding of Ca^" to the B-subunit allows the enzvme 
to overcome this auto-inhibition.^"
Inhibition of calcineurin activity towards model substrate peptides by the 
immunosuppresent/immunophohn complex (FK506.FKBP) is mediated by both 
calcineurin subunits.^^ Association of calcineurin with FK506/FKBP is dependent 
on Ca  ^ unless the auto-inhibitory domain on the catalytic subunit is removed. 
Recent studies have indicated FK506/FKBP interacts with the latch region of the 
CKB subunit. However, the association of the CNB with CNA is required for the 
former to adopt the correct conformation to permit interaction with 
dmg/immunophilin complexes.
PP2B has a rather restricted substrate specificity. The a-subunit of phosphorylase 
kinase, I-l, DARPP-32 and the type II regulatory subunit of cANIP-PK are 
excellent m vitro substrates.
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1.4.7.2 Physiological role of PP2B
T-cell activation, in response to the interaction of the T-ceil receptor with antigen, 
is mediated by induction of interleukin-2 gene expression. Activation of at least 
two signalling pathways are needed for this in d u c tio n .O n e  pathway can be 
activated with Ca  ^ ionophores, and the other with phorbol esters. At the level of 
the promoter, induction of the interleukin-2 gene expression requires co-operative 
interactions of several transcription factors.
The Ca^'-dependent pathway is mediated via activation of calcineurin. This leads 
to dephosphorylation of the cytosolic subunit of the transcription factor, NT-AT. 
The dephosphorylated subunit then migrates to the nucleus where it combines with 
nuclear factors to form the transcription factor NT-AT. NT-AT binds to, and then 
activates, the interleukin-2 promoter.
1.4.8 Protein Phosphatase 2C
PP2C was originally identified as a Mg"‘-dependent protein phosphatase, which is 
structurally different from all other Ser/Thr protein phosphatases.^^ The enzyme is 
a member of a multigene family, is monomeric (with a molecular mass of 43-48 
kDa) and has demonstrated a relatively broad substrate specificity, Two 
isoforms (a  42 kDa, [5 44 kDa) of PP2C have been cloned.*'  ^ Further analysis has 
revealed the existence of subtypes for both isoforms. Three a  subtypes have been 
identified, with a l  being the most dominant species, whereas only two subtyyies of 
the P-isoform have been found.
Whereas PP2C shares no structural homology with PPl, PP2A or PP2B, some 
sequence homology was observed with the mitochondrial enzvme pyruvate 
dehydrogenase phosphatase. 50
In viP'o studies show PP2C has unusually high activity towards the enzymes of 
cholesterol metabolism. However, in vivo studies designed to examine the role of
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PP2C in this metabolism pathway have not been carried out, and thus, the 
physiological significance of PP2C remains to be established/^
1.4.9 Novel protein phosphatases
Ser/Thr protein phosphatases which differ in their biochemical properties from 
PPl, 2A, 2B and 2C have been isolated from their cDNAs. These all belong to the 
PPP class of protein phosphatases.
1.4.9.1 Protein phosphatase-3 (PP3)
PP3, an okadaic acid-sensitive phosphatase, has been extracted from bovine brain 
and is found to be active in the absence of divalent cations/^ This putative, 
membrane-bound enzyme demonstrates substrate specificity similar to PPl, yet it is 
not inhibited by 1-2. PP3 has a molecular mass of 36 kDa, which has a conserved 
six amino acid region with PPl and PP2A. The remainder of PP3 has no 
additional identity with PP l, but has 50% identity with PP2A. The physiological 
function of PP3 is unknown, although current evidence suggests a role in cell 
proliferation/^
1.4.9.2 Protein phosphatase-4 (PP4)
PP4, which was originally termed PPX, is isolated from rabbit l iv e r .P P 4  is a 
35 kDa protein which shows 65% primary sequence homology with PP2A and 
45% identity to PPl. As with PP2A, PP4 preferentially dephosphorylates the a  
subunit rather than the |3 subunit of phosphorylase kinase, and is unaffected by I-l 
and 1-2.®^  The sensitivity of PP4 to OA is similar to PP2A. PP4 is localised mainly 
in the centrosomes, and is thought to play a role in their function, possibly in the 
control of microtubule assembly.
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1.4.9.3 Protein phosphatase-5 (PP5)
A novel human Ser/Thr protein phosphatase, PP5, and a structurally related 
phosphatase, PPTl, have been identified/^ Their predicted molecular mass is 
58 kDa and they comprise a C-terminal phosphatase catalytic domain, which 
shows homology with the phosphatase domain of other members of this family, 
and an N-terminal domain. PP5 is related to PPl, PP2A and PP2B, but has an 
N-terminal extension of 200 amino acids. This extension contains four 
tetraterpeptide repeats (TPR) i.e. four repeats of 34 amino acids, three of which 
are tandemly arranged. These repeats are found in proteins which are involved in 
the regulation of RNA biogenesis and mitosis.
1.4.9.4 Protein phosphatase-6 (PP6)
A novel Ser/Thr protein phosphatase has been identified by cDNA, designated 
PP6 63 predicted amino acid sequence indicates a 35 kDa protein showing 
57% homology to PP2A. In human cells, three forms of PP6 mRNA have been 
found, with the highest levels of expression in human body in testis, heart and 
skeletal muscle. It is thought PP6 may be involved in cell cycle regulation.^’
1.4.10 Structure and mechanism of Ser/Thr phosphatases
Despite a wealth of information about the biological processes involving Ser/Thr 
protein phosphatases, chemical and structural information about the enzymes is 
sparse and little is known about how they catalyse phosphate hydrolysis.
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1.4.10.1 Structure and catalytic mechanism of the PPP family
Most of the mechanistic information on these proteins stem from mutagenesis 
studies of bacteriophage X phosphatase and purple acid phosphatase, phosphatases 
with substantial homology to the catalytic domains of PPl, PP2A and PP2B^ '*
□ Catalytic site - solution of the X-ray crystal structures of PPU /'"’  ^ the PP2B 
holoenzyme^^ and the PP2B complex with FK506/FKBP12,^^‘"^  provide an 
understanding of some of the fundamental properties of these proteins, namely 
molecular mechanisms of catalysis, substrate recognition and regulation.
The first co-crystallisation of the catalytic subunit of PPl complexed to 
microcystin 2 was reported in 1994 by Barford et cil^^ The crystals were reported 
to be orthorhombic at a resolution of 2.8 Â. Later, the crystal structure of the 
mammalian protein phosphatase-1, PPL, complexed with the hepatoto.xin, 
microcystin, at 2.1Â resolution, was delineated by Goldberg et In the same 
year, the catalytic subunit of human PPLy and its complex with tungstate at 2.5 a 
was reported by Egloff et al.^^
Recently, Egloff et reported the crystal structure of PPL with the M-subunit 
at 3.0 a.
The structure of PP2B was determined by Griffith et al. at 2.5 a as a complex 
containing both, FK506 3 and the FK506 binding protein (FKBP).'^ The same 
complex was also described by Kissinger et al. who also reported the crystal 
structure of human PP2B heterodimer at 2.1 A.^^
The catalytic domains of PPl and PP2B adopt an identical core structure based on 
a central distorted (3-sandwich of 11 (3-strands surrounded on one side by seven 
a-helices and a three-stranded g-sheet (see Fig. 1.6).^^
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Figure 1.6: Piew o f  the catalytic suhunit o f  P P l y  onto the catalytic-site channel
Metal ions are shown as green spheres within a hi nuclear metal centre to which a 
tungstate ion (an analogue o f  phosphate) is co-ordinated. Regions o f the 
polypeptide which correspond to the tht ee invariant secf uence motifs present in 
the PPP fam ily o f  phosphatases and other metallophosphoesterases, such as X 
bacteriophage phosphatase and kidney bean purple acid phosphatase, are shown 
in red. The C a  positions o f  residues which co-ordinate the divcdent metal ions 
and tungstate ion are indicated as blue and red spheres.
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The interface of the two (3-sheets at the top of the P-sandwich creates a shallow 
channel. Three parallel P-strands of sheet I constitute a mononucleotide-binding 
domain with the secondary structure organisation P-a-P-a-p. The three invariant 
sequence motifs form the loops connecting with the carboxy terminus of the 
p-strand with a-helices (see Fig. 1.7). These loops, together with those emanating 
from the carboxy terminus of two p-strands of the opposite p-sheet, provide the 
catalytic residues. This scaffolding contains the Ser/Thr protein phosphatases 
signature motif identified during studies with bacteriophage X phosphatase.^^
Ser/Thr protein phosphatases are metalloenzymes^^‘^ ’^^ “ and two divalent metal 
ions (Mn^" and Fe^" in PP l, Zn"^ and Fe^" in PP2B) at the centre of the catalytic 
site are co-ordinated by Asp64, Asp92, Asnl24 and His66 of the 
mononucleotide-binding motif and His 173 and His248 of sheet 2 (Note: Residue 
numbers refer to PPl].
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Figure 1.7 (a) Detailed view o f  the catalytic site o f P P l in the presence o f  a
tungstate ion, an analogue o f phosphate. One o f  the two water 
molecules shown co-ordinated to the metal ions is proposed to act 
as a nucleophile during the catalytic reaction
(b) Schematic o f  the reaction mechanism catalysed by PPPs.
The side chain o f Asp92 and a water molecule bridge both metal ions to form a 
binuclear metal centre. A second metal-bound water molecule is co-ordinated to 
the Fe^  ion. The catalytic sites o f two o f the phosphatase ciystal structures 
contain bound oxyanions; tungstate in PPlyl and phosphate in one o f the PP2B
structures 70
□ Mechanism  - a catalytic mechanism, suggested by the X-ray structures, is 
entirely consistent with site-directed mutagensis performed on PPl’  ^ and the X 
bacteriophage phosphatase.^** A metal-bound water molecule acts as a nucleophile 
to attack the phosphorous atom of a phosphate group in an Sn2 mechanism.
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Metals assist in this catalysis in two ways;
® as Lewis acids to enhance the nucleophilicity of the metal-bound water; and 
® by enhancing the electrophilicity of the phosphorous atom.
The sidechain of His 125 probably donates a proton to the leaving-group oxygen of 
a Ser or Thr sidechain. Such a role for His 125 is consistent with the loss of 
catalytic activity of PPl His 125 mutants^’ and mutations of the equivalent residue 
of X phosphatase.^** Other mutational studies have shown replacement of any of 
the metal-co-ordinating residues in PPl and X PPase leads to either severe loss in 
activity or production of insoluble proteins during over-production in E. coli. The 
proposal for a single-step déphosphorylation reaction is consistent with earlier data 
suggesting PP2B cannot catalyse //wzsphosphorylation reactions^^ and the fact 
phosphorylenzyme intermediates do not appear to form during the reaction 
catalysed by PPPs.
1.4.10.2 Structural mechanism of regulation
Most available evidence suggests the carboxy-terminal regions of PPP catalytic 
domains are crucially important for communicating regulatory signals to the 
catalytic site.**
The mechanisms of inhibition of PPL by microcystin-LR 2, and PP2B both by its 
natural inhibitor the auto-inhibitoiy (Al) domain, and by the FKBP12-FK506 
complex, have been defined by the structure of the PPl-microcystin complex’*’ and 
from two PP2B structures.
□ Inhibition o f  PPlc by microcystin - microcystin-LR 2 is a complex cyclic 
heptapeptide which interacts with three distinct regions on the surface of PP 1 (see 
Fig. 1.8).
IN'I’R O D Ü C T IO N PAO 1:26
,U ï ..  
'■ • v r t - /  - ■ • " ' - - S
' 74 s
Figure 1.8: Protein Phosphatase la  complexed to microcystin-LR
Microcystin interacts with the hydrophobic groove, the metal sites and to Cys273.
One o f these involves a carboxylate and carbonyl group o f the toxin which interact 
with two o f the metal-bound water molecules, hence blocking substrate binding 
directly. Other sites consist o f a protein hydrophobic groove and the pi2/pi3  
loop where the Sy atom of Cys273 o f PPL forms a covalent bond to one o f the 
side-chains o f the toxin,^ ** and the side-chain o f Tyr272 packs against a leucine 
residue o f the toxin.**** Interestingly, the conformation o f microcystin-LR does not 
change from its solution structure when in complex with PPl whereas the pi2/pl3  
loop if PPl undergoes a conformational change which avoids steric conflict 
between Tyr276 o f PPl and the Mdha sidechain o f microcystin-LR. The solution 
structure o f another PP1/PP2A t o x i n , a  pentapeptide, motiiporin 4 which
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resembles microcystin-LR suggests a similar model of interaction between PPl and 
this inhibitor.**
□ Resistance to toxins - the role of the p l2/pi3  loop as a site of interaction with 
toxins was anticipated earlier from the finding the substitution of Cys269 of PP2A 
to Gly within the p l2 /p l3  loop causes resistance to okadaic acid. The equivalent 
residue in PPl is a Phe, and replacing this with a Cys enhances okadaic acid 
binding activity.^^ Other studies showed mutation of Tyr272 of the pl2/pl3 loop 
causes a dramatic loss of potency of okadaic acid, calyculin A 5 and tautomycin 6 
as well as microcystin and motuporin.*'® These findings suggest toxins of PPl and 
PP2A despite their dissimilar structures interact with their target through the 
P12/pl3 loop. Significantly, the equivalent loop appears to play a role in 
interactions ofPP2B with immunosuppressant/immunophilin complexes.**
In the structure of the full-length PP2B holoenzyme, the A1-domain lies over the 
substrate-binding channel of the catalytic domain such which a Glu sidechain 
hydrogen bonds with two of the metal-bound water molecules. This interaction 
sterically hinders substrate and is reminiscent of PPl inhibition by microcystin.^
□ FKBP12 and FK506 binding - neither FKBP12 or FK506 individually can 
associate with PP2B; their interaction with PP2B requires a composite recognition 
surface of the binary complex.** The quaternary complex of the PP2B holoenzyme 
with FKBP12 and FK506 indicates the conformation of FKBP12 is nearly identical 
to the form in the binary complex of FKBP12 and FK506 with minor flexibility’s 
observed in the His87 and IIe90 loop of FKBP12.^^’^** The major site of interaction 
of PP2B is the base of the B-subunit-binding helix of the A subunit, and the 
B-subunit with a minor interaction with the p i2/pi3 loop of the catalytic site.** 
FK506 is situated 25 À from the catalytic site and cannot participate directly in 
phosphatase inhibition. FKBP12 sterically blocks access to the catalytic site for 
large macromolecules, although since its closest approach to the catalytic site is 
10 A, it does not prevent dephosphorylation of small molecule substrates such
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/7-nitrophenol phosphate (pNPP). The region of FKBP12 forms most of the 
interactions with PP2B, suggesting PP2B interacts with its anchoring protein and 
with FKBP12 by similar mechanisms/^
1.4.10.3 Structure and catalytic mechanism of the PPM family
The sequences of protein phosphatases of the PPM family share no similarity with 
those of the PPP family; however, the structures of these two families are 
strikingly similar. Recently, Barford et a i, published the crystal structure of PP2C 
at 2 Â resolution (see Fig. 1.9).^ **
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Figure 1.9; Crystal Structure o f  PP2C
( a )  Rihhon represenlalicm o f  PP2C.
(b) Detailed \new o f  the catalytic site o f  PP2C. t he two 
Mn~ ' ions are shown as green spheres co-ordinated 
by invariant aspartate residues, and water 
molecules are shown as gold spheres.
Mammalian PP2C consists o f two domains:
• an amino-terminal catalytic domain with six a-helices and 11 P-strands, 
common to all members o f the PP2C family; and
• a 90-residue carboxy-terminal domain o f three a-helices.
The catalytic domain is dominated by a central buried P-sandwich, formed by the 
association o f two anti-parallel P-sheets, both o f which are flanked by a pair of 
anti-parallel a-helices, which are inserted between the two central p-strands. The 
carboxy-terminal domain is formed from three anti-parallel a-helices which are
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remote from the catalytic site, suggesting a role in defining substrate specificity 
rather than catalysis/”
At the catalytic site of PP2C, two iVIn"~ ions within a binuclear metal centre are 
co-ordinated by four invariant aspartate residues and a non-conserved glutamate 
residue. These residues are situated at the top of a central P-sandwich. Six water 
molecules co-ordinate the two metal ions. One of these water molecules bridges 
the two metal ions and four form hydrogen bonds to a phosphate ion at the 
catalytic site. Dephosphorylation is probably catalysed by metal-activated water 
molecules which act as nucleophiles and general acids in a similar mechanism 
proposed for the PPP family.**
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1.5 Serine/Threonine Protein Phosphatase Inhibitors
1,5.1 Introduction
Inhibitors of eukaryotic protein kinases and phosphatases are a chemically diverse 
array of natural and synthetic compounds.
These include:
4 Medicines (immunosuppressants, tumour suppressants and anti-inflammatory 
agents);
^ Potions (a purported aphrodisiac which doubles as a wart remover!); and
^ Poisons (diarrhetic toxins, liver toxins, tumour promoters, an insect defence 
chemical and herbicides).**
These substances are valuable pharmacological probes and' affinity ligands for 
enhancing our knowledge of cellular effects of the signalling pathways. More 
broadly, this basic research is also leading to the development of drugs to control 
specific cellular responses, and enzyme based assays to detect toxins in food and 
water.
There are two functional classes of natural inhibitors:
* ‘Endogenous’ Proteins and Peptide Inhibitors - which regulate particular 
protein phosphatases within eukaryotic cells [for example inhibitors 1 and 2, 
which are specific for PPl (see section 1.4.5.3, P 12)], and
* Secondary Metabolites - produced by bacteria, fungi, plants, dinoflagellates and
insects, whose natural roles may be ecological - in signalling, attack and defence 
interactions among organisms.* '^*"’
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1.5.2 Type 1 and 2A Serine/Threonine Phosphatase Inhibitors
1.5.2.1 Okadaic Acid Class of Compounds
There are over 30 compounds in the okadaic acid class of inhibitors which all 
apparently bind to the same site on PPl and PP2A and inhibit their activities. 
These include the four structurally diverse different classes; okadaic acid, calyculin, 
tautomycin and microcystin. Since okadaic acid was the first member of this group 
to be isolated, they are referred to the Okadaic Acid Class of Compounds.*"*'**
Okadaic acid is 50-100 times more effective an inhibitor for PP2A than for PPl. 
This is not the case for the other compounds in this class, which are equally 
effective against PPl and PP2A (see Table 1.1).*^
Table 1.1: Inhibition o f  Ser/Thr Protein Phosphatases by the Okadaic Acid
Class o f  Compounds
PPl 
IC;o (nM)
PP2A 
ICjo (nM)
Okadaic Acid 3.4 0.07
Calyculin A 0.3 0.13
Tautomycin 0.7 0.65
Microcystin-LR 0.1 0.1
1.5.2.2 The Okadaic Acid Pathway of Tumour Promotion
Human carcinogenesis occurs in multi-stages, which include initiation, promotion 
and progression, and later metastasis associated with genetic changes, such as 
mutation and deletion (see Fig. 1.10).
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Cancer development in humans takes a long period of time; for example, the 
preneoplastic changes may be already present in the cells many years earlier than 
the appearance of cancers. Thus, occurrence of cancer is often associated with 
ageing.
Initiation and tumour promotion, are usually defined thus;
□ Initiation - is the mutation of a protooncogene in a normal cell, and
□ Tumour promotion - is the clonal growth of initiated cells.
Initiation Promotion Progression
( 5 ^  ) ___> ^ Cancer  > Metastasis
Normal cell in itiated cell Benign tum or
Figure 1.10: Cancerogenesis
Compared with the long period of tumour development in humans, the tumour 
promotion stage in a two-stage carcinogenesis experiment on mouse skin takes 
only about ten weeks. Thus, mouse skin is ideally suited for biochemical and 
molecular studies of tumour promotion with various tumour promoters.^
Tumour promoters can be classified into two groups;
□ TPA-type tumour promoters, and
□ non-TPA-type tumour promoters.
TP A (12-0-tetra-decanoylphorbol-13-acetate) 15 was the first tumour promoter 
to be isolated, and indeed was only known tumour promoter until the late 1970s.^^
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HO,,
TPA (15)
Classically, all TPA-type promoters are defined as those which bind to phorbol 
ester receptors in cell membranes, activating Ca"'-activated 
phospholipid-dependent kinase C (PKC) in Therefore, all tumour
promoters of the TPA-type induce the same biochemical and biological activities. 
In contrast, the non-TP A type tumour promoters do not bind to the phorbol esters 
or activate PKC. As for the mechanisms of action of non-TP A type tumour 
promoters, each class may act upon cells through different pathways.
In 1988, okadaic acid and dinophysistoxin-1 were reported to induce tumour 
promotion in two-stage carcinogenesis experiments, on mouse skin initiated with 
7, 12-dimethylbenz[a]anthracene (DMBA) 16.^’' Later, it was also found okadaic 
acid induced tumour promotion in rat glandular stomach initiated with 
TAmethyl-^A-nitro-A-nitrosoguanidine (MNNG), 17, (see Fig. 1.11).'94
F ig u re l .i l :  Tumour Initiators
These experiments established okadaic acid had a different mode of action to TPA. 
Hence, okadaic acid belongs to the non-TP A type tumour promoters.
I n t r o d u c t i o n  p a g e  35
Okadaic acid interacts with receptors (identified as PPl and PP2A) in cells and 
inhibits their action. The biochemical consequence of inhibition is an increase of 
phosphorylation, causing hyperphosphorylation, which results in causes discordant 
regulation of both protein kinases and protein phosphatases. This mechanism is 
now generally accepted as the Okadaic Acid Mechanism o f Tumour Promotion 
(see Fig. 1.12).
H,N COOHPhosphorylation
Signal
Déphosphorylation
Figure 1.12: Hyperphosphorylation
Two stage carcinogenesis experiments revealed microcystin-LR was a new tumour 
promoter in rat liver, initiated with diethylnitrosamine (DEN), 18 Nodularin was 
also thought to be a liver tumour promoter, because both nodularin and 
microcystin-LR inhibited PPl and PP2A with the same specific activity. 
Nodularin turned out to be a more potent tumour promoter than microcystin-LR, 
and in addition, to have a slightly lower initiating activity. The results suggested 
that nodularin is a new environmental carcinogen rather than simply a tumour 
promoter.^^
Okadaic acid binds to PPl and PP2A in particulate (membrane) and cytosolic 
fractions of various tissues. Since the microcystins and nodularins are also liver 
tumour promoters which inhibit PP l and PP2A, experiments were carried out to 
see if these compounds bind to the same receptors/^ Inhibition of specific 
[^H]-okadaic acid binding to particulate and cytosolic fractions of mouse liver was 
first studied .M icrocystin  and nodularin inhibited the specific binding of specific 
[^H]-okadaic acid dose dependently, hence have the same mode of action and so
In t r o d u c t io n PAge  36
belong to the Okadaic Acid Class o f Inhibitors. Moreover, additional receptor 
binding testing with ’H-okadaic acid, has identified over thirty compound in the 
okadaic acid class, including calyculin A and tautomycin. IVIicrocystin-LR is the 
most potent liver tumour promoter to daie.^^
1.5.2.2.1 Okadaic Acid
Okadaic acid is a C38 polyether fatty acid with a molecular backbone spanning six 
tetrapyran rings and one tetrafuran ring (see Fig. 1.13).^  ^ It was first isolated from 
the common black marine sponges Halicho?idria okadaii and Halichondria 
melanodocia.^^^ The structure is very similar to acanthifolicin 7 isolated from the 
sponge Pandoras acanthafolium, which was the first polyether carboxylic acid to 
be reported from marine s o u r c e s . Ok a d a i c  acid has subsequently shown to be 
produced by several types of dinoflagellates (marine plankton) including 
Prorocentnim lima mid Dinophysis sp.
■Okadaic Add
iAcanthifolicin 
• binophysistoxm-l :
Okadaic Acid Tetrarriefhvl Ether 10
0 =
ÔR1
Ri R: Rj
H . H H
H H H
. H H : CHj
CH3 CH] H
Figure 1.13: Okadaic Acid and Analogues
Okadaic acid is the causative agent for diarrhetic shellfish poisoning (DSP), 
regulates mitosis in the cell cycle and specifically inhibits PPl and PP2A resulting 
in the accumulation of phosphorlylated proteins in cells.
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Diarrhetic shellfish toxin was first isolated from the digestive glands of mussels and 
named dinophysistoxin I (DTXl) 8 after the genus of the causative 
dinoftagellate/'^'* By spectral comparison with okadaic acid, DTXl was identified 
to be 35-(i^)-methylokadiac acid/"^ "^  A series of congeners substituted with various 
fatty acids, 7-0-acyl-35-(i^)-methylokadiac acids (DTX3) 9, were isolated as the 
toxic component of poisonous scallops from North-eastern Japan. Recently 
31-dimethyl-35-methylokadaic acid (DTX2), [okadaic acid tetramethyl ether 10] 
has been isolated from Irish mussels.
The total synthesis of okadaic acid was reported in 1987 by Isobe et The
X-ray crystal structure of the 0-bromobenzyl ester of okadaic acid was reported in 
1981.^ *^^  A full NMR study of the solution structure okadaic acid revealed that it 
was identical to the crystal structure. The fact the solution and solid state 
conformations are comparable suggests the biologically active conformation of 
okadaic acid is likely to be similar. With this information available, okadaic acid is 
a good template for the generation of a pharmacophore model of the okadaic class 
of compounds.
Okadaic acid is found to inhibit PP2A at the lowest concentration (X, of 30 pM), 
PPl at the next lowest concentration {K\ of 150 nM), and PP2B at the highest 
concentration {K\ of 5 piM); it shows no eftect on PP2C.*®^
1.5.2.2.2 Calyculin A
Calyculin A 5A was first isolated in 1986 from a marine sponge, Discodennia 
calyx, collected in the Gulf of Sagami in Japan. It is a strong inhibitor of starfish 
development and a strong toxic compound against leukaemia cells. It was later 
found to belong to the okadaic acid class of inhibitors, having subnanomolar 
inhibitor activity towards PPl and PP2A"*^’^^ ‘
Structurally, calyculin A differs markedly from okadaic acid, in spite of their 
overlapping binding properties (see Fig. 1.14). Calyculin A has a varietv* of
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interesting functional groups. It contains an octamethyl polyhydroxylated Cis fatty 
acid which is linked to two y-amino acids and esterified by phosphoric acid. The 
phosphate monoester is highly resistant to acid or enzymic hydrolysis, and is 
thought to play a central role in the interaction of calyculin A with its binding sites,
although this remains to be demonstrated. 109
o
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Figure 1.14: Structural Calyculins
Seven other calyculins have since been isolated from Discodermia calyx, (calyculin 
The absolute stereochemistry was elucidated in 1 9 9 1 , and found 
that calyculins E -  H are geometrical isomers (at C-2 and C-6) of calyculins A-D. 
The stereochemistry of calyculin A was shown to be enantiomeric to the original
report. 109
Earlier this year the dephosphorylated derivative of calyculin A was reported. This 
was isolated from D. calyx by Fusetani et a l, and was found to be a potent 
inhibitor of PPl and PP2A with IC50 values of 3.0 and 8.2 nfvl, respectively.
There are have been several attempted syntheses of calyculin A, including a total 
synthesis reported in 1992 by Evans et This turned .out to be the enantiomer 
of calyculin A [(+)-calyculin A].
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Recently the total synthesis of the correct enantiomer [(-)-calyculin A] was 
reported by Masamune et al}^^
1.5.2.2.3 Tautomycin
In 1987, Isono and co-workers isolated an antifungal antibiotic named tautomycin 
6 from the culture of Streptmyces spiroverticillatus,^^^ and later determined its 
structure.
OH
Tautomycin (6)
It was found that tautomycin specifically inhibits PPl and PP2A with an IC50 of 20 
nM, and binds to the same site as okadaic acid.^^° This antibiotic also causes 
morphological change of human leukaemia cells.
Although the total synthesis of tautomycin has not been reported, there have been 
several partial syntheses.
1.5.2.2.4 Microcystins and Nodularins
1.5.2.2.4.1 Introduction
Cyanobacterial blooms (or blue-green algae blooms) occur on 70 per cent of 
reservoirs world-wide, and have a wide range of social, economic and 
environmental i m p a c t s . N o t  only does their high biomass contribute to 
aesthetic problems such as surface scums and unpleasant odour, but of particular 
concern for animal and human health is the production of bioactive secondary 
metabolites which have highly toxic properties. These secondary metabolites 
include both cytotoxins and biotoxins, but only the biotoxins are a primary
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concern for animal and human health. The most common biotoxins include the 
potent neurotoxic alkaloids [anatoxin-a 11, anatoxin-a(s) 12, saxitoxins 13 and 
related paraKtic shellSsh poisons], plus the more commonly occurring hepatotoxic 
cyclic peptides [microcystins and nodularin 14] and the hepatotoxic alkaloid 
[cylindrospermopsin 15]. High doses of some of these toxins, the hepatotoxic 
cyclic peptides (microcystins and nodularins) in particular, severely damage the 
liver and can be fatal. Recent research has also highlighted the risk that low 
doses may promote human liver tumours.
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Figure 1.15: Cyanobacterial Toxins
The hepatotoxic cyclic peptides (microcystins and nodularins) are discussed in 
more detail below.
1.5.2.2.4.2 Chemical Structures and Their Characteristic Features
The microcystins are produced by both filamentous {Ajjabaena flos-aqnae, 
Oscillatoria agardhii\ Nostoc sp, Hapalosiphoti) and colonial {Microcystis 
aeruginosa and Microcystis viridis) cyanobacteria [see Appendix 1]. The 
nodularins are produced by Nodidaria sptimigena, a filamentous brackish water 
cyanobacterium.
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Microcystin was first isolated was in 1959 by Bishop et al. Microcystis 
aeruginosa is also the most common bloom-forming cyanobacterium present in 
cases of human and animal poisoning.
Nodularin was the first blue-green algae implicated in hepatotoxic animal 
poisonings. Although, Nodidaria spiimigena was isolated in 1878,"'^ the total 
structure of nodularin was not delineated for over a century.
The gross structures of the hepatotoxins contained in M. Aeruginosa were 
elucidated by Botes et as cyclic peptides in 1985, and Rinehart et
reported the total structure three years later. The general structure is 
cyc/o[-(i^)-Ala^-(5)-X--(i?)-PMeAsp^-(5)-Y"-ADDA^-(i?)-AoGlu^-Mdha'-]. The 
structure uniformly is composed of the (i^)-amino acid, alanine (Ala); P-linked 
erythro-P-methylaspartic acid (P-Me-Asp); y-linked glutamic acid (Glu); two 
variable (Q-amino acids {X and Y) with combinations known to include, for 
example, leucine and alanine (LA), leucine and arginine (LR), tyrosine and arginine 
(YR), tyrosine and alanine (YA), and tryosine and methionine'(YM); and the two 
unusual amino acids, A-methyldehydroalanine (Mdha) and 
3-amino-9-methoxy-10-phenyl-2, 6, 8,-trimethyldeca-4, 6-dienoic acid (Adda). 
The stereochemistry of Adda has recently been determined and assigned as 25, 35, 
85, 95, thus completing the absolute structures of microcystins. The two 
variable (5)-amino acids provide the basis of the nomenclature for the 
microcystins.
Once the basic structure was determined, many reports on microcystins quickly 
followed. More than 50 microcystins have been isolated to date [see 
Appendix 1].^ "^  ^ The structural differences among microcystins depend on mainly 
on two variable (5)-amino acids {X and Y), and secondly, on the presence or 
absence of methyl groups on p-Me-Asp and/or Mdha. '^^  ^ Several components 
possessing modified structures have also been isolated which have a 
9-G-acetyl-Adda or a 9-0-demethyl-Adda moiety; isopropyl or methyl monoester
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of the a-carboxyl group on the Glu moiety; and the iV-methyl serine or serine 
instead of Mdha.
One of the characteristic structural features in microcystins is the presence of a 
P-amino acid, Adda; this amino acid is also conserved in nodularins. The 
geometric isomer at C-7 in the Adda moiety having 4(£), 6{E) is considered to be 
essential for biological activity. This amino acid increases the hydrophobicity of 
the whole microcystin molecule. Microcystins possess another unusual
unsaturated amino acid, Mdha, which serves as a Michael addition acceptor. 
Indeed, microcystins react smoothly with glutathione and cysteine to give their 
adducts.
Although nodularin is a pentapeptide, its structure is closely related to 
microcystins. Nodularin is composed of Adda and (i^)-erythro-P-methylaspartic 
acid (p-MeAsp) as well as 2-(methylamino)-2-dehydrobutyric acid (Mdhb) instead 
of A-methyldehydroalanine (Mdha) of microcystins, however, nodularin lacks the 
variable (5)-amino acid (X) and the (R)-A\a residue (see Fig. 1.15).
Motuporin ([(iS)-VaP]-nodularin) is a new member of the microcystins/nodularin 
family. It is closely related to nodularin where the (5)-Arg at the variable (X) 
position is replaced with (5}-Val in the case of nodularin. Motuporin was isolated 
from a sponge, Theomlla swinhoei, collected from Papua New Guinea, and is 
shown to be a potent inhibitor PPl and PP2A.^"‘^
1.5.2.2.4.3 Relationship Between Structure and Toxicity
As mentioned above, over 50 microcystins have been observed thus far. Clinical 
signs of hepatotoxicosis have been observed in both wild and domestic animals. 
The finding that microcystin activates phosphorylase a is consistent with 
microcystin and nodularin being potent inhibitors of PPl and PP2A. This finding 
is important because inhibition of protein phosphatases implicates microcystins as 
potent tumour promoters and carcinogens.
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There are several modifications at different sites of the microcystin molecule; two 
variable (5)-amino acids; methyl groups Mdha and/or p-Me-Asp; Adda; Glu; and 
Mdha. The toxicity is classified roughly into three groups, depending upon the 
replacement of the two variable (5)-amino acids: strong; -LR, -LA and -YR', 
medium, -WTl; or weak, -RR and -M(0)R.^^*  ^ Desmethylated components on 
Mdha and P-Me-Asp show medium hepatotoxicity.^'^
Adda appears to be of great importance in the hepatotoxicity.^^" Removal or 
saturation of Adda greatly reduces the toxicity of microcystin-LR. Additionally, 
geometrical isomers at C-7 of Adda in microcystin-LR and -RR were essentially 
non-toxic. Replacement of the methoxy group at the C-9 in Adda by acetox)' 
and hydroxy groups does not reduce the toxicity. The toxicity of microcystin-LR 
was substantially reduced by the (C3H7O) unit in the Glu residue, suggesting a free 
carboxylic acid on the Glu unit may be important in toxicity. Reduction of the 
double bond and addition of glutathione in Mdha do not significantly reduce the 
toxicity of microcystin-LR. These accumulated results, suggest the Adda and 
Glu residues of the microcystin-LR play highly important roles in the 
hepatotoxicit>' of microcystins.
1.5.2.2.4.4 Toxic mechanism
The cellular uptake mechanisms of microcystin have been studied using 
radiolabelled dihydromicrocystin. The uptake of radiolabelled microcy stins were 
shown to be specific for rat hepatocytes.^'^
First, the membrane penetrating capacity of microcystin was analysed, but found to 
be low.^^  ^ Therefore, there was no support for the assumption that microcystin 
could penetrate cell membranes by simple diffusion. This conclusion indicated that 
microcystin required an active uptake mechanism.
The hepatocytic membrane contains carriers responsible for the active uptake of 
bile acids. These carriers are often collectively referred to as the bile acid transport
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system, which acts in a multi-specific manner, that is many organic substances can 
be transported as bile salts.
Because complete inhibition of the hepatocellular uptake is achieved with 
microcystin in the presence of bile acid transport inhibitors and bile acid/^^ 
suggests the bile acid transport system is a carrier for microcystin.
The consequence of acute liver intoxication, is a rapid and progressive alteration of 
the cells microfilaments which leads to aggregation of microfilaments near the 
centre of the cell.^^  ^ As a result of this loss of cellular support, the hepatocytes 
shrink. These shrunken cells separate firom one another and from the sinusoids. 
The cells of the sinusoids separate as well, causing blood to spill into the liver 
tissue. Collectively the signs of poisoning in these animals include weakness, 
vomiting, cold extremities and diarrhoea. Death most usually results nom 
intrahepatic haemorrhage and hypervolemic shock. This bleeding swiftly leads to 
death.
1.5.2.2.4.5 Biosynthesis
There have been two reports published on the biosynthesis of microcystins and 
nodularins.
Moore et al. investigated the biosynthesis of microcystin-LR from M  Aeruginosa 
PCC-7820. (25)-Methionine, (25)-phenylalanine, glutamic acid, acetate and 
pyruvate were found to be the precursors.
Converted products were analysed by '^C NMR spectra. The biosynthetic labelling 
pattern of these precursors, as determined by ^^ C NN'fR spectroscopy, for 
microcystin-LR is shown below (see Fig. 1.16).
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Figure 1.16: Biosynthesis o f  Microcystin
> Adda is biosynthesised from the carbon skeleton of phenylalanine and four 
molecules of acetate
> The Me groups on C6 and C8 of Adda are methionine-derived, whereas the 
C2 of Adda appears to arise from two sources one of which was methionine
> The (i?)-Glu residue is derived from (5)-glutamic acid, but P-Me-Asp does 
not arise from rearrangement of glutamic acid, instead it was synthesised 
from acetyl-CoA and pyruvic acid; and
> (.S)-Glutamic acid and acetate are incorporated into the Arg residue.
Difficulties were encountered when studying the biosynthesis of nodularin due to 
the low yield of nodularin from the producing organism. Nevertheless, studies by 
Rinehart et a l reported similar findings to Moore.
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1.5.2.2.4.6 Linear Peptides Relating to Microcystins
Rinehart et al}^^ reported the isolation of a linear peptide, 
Adda-(i?)-Glu-Mdhb-(i?)-P-Me-Asp“(iS)-Arg-OH, from cultured Nodidaria 
spiimigena, and three linear peptides;
1) Adda-(i?)-Glu-Mdha-(i?)-Ala-(6)-Leu-(i?)-p-Me-Asp-(S)-Arg-0H,
2) (*S)-Leu-(i?)-p-Me-Asp-(S)-Arg-Adda-(i?)-Glu-Mdha-(i?)-Ala-OH, and
3) (.S)-Phe-(i?)-p-Me-Asp-(S)-Arg-Adda-(i?)-Glu-Mdha-(i?)-Ala-OH
from a water bloom of M  sp. The peptides obtained did not show apparent 
toxicity, and are considered to be biogenetic precursors of nodularins and 
microcystins.
1.5.2.2.4.7 Bacterial Degradation of Microcystin-LR
Recently it was reported degradation of microcystin-LR was mediated by at least 
three intracellular hydrolytic enzymes.
Microcystin-LR was cleaved between the Adda and Arg peptide bond by an 
enzyme designated, microcystinase to yield an identical linear peptide, as first 
identified by Rinehart et aO^^ (see above). The linearised microcystin-LR was 
then cleaved between Ala and Leu with a second proteinase to give a tetrapeptide, 
Adda-(i?)-Glu-Mdha-(iS)-Ala-OH. The third enzyme gave rise to undetected 
smaller peptides and amino acids.
1.5.2.2.4.8 Synthesis of Microcystins/Nodularins
Several groups have reported the synthesis of the C20 amino acid,^^  ^ Adda, the first 
in 1989 by Carmichael et In this synthesis, the Adda residue was
retro-synthetically divided into an amino acid part (Ci to Cg) and an aromatic part 
(C7-C10).
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Using a combination of solid phase peptide synthesis and p-elimination in solution, 
Zetterstrom et synthesised the tetrapeptide fragment from microcystin
containing the iY-methyldehydroalanine (N-Mdha) amino acid. This was achieved 
by synthesis of the tetrapeptide, Ac-i?-y-Glu-[A-^-diiVIeCys]-i?-Ala-Leu on MBHA 
resin and subsequent removal,. followed by simple reduction of the dLMeCys 
fragment.
In 1995, Shreiber and co-workers, published the first total synthesis of the natural 
product, motuporin. More recently, another total synthesis was reported by 
Chamberlin and co-workers, who synthesised Nficrocystin-LA.*^^ A solid phase 
synthesis of the microcystin macrocycle has also been published, using MBHA 
resin.
1.5.2.2.5 Molecular Modelling and NMR Studies
1.5.2.2.5.1 Molecular Modelling
Before the co-crystallised structure of human PPl with microcystin (elucidated by 
Baiford et insight into the possible receptor-bound conformation of the
okadaic acid class of compounds had to be gained from the free ligand
information.
Partial structure elucidation of microcystin-LR was published by Rinehart in
1988.^ **^  The configuration of the novel amino acid, Adda, was determined by
NMR spectroscopy. These NMR spectroscopy studies did not reveal the complete 
solution structure of microcystin-LR. This provided the basis for Quinn and 
co-workers to use molecular modelling to determine the low energ>' conformation 
of the okadaic acid class of compounds with their receptors. The fact that 
microcystin-LR is conformationally restrained, due to its cv'clic nature, and that it 
displays high affinity for the receptor, allowed it to be a useful tool for
pharmacophore elucidation.
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During the development of the pharmacophore model, a report describing the 
superimposition of microcystin-LR and nodularin was published by Lanaras et 
al}^^ This work proposed that the Adda group in both microcystin-LR and 
nodularin were fitted together, the peptide rings of microcystin-LR and nodularin 
formed an angle of 90°.
Rigid superimposition of microcystin-LR and nodularin using ‘equivalent’ atoms of 
the two Adda residues, the arginine residues and the (i?)-/50glutamic acid showed 
both the peptide rings aligned in the same plane as did the Adda amino residues. 
Contrary to the findings of Lanaras et these results show that
microcystin-LR and nodularin inhibit PP1 and PP2A with almost the same actirity.
Quinn et al. then extended the model to include okadaic acid and calyculin 
In this study, okadaic acid was found to assume a cyclic conformation forming a 
cavity held together by an intramolecular hydrogen bond between the Gi carboxyl, 
attached to the first tetrahydropyran ring and the C24 hydroxyl group attached on 
the fourth tetrapyran ring.
The minimum energy conformation of calyculin A  was shown to have a number of 
hydrogen bonds within the molecule forming a cavity similar to that formed in 
okadaic acid.^^^
Molecular modelling allowed common regions of okadaic acid, calyculin A and 
microcystin-LR to be recognised and a pharmacophore model was developed. 
The Conserved Acid Binding Domain Pharmacophore Model, consists of a central 
core containing one conserved acid group and two potential hydrogen-binding 
sites (I and II), and a non-polar side-chain (see Fig. 1.17).
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Cooserved 
Acidic site
Figure 1.17; The conserved aci4 binding site o f okadaic acid, calyculin A and 
microcystin-LR showing the potential hydrogen bonding areas I  and II, and the
hydrophobic side chains,
1.5.2.2.5.2 NMR Studies
Two three-dimensional structures of microcystins (microcystin-LR and -LY) were 
compared by Rudolph-Bohner et al}'’^  using 2D NMR spectroscopy in DMSO, 
and distance geometric calculations.
For microcystin-LY a single family of highly convergent structures was obtained.
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Figure 1.18: Superposition o f the most convergent microcystin-LR structures 
subdivided in the three conformational families A, B  and C.
This family is characterised by a relatively compact boat-like ring structure with 
the large side chain of the Adda residue protruding from the concave side, in close 
proximity to the Tyr side chain. Conversely, for the microcystin-LR the 
calculations result in three conformational families characterised by an even more 
compact ring structure. The Adda and Arg side chains protrude from the ring 
distal from one another caused by the access of the Adda side chain, an essential 
residue for activity, which results from the close proximity of the aromatic Tyr 
residue. A significant enthalpic cost would be expected for disturbance of this 
hydrophobic collapse and corresponding lower binding affinity to receptor 
molecules would be predicted. From the structures of the two related 
microcystins, and homology with other known toxins, a working hypothesis was 
proposed whereby, the Adda side-chain interacts with a hydrophobic groove of the 
phosphatases while the rest of the microcystin acts as a scaffold to help stabilise 
the interdigitation of the Adda with additional intermolecular interactions.
More recently, Bagu and co-workers extended this hypothesis to include 
motuporin. Microcystin-LR and motuporin solution structures were determined 
by 2D NMR spectroscopy in water. Once again, both structures consisted of a 
boat-like ring or saddle-shaped motif.
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Furthermore, the solution structure of nodularin in water was published by Annila 
et The three-dimensional solution structure was studied by NMR
spectroscopy and molecular dynamics simulations. From these studies, it was 
shown the cyclic backbone adopts a well defined conformation, but the remote 
parts of the side chains of arginine as well as the Adda, have large spatial 
dispersion. This resembles very closely that of microcysitn-LR in the chemically 
equivalent segment.
Instead of analysing the solution structures of the microcystin-LR in water^ '^’ or 
DMSO^^^ alone, Trogen et used a mixture of DMSO and water in order to 
determine the three-dimensional structures.
The receptors for these molecules are most likely to be composed of both 
hydrophilic and hydrophobic potions and therefore, DMSO will presumably better 
mimic these properties than can aqueous solutions. Furthermore, in order to 
mimic the viscosity in cells a DMSO/H2O (80/20, v/v) cry^oprotective mixture was 
chosen.
The conformational studies revealed only one conformational family in each 
solvent. Once again, the peptide ring has a saddled-shaped form, and the 
side-chains of Arg and the remote part of Adda are quite flexible without any 
well-defined structure. Structural differences are found in the residues Mdha, Ala 
and Leu for the two solvents. The DMS0/water structure resembles more closely 
the structure of microcystin-LR complexed to PP-1.^^ However, these structural 
differences do not affect the toxicity, since this part of the molecule is absent by 
Mdhb in the equally toxic nodularin.
1.5.2.2.5.3 Molecular Models for Bound Motuporin, Microcystins, Okadaic 
Acid and Calyculin A
Predictions for the bound conformations of the okadaic class of inhibitors have 
used a combination of solution structures from NMR studies, molecular modelling,
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and X-ray structures of the bound inhibitors to PP 1 and the free ligands (see Fig. 
1.19).
Figure 1.19: Superimposition o f  the three-dimensional structures o f  okadaic 
acid, calyculin A and microcystin-LR
The free NMR solution structure of microcystin-LR matches its cr\'stal structure 
when bound to PPL (see Fig. 1.20). The rigid saddle-shaped backbone pro\ides a 
proper framework for the hydrophobic, ionic and covalent interactions between 
microcystin-LR and the phosphatase. These interactions involve the Adda and 
Masp/Glu residues, which are essential for inhibition, and the Mdha which is 
required for the secondary covalent linkage. The hydrophobic, Adda, group 
located behind the rigid saddle of microcystin-LR, is flexible in solution and 
therefore, able to adjust to fit into the hydrophobic groove of PPR. Because 
hydrophilicit>' may be the initial driving force behind the binding of microcystin-LR 
into PPlc, the Adda residue could be responsible for anchoring the cyclic backbone 
ring into its bound position. The other contributing residues for inhibition, Masp 
and Glu, have orientated, negatively charged carboxyl groups, underneath the 
saddle, to interact with positively charged Arg-96 of PPL Finally, the secondary 
covalent linkage that forms after inhibition is dependent on the modified amino 
acid Mdha being located at the front and top of the toxin saddle to link covalently 
to Cys-273.
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Figure 1.20: Stereo view o f  comparison hetyveen the free  solution 
microcysitn-LR and hound microcystin-LR.
'I he free minimised NMR slruclnre o f microcystin-LR is red, and the hound
crystal structure in blue.
Accurate docking o f the unbound structures o f microcystin-LL, motuporin, 
okadaic acid and calyculin A relies on the assumption that, like microcystin-LR, 
each o f the free structures o f these toxins would not change dramatically upon 
binding. It is also dependent on the assumption that PPL itself does not differ 
greatly in conformation when microcystin-LR or the other inhibitors are bound. 
The latter assumption is supported by X-ray crystallographic determination of free 
PPL {i (^ . without microcystin-LR)^^ which was found to be in overall agreement 
with the previously reported microcystin-LR-PPL bound c o m p l e x . T h i s  
indicates that the ligand does not have a significant impact on the overall tertiary 
structure o f PPL when bound to the enzyme. Because microcystin-LL and 
motuporin are similar to microcystin-LR in terms o f their structure and function, 
they were superimposed onto the bound crystal structure of microcystin-LR as a 
starting point for docking onto PPL A similar approach was employed for
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okadaic acid and calyculin A, whose free crystal structures are very similar to the 
tertiary structure o f microcystin-LR.
The absence o f a covalent linkage between motuporin and PPL. is the only 
functional difference between bound motuporin and microcystin-LR. Docking of 
motuporin solution structure onto the crystal structure resulted in only a minor 
displacement from the starting point (see Fig. 1.21). Comparison o f motuporin 
docked onto P P L  with the crystal structure complex between microcystin-LR and 
P P L  shows how the Mdhb residue in motuporin is not only surface accessible, but 
highly exposed to solvent, which is not true for the covalently bounded residue 
Mdha in microcystin-LR. The inability o f motuporin and nodualrin to form a 
covalent link to P P L  and PP2Ac may ultimately explain why the nodularins may be 
able to function as carcinogens.^^ Since these toxins form no covalent linkages to 
PPases, their electrophilic Mdhb residues may be free to form direct adducts with 
nucleophilic groups on other informational macromolecules. “
GI U MASP GI U MASP
Figure 1.21: Superimposition o f  the free  averaged solution structure o f  
motuporin onto the bound crystal structure o f  microcystin-LR.
Motuporin and its labelled residues are in yellow, The blue structures and 
labelled residues belong to microcystin-LR. The white labelled residues are 
common between the two structures.
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The model for the docked okadaic acid has distinct similarities to the bound 
microcystin-LR. This would explain how these structurally diverse toxins are able 
to inhibit PPl. The model of calyculin A, like okadaic acid, shares many features 
with bound microcystin-LR. In calyculin A,' the unusual phosphate group is 
predicted to contribute to binding, possibly interacting with Arg96 and/or Arg221.
1.5.2.3 O ther P P l and PP2A Inhib itors
1.5.2.3.1 Cantharidin and Endothall
Cantharidin (exo, exo-2,3-dimethyl-7-oxobicyclo[2.2.l]heptane-2,3-dicarboxylic 
acid anhydride), 19 is a naturally occurring toxin present in over 1500 different 
species of the Chinese blister beetle {Mylabris phalerata), (see Fig. 1.22). The 
toxin has also been isolated from the Spanish fly {Ccitharis vesicatorid). The dried 
body of the Chinese beetle was first uses by the people of China as a traditional 
medicine over 2000 years ago. The toxin was isolated in Europe during the 1800's 
and used in the treatment of warts, as an aphrodisiac and as an abortifacient. By 
the early 1900’s cantharidin was determined to be too toxic for the use as an 
internal medicine.
OH
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Figure 1,22: Cantharidin (19) ànd Endothall (20)
In 1992, Li and Casida reported cantharidin, and a series of cantharidin analogues, 
including its herbicidal analogue, endothall 20,- were mM inhibitors of PPl and 
PP2A.^^^
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1.5.2,3.2 Rubrolides
In 1991, Miao and Anderson reported the isolation of rubrolides A to H (21 A to 
H), a new family of tunicate metabolites, from Rilterella nibra (see Figure 
1.23).^^°
0 0
R3 & Ri Br
V Of% /  V -O H
R4 B r - y y Br
R.0 R? HO Or
Ri Rz R] R4 R5 R, R2
21A H Br H Br H 21G H H
21B H Hr CI Br H 21H Cl H
21C H H H Br H
21D H Br H H H
21E H H H H H
21F Me H H H H
Figure 1.23: Rubrolides A -  H
The rubrolides are potent in vitro antibiotics, and they show moderate, but 
selective, inhibition of PPl and PP2A. They also represent a new family of 
biologically active tunicate metabolites which do not contain nitrogen, and two 
members of the family (B and H), are chlorinated which is unique to this t>pe of 
metabolite.
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1.5.2.3.3 Isopalinurin
A weak protein phosphatase inhibitor (IC50 2.5 mmol), was isolated from an 
Australian marine sponge, Dysidea Isopalinurin 22, a sesterterpene tetronic 
acid was identified as an agent for antibiotic activity and also as a protein 
phosphatase inhibitor. This latter activity was not sufficient to warrant further 
testing of the compound, although related compounds and structural analogues are 
subject to ongoing investigations.
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1,5,3 Type 2B Serine/Threonine Phosphatase Inhibitors
1.5,3,1 Cyclosporin A, FK506 and Rapamycin
Cyclosporin A 23, FK506 3 and rapamycin 24 are naturally occurring secondary 
metabolites which inhibit PP2B (see Fig. 1.24).
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Figure 1.24: Cyclosporin A (2), FK506 (3) and Rapamycin (24)
Cyclosporin A is a lipid soluble, cyclic undecapeptide produced by Tolypocladhtm 
inflatiim, a fungus isolated from a Norwegian soil sample. Cyclosporin A is 
valuable clinically as an immunosuppresent drug for organ transplant patients.
FK506 and rapamycin structurally related to each other, but not to cyclosporin A, 
are lipid soluble macrocyclic lactones. FK506 is produced by Streptomyces 
tsiikabaensis, a soil bacterium from northern J a p a n . R a p a m y c i n  is produced 
from Streptomyces hygtvscopicus, a bacterium isolated from a soil sample 
collected in Easter Island. Although FK506 and rapamycin are both 
immunosuppresents, they are still under evaluation as therapeutic agents.
On entering eukaryotic cells, cyclosporin A, FK506 and rapamycin bind to a 
distinct protein before binding to PP2B; cyclosporin A binds to the protein.
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cyclophiiin, whereas FK506 and rapamycin bind to the FK506-binding protein
Both these protein-drug complexes (cyclosporin A-cyclophilin and FK506-FKBP) 
specifically inhibit PP2B with nanomolar affinities.
Inhibition of PP2B prevents T-cell activation and hence, has revolutionised organ 
transplantation through its widespread use in the prevention of graft rejection.
1.5.3.2 Pyreth ro id  Insecticides
The pyrethroid insecticides contain two distinct classes; Type I and Type II class. 
A recent report by Enan and Matsumura have shown Type II pyrethroids 
[cypermethrin 25, deltamethrin 26, permethrin 27 and fenvalerate 28] are 
extremely potent inhibitors of PP2B with IC30 values ranging from 0.01 to 1 niVI 
(see Fig. 1.25).®^
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Figure 1.25: Pyrethroid Insecticides
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1.6 Serine/Threonine Protein Phosphatase Substrates
Ser/Thr protein phosphatases can be differentiated by their abilii}' to 
dephosphorylate small phosphopeptides.^^^
1.6.1 Substrates for Protein Phosphatase 1
The substrate specificity of PPl appears to be principally mediated by targetting 
subunits which associate with the catalytic subunit of PPl and direct it to the target 
locus, thus increasing its activity toward specific s u b s t r a t e s . P P l  is the protein 
phosphatase most reluctant to dephosphorylate phosphopeptide substrates, even if 
they are quite long, suggesting that a higher order of structure in the protein 
substrate is needed to optimise PP1 catalytic activity.
Like PP2A and PP2C, PPl by far prefers Thr-P over Ser-P. Moreover, a prolyl 
residue immediately C-terminal to the phosphoamino acid is a strong negative 
determinant.^^ Unlike PP2C and PP2B, however, PPl activity towards peptides is 
not abolished by an acidic cluster C terminal to the phosphorylated residue, and 
seems to be substantially increased by multiple basic residues on the N-terminal 
side.^^^
Recently, a very basic 25-amino acid corresponding to the phosphorylation site 
domain of the MARCKS protein, which contains several residues phosphorviated 
by PKC, has been reported to be dephosphorylated by PPl as rapidly as 
phosphorylase-a, although not as efficiently as the intact MARCKS protein.^"
1.6.2 Substrates for Protein Phosphatase 2A
In contrast to PPl, PP2A is able to dephosphorylate a number of short 
phosphopeptides as efficiently as protein substrates, or even faster. This property 
of PP2A has been assessed with a variety of peptides.
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Once again with PP2A it was found that short phosphothreonyl peptides were 
invariantly dephosphorylated much more efficiently than their phosphoseiyl 
counterparts/^ Two such peptides in particular, RRATpVA and 
RRREEETpEEE(AA), proved far better substrates than phosphorylase itself
1.6.3 Substrates for Protein Phosphatase 2B
Unlike PP2A and PP2C, PP2B is unable to dephosphorylate short peptide 
substrates (10 residues or less)/^"’ Two phosphorylated nonadecapeptides, 
however, one corresponding to residues 20-38 of DARPP-32 were almost as good 
substrates as the parent protein/^'"’ This suggests an extended stretch of 
N-terminal amino acids, possibly in the conformation of an amphipathic j3-sheet. is 
required for efficient déphosphorylation/^''
1.6.4 Substrates for Protein Phosphatase 2C
The capacity of PP2C to dephosphorylate short phosphopeptides is reminiscent of 
PP2A. Also reminiscent of PP2A is the marked preference for phosphothreonyl 
peptides over their phosphoseryl homologues/'^ Consequently, the 
phosphothreonyl hexapeptide, RRATpVA is an excellent substrate for both PP2C 
and PP2A/^’’ In contrast to PP2A, however, PP2C is inactive towards 
phosphopeptides bearing acidic residue(s) adjacent to the C-terminal side of the 
phosphorylated residue.
1.6.5 Conclusions
The classes of substrates of Ser/Thr protein phosphatases fall into two categories:
□ those whose activity toward short peptides is negligible as compared to 
protein substrates, namely PPl and PP2B, and
□ those which dephosphorylate a number of short phosphopeptides as readily 
as their protein substrates, namely PP2A and PP2C.
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The two former phosphatases presumably require structural determinants outside 
the immediate vicinity of the phosphorylation site, for efficient dephosphorylation, 
while the latter are able to recognise such features which are included in the 
primary structure around the phosphorylated residue.
The principal phosphopeptide used for the sensitive and specific monitoring of 
Ser/Thr protein phosphatases are summarised below (see Table 1.2).
Table 1.2: Principal phosphopeptides used fo r  Assays
PHOSPHOPEPTIDES USAGE
KKKKKJRESpFKKSpFKLSGFSpFKKNKK 
(MAJR.CKS peptide)
assay of PP 1
RRATpVA sensitive assay of PP2A and PP2C
RRREEETpEEE sensitive assay of PP2A
LDPRQVEiMIRRRRPTpPAML 
(DARPP-32 peptide) 
DLDVPIPGRFDRRVSpVAAE
assay of PP2B
(also dephosphorylated by PP2A)
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2. Results and Discussion
2.1 Introduction
The design and synthesis of specific inhibitors for either PPl or PP2A is of vital 
importance, because they can provide valuable tools for the study and 
identification of cellular processes which are mediated by these PPases. 
Intervention in the signalling mechanisms of specific cell types could offer 
therapeutic opportunities in several areas of medicine, including cancer, host 
defence, arthritis and atheroma. At present there are no specific inhibitors for 
either enzyme. Once specific inhibitors are synthesised detailed SAR study can be 
carried out.
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2.2 Design of Nodularin Analogues
The hepatotoxins, nodularins and microcystins, are cyclic isopeptides (see Fig. 
2.1). Although they are of different size, they are very potent inhibitors of PPl 
and PP2A (0.1 nM). Recent analysis has shown that the key functional groups on 
both systems could occupy similar enzyme bound positions in space, 
simultaneously. Hence, the similar groups in microcystins and nodularins can be 
assumed to be functionally equivalent.
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Figure 2,1: Microcystin-LR and Nodularin
The cyclic toxins contain two free carboxylic acid groups, an N-methyl 
dehydroamino acid moiety and an unusual, C20 lipophilic moiety (Adda).
The two a-carboxylic acids groups, (2R)-G\u and (2R, 35)-3-methylaspanic acid 
residues, are known to be important since the ester derivatives of active toxins 
were inactive. Thus, both of these would have to be retained in the cyclic target. 
Several variants of microcystin, which retain biological activity, do not have the 
3-methyl group of {2R, 35)-3-methylaspartic acid.
The Adda residue, (2S, 3S, 86", 9Q-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl 
-4,6-decadienoic acid, is highly conserved in both families of the toxin. However, 
it has been reported that the stereochemistry of the double bond at C-6 of the 
Adda residue in both microcystin-LR and microcystin-RR is not crucial for 
biological activity and that the 6Z-isomer is only 100-fold less active against PP2A
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(ED50 = 80 nM for both isomers) than the more common 6E-isomer (ED50 - 
0.28 M for microcystin-LR and 0.78 nM for microcystin-RR). Unsurprisingly, the 
Adda residue itself is totally inactive. A microcystin variant possessing a C-9 
hydroxyl group in place of the methoxy group in the Adda side-chain was fully 
active. However, the catalytic hydrogenation product of microcystin-LR showed 
little or no activity as a hepatotoxin. Since, the hydrogenation reaction reduced 
not only the diene, but presumably also the dehydroamino acid residue this would 
indicate that either a rigid lipophilc Adda side-chain, or a Michael-type acceptor is 
required for biological activity, or possibly both.
Dr AP Mehrotra tested the importance of the dehydroamino acid, which is thought 
to serve as a Michael adduct with Cys-273 of PPL, by the reduction of
microcystin-LR with sodium borohydride. 195 The resulting mixture of
diastereoisomers {ca. -5.1) were found to be as potent inhibitors of PP2A as 
microcystin-LR (Scheme 2.1). This result was also confirmed by the group of 
Mackintosh et a l  who replaced the Cys-273 by alanine and found no significant 
detriment to activity which suggests that covalent bond formation is a secondary 
event and occurs reversibly.^^
0 0
CH2 H Me
Scheme 2.1: NaBH^ Reduction
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Therefore, designing a simpler macrocycle target for synthesis has to incorporate 
four of the five principal conserved features to retain biological activity:
o the cyclic isopeptide;
® the two carboxylic acids; and 
® the rigid lipophilic amino acid.
The basic structure of nodularin was initially chosen to form potential protein 
phosphatase inhibitors, as it contains two fewer residues than microcystin without 
reduced potency.
Although the Adda moiety has been shown to be essential for inhibition, the first 
analogues chosen contained p-alanine as a simple replacement (see Fig. 2.2).’^ '
It was reasoned, on the basis of computer aided design, that the variable (25)-Arg 
residue could be replaced by the less polar hydrophobic amino acid [(2ri)-Phe]. 
This has the added advantage that it contains an UV chromophore which would 
aid chromatographic separation of intermediates during the synthesis of the 
macrocycle. The stereochemistry around the C-ct centre of the N-methylalanine 
residue in the dihydromicrocystin samples had no affect on biological activity, 
therefore, it was first chosen to use glycine and later sarcosine as a replacement in 
the stripped-down macfocycle. Finally, the two a-carbo.\ylic acids were retained 
in the analogues, but the (2R, 36)-3-methylaspartic acid was replaced with simply 
(2i?)-aspartic acid (see introduction).
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Figure 2.2: Nodularin (14) & Analogue (29)
2.3 Solution Phase Peptide Synthesis
Peptide synthesis originated in the work of Emil Fischer, whose goal was to 
prepare “alubumoses,” or proteins. This early work led to the formation of the 
peptide bond between a-amino acids, and established the importance of optical 
purity in synthetic products. In the 1930s attempts to synthesise a variety of 
small peptide substrates for the recently discovered proteolytic enz}'mes led to the 
development of the first reversible protecting g r o u p . T h e  discovery of naturally 
occurring biologically active peptides stimulated an explosion of synthetic activity 
in the 1950s and 1960s, which laid the foundation for modem day synthesis.
Today, there are numerous methods for synthesising peptides in the solution phase, 
including the use of carbodiimides and active e s t e r s . T h e  method chosen for the 
majority of the peptide synthesis in this work, was the mixed anhydride method of 
peptide coupling. This method was chosen for its advantages of high yield, speed 
and relative purity of products. The mixed anhydride method has been studied in 
detail to minimise the possibility of racemization and increase yield. The 
reaction involves a reaction of a protected amino or peptide acid with an alkyl 
chloroformate in the presence of a tertiary amine base, to form an anhydride. The 
anhydride is then reacted with an amine to form the peptide linkage.
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It has been found that racemization at the amino acid peptide centres can be 
minimised depending on the steric bulk of the base and choice of solvent. It was 
found that, although methylamine reacts the fastest, it causes maximum 
racemization. The best results were achieved when a combination of NTvIM, 
750-butyl chloroformate and dry THF were used. A minimum volume of dry DjVEF 
is often added when there is a problem with the solubility with one or more of the 
starting materials.
2.4 Original Design and Strategy
The preliminary target, replacing the Adda residue by p-alanine was thus identified 
as cyclo[-P-Ala-(2R)-Glu-cx-OMe-y“Sar-(2R)-Asp-ct-OMe-P-(2S)-Phe-] 30. 
Disconnection of the cyclic nodularin analogue gives the linear pentapeptide 
H2N-(27?)-Asp-a-OMe-p-(26)-Phe-P-Ala-(2i?)-Glu-a-OMe-Y-Gly-OH31. 
Subsequent disconnection of the linear pentapeptide gave two peptide fragments; 
AspPhe dipeptide 32, and SarGluGly tripeptide 33, (Scheme 2.2).
NH .OH
' a  o  H COoH Me
OH
.OH
Scheme 2.2: Disconnection o f the nodularin based analogue
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Initial work, by Dr AP Mehrotra, made use of orthogonal protecting groups on the 
N- and C- terminal (N-benzyloxycarbonyl and benzyl ester respectively) of the 
pentapeptide 31.^ ^^
All attempts at cyclising the in situ pentapeptide failed. A t ho ugh it was difficult to 
understand why the model cyclisation did not occur, it was conceivable that the 
NH moiety of the glycine residue, which is replaced by an NMe moiety in the 
natural toxins, was stabilising an unreactive conformation through transannular H- 
bond formation. Accordingly the synthesis was repeated using sarcosine in the 
place of glycine.
At the same time, the strategy for the use of protecting groups was altered so that 
the N-terminal and C-terminal functionality’s could be unmasked separately in 
order to take advantage of a wider range of activated ester cyclisation protocols, 
including the pentafluorophenyl ester method. Hence, the linear pentapeptide, 
Boc-(2i?)-Asp-a-OMe-p-(25)-Phe-P-Aa-(2i?)-Glu-a-OMe-y-Sar-OBn 34 was 
chosen as our first target compound.
2.4.1 Synthesis of Linear Pentapeptide 34: Boc-(2i<!)-Asp-a-OMe-p- 
(251-Phe-p-Ala-(2/?)-Glu-a-OMe-y-Sar-OBn
(2i^)-y-BenzyI-iV--butoxycarbonylglutamate 35 was treated with ethereal 
diazomethane to give the methyl ester 36 as a white amorphous solid (see Scheme 
2.3). Catal)tic hydrogenation of the benzyl ester followed by activation of the 
y-carboxy group of compound 37 by using N-methyl morpholine (NMM) and 
isobutylchloroformate (IBCF) to give the mixed anhydride, which was then treated 
with benzyl sarcosinate / 7-toluene sulfonate 38 to afford the required amide 39 in 
94% overall >ield {mp 76-7 °C; [a]o +13.4 (MeOH)}. The N-Boc protection was 
then removed using hydrogen chloride gas in ethyl acetate to give the amine salt 40 
in 85% yield. Treatment with N-Boc-pAa then gave the tripeptide ester 41 in 
82% yield (mp 78-9 °C; [a]o +26 (MeOH)}. The ^H NMR spectrum showed two 
sets of signals, one set for each of the cis- and tï'ans- rotomeric forms of the 
y-Glu-Sar amide bond. Subsequent removal of the N-Boc protecting group using
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hydrogen chloride gas in ethyl acetate afforded the hydrochloride salt 42 in 85% 
yield as an amorphous hydroscopic solid (see Scheme 2.3).
35 36 R = Bn . ^  39 R = BocNH
37 R = H 40 R = C1'H3N"
41
o H CO,Me M. O
or
42
Reagents and conditions: i, CH2 N 2 , EtzO, 0 °C, 1 h, 100%; ii, H2 . 10% Pd/C, EtOH, r.t., 18 h, 100%; 
ui,NM M , i-BuOCOCl, Sar-OBzI.p-TsOH 38, THF/DMF, -15 “C -> r.t., 1 h, 94%; iv, EtOAc, 
0 °C -> r.t., 1.5 h, 85%; v, NMM, i-BuOCOCl, Boc-P-Ala, THF/DMF, -15 °C -> r.t., 1 g, 82%;vi, 
HCl(g), EtOAc, 0 “C -> r.t., 1.5 h, 85%.
Scheme 2.3: Synthesis o f  fAlaGluSar Tripepti'de 42
The required N-terminal p-aspartyl phenylalanyl dipeptide fragment 48 was 
prepared starting from (2i?)-N-‘’butoxycarbonyl-p-benzyl aspartate 43, which was 
treated with ethereal diazomethane to give the methyl ester 44 as a white solid. 
Catalytic hydrogenation of the benzyl ester group followed by activation of the 
Y-carboxy group of compound 45 using NMM and IBCF to give the mixed 
anhydride which was then treated with benzyl phenylalaninate p-toluenesulfbnate 
46 to give the dipeptide 47 in 72% yield {mp 132-3 °C; [a]o -4.4 (MeOH)}. The 
benzyl ester group was removed with catalytic hydrogenation to give the required 
dipeptide 48 in quantitative yield.
The resulting free acid 48 was then activated by using NMM and IBCF and the 
resulting mixed anhydride was treated with the tripeptide hydroclrloride 42 to 
afford the fully protected pentapeptide 34 in 72% yield (mp 82-3 °C; [a]o +6.22 
(MeOH)}.
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In order to effect cyclisation, the pentafluorophenyl ester method was first 
considered. Thus, pentafluorophenyl ester 49 was prepared in three steps through 
catalytic hydrogenation of the benzyl ester group of pentapeptide 34, activation of 
the unmasked carboxylic acid group with EDCI, and finally, reaction of the 
activated ester with pentaflurophenol. The required PFP ester 49 was obtained in 
63% yield after chromatographic purification (see Scheme 2.4).
R = H. R' = Bn 
43
O H CCNMe
fj
44 R = Bn
, o  CQjMe 
H
45 R = H
47 R = Bn
48 R = H
O C02Me 
H
"'C
O o  H COWfe
34 R = B n
48 R = H
49 R = CgHj
Q COîMe
Reagents and conditions: I, CH2 N 2 . EuG. 0®C, 45 min, 100%; iL H,. 10% PdC  EtOH, r.t. 18 h, 100%: üi, 
NNIM, f-BuOCOCL (25)-Phe-OBn.p-TsOH 46, THF, -1 5  °C -> r.L 18 h, 72%; iv, H 2 , 10% PdC EtOH. r.c, 18 
h, 100%; V, NMM, /-BuOCOCl, 42 THF, - 15 °C -> r.L, 18 h, 72%; vi, H ,, 10% Pd/C EtOH. r.t., 18 h, ICOTo; 
EDCI. CgHgOH, CH,C1,, 0 °C -> r.t., 12 h. 63%.
Scheme 2.4: Synthesis o f Linear Pentapeptide 49
However, after several attempts, none of the expected cyclic peptide 50 was 
obtained (as judged by ^H-NMR and mass spearometry) after the N-protection 
was removed with TFA, and the amine salt treated with DIPEA (see Scheme 2.5).
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NH
''H o  H CO jM e
R eagen ts and C onditions: i, TFA, CH2 CI7 , 45 min: Ü, DIPEA, CH^CH, r.t., 7 days
Scheme 2.5: Attempted Cyclisation
This was in concordance with'Dr AP Mehrotra's findings/^i* when glycine was 
used instead of sarcosine. It is difficult to offer an explanation as to why this 
reaction repeatedly failed to work.
In order to offer an explanation as to why this reaction did not work, modelhng of 
the amine salt was carried out by Dr John Wilkie, using Discover by Biosym (a 
molecular mechanics program using the AMBER forcefield). This revealed, 
through dynamics run for 0.5 ns, that the lowest energy conformations in which 
the amine sat approached the pentafluorophenyl ester was not in the required 
orientation. The amine approached the ester at an angle of 68.1° which did not 
interact favourably with the electron density surrounding the carbonyl group (see 
Fig. 2.3).
R e su l t s  a n d  D isc u ssio n P a g e  73
Figure 2.3: Modelling o f  Linear Pentapeptide
In view of the fact that we were unable to effect macrolactamisation via this 
disconnection, a new disconnection (between the Phe and Asp, see Scheme 2.2) 
was examined which gave the linear pentapeptide precursor 
H2N-(26)-Phe-P-Ala-(2/?)-Glu-a-OMe-Y-Sar-(2i^)-Asp -a-OMe-P-Opfp 51.
Once again, this peptide was modelled using the same dynamics as before (see 
above). The modelling revealed that the amine could this time approach the ester 
in an orientation which should affect cyclisation. The angle was favourable with 
the electron density surrounding the carbonyl group (90.3°), and the distance 
between the two ends o f the linear pentapeptide was 3.53 Â which is close enough 
for cyclisation (see Fig. 2.4).
R e su l t s  a n d  D isc u ssio n P a g e  7 4
Figure 2.4: Modelling o f  Pentapeptide
Indeed when Dr AP Mehrotra attempted the cyclisation o f 51, the desired cyclic 
peptide 29 was obtained in 24% overall yield.
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2.4.2 Synthesis of Restrained Proline-containing Cyclic 
Pentapeptides;
cyclo[p-Ala-(2i?>-Glu-a-OMe-y-Pro-(2i?)-Asp-a-OMe-p-(2^Phe] 52
The NNjDR spectral data for the sarcosine-containing cyclic pentapeptide, prepared 
by Dr AP Mehrotra, showed the existence of three stable populated 
conformations. These were assigned using TOCSY, HSQC and COSY NMR 
experiments. However, it was not possible to assign specific NMR signals to the 
conformational structures for the macrocycle, as the sarcosine residue allows free 
movement about the C“-N bond and possesses no N-H proton which can report on 
the torsional angle about that bond. Therefore, we decided to consider the 
syntheses of restrained analogue containing (2S) and (2R)-Pro in the place of Sar 
in order to circumvent these problems.
Disconnection o f the proline containing pentapeptide 52, gives the linear 
pentapeptide precursor H2N-(26)-Phe-P-Aa-(2i?)-Glu-a-OMe-y-Pro-(27?) 
-Asp-a-OMe-P-OH 53. Subsequent disconnection gives two peptide fragments; 
PhePAa dipeptide 54, and GluProAsp tripeptide 55 (see Scheme 2.6).
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NH
NH
HO OH
H 'CO2H
NH
HO' OH
Scheme 2.6: Disconnection o f  Pro- Pentapeptide (52)
We decided to embark on the synthesis of the (25)-proline containing constrained 
macrocycle.
In order to construct the GluProAsp tripeptide 55, two alternative approaches 
were considered; one starting from the C-terminal (see Scheme 2.7) and the other 
starting from the N-terminal (see Scheme 2.8)
The synthesis of the N-terminal tripeptide started with (26^-proline which was 
reacted with /7-toluene sulfonic acid and benzyl alcohol under Dean-Stark 
conditions to give benzyl prolinate /7-toluene sulfonate 56A as a yellow oil, which 
was contaminated with benzyl alcohol (see Scheme 2.7). The crude benzyl ester 
was then coupled with Boc-(2i?)-Glu-a-OMe 37 to give the dipeptide which was 
subsequently deprotected and reacted with (2R)-Asp-aOMe-pOBzl 58 to give the
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tripeptide 59A. However, due to the difficulty encountered with the purification 
of the intermediates (due to benzyl alcohol contamination), this route was 
abandoned.
H
^  p-TsO* N
56A OH58A
NH
NH
OMe
OMe
60A 61A
Reagents and conditions: i.p-T sO H . BnOH, toluene, reflux, 6 h; ii. NM M . r-BuOCOCi. Boc-Glu-a-OMe 
37, THF. DMF. -15 °C->r.t., 12 h; Hi. H ,. 10% Pd/C, EtOH, r.t., 12 h; iv. NM M . /-BuOCOCl. 
Cr(2/?)-Asp-OBzi THF 59. DMF, -15 °C->r.t.. 12 h; v, HCl(g). EtOAc, 0 “C->r.t.. 2 h, 84%.
Scheme 2.7: Synthesis o f  Tripeptide (61A)
The synthesis of the C-terminal, on the other hand, started with P-benzyl {2R)- 
A^-(/e/T-butoxycarbonyl)aspartate 63. Treatment of the benzyl ester with ethereal 
diazomethane followed by N-Boc deprotection using dry HCl gas in ethyl acetate 
gave the amine salt 59 as a colourless oil in 91% yield. Reaction of the amine salt 
59 with the mixed anhydride of N-Boc-(2S)-proline, afforded the dipeptide 64A as 
a clear oil in 78% yield, {(Found; C, 61.1; H, 7.3; N 6.2. requires C22H30N2O7: C, 
60.8; H, 7.0; N, 6.4%); [a]o -5.41 (MeOH)}. N-terminal deprotection of the 
dipeptide 64A with dry HCl, and subsequent mixed anhydride coupling to 
N-Boc-(2R)-Glu-aOMe 37, gave the tripeptide 66A in 82% yield (mp 92-3 °C; 
[ajo -19.2 (MeOH)}. Finally, the tripeptide was N-terminal deprotected with dry 
HCl gas, to give the hydrochloride salt 67A in 84% yield (see Scheme 2.8).
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62
'' " ^ CI'HsN
MeOjC H 0
59
0 = \  H IV, V
NH Q
( /  / l - Ç H w e
64A
5  H ‘COsMe
66A
Cl H3N >5.H COaMe
VI
67A
R eagen tsm dconditions: i, CH2 CH2 , Et20, quant.; ii, HCL j, EtOAc, 0 ‘°C->r.t., 2 h, 91%; 
iii, NM M , /-BuOCOCl, Boc-Pro, THF. DMF, -15 °C->r.t.. 12 h, 78%; iv, H C M . EtOAc, 0 
°C->r.t., 4 h, 94%; v, NMM, /-BuOCOCl, Boc-Glu-aOMe 37, THF, DMF, -15 °C->r.t., 
12 h, 69%; \ i ,  HC1( ), EtOAc, 0 °C->r.t, 2 h, 84%.
Scheme 2.8: Synthesis o f  Tripeptide 67A
2.4.2.1 Synthesis of the N-terminal Dipeptide
The required N-terminal phenylalanyl (3-alanyl dipeptide fragment of target 68A 
was prepared by first activation of N-Boc-(2S)-phenylaIanine 69 by IBCF and 
NN'IGSf, to give the mixed anhydride, followed by reaction with benzyl (3-alaninate 
^-toluene sulfonate 70 to yield the dipeptide 71 in 85% {mp 92-3 °C; [ajo 4-0.63 
(MeOH). Deprotection of the benzyl ester group by catalytic hydrogenation then 
gave the free acid 72 in quantitative yield (see Scheme 2.9).
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B oc. OR
71 R = Bn
72 R = H
O H C02Me
H
.  6 8 A R  = Bn 
> 7 3 A R  = H 
^  74A R = Q H ; %
VI, VII
O |-| CO2M6
H o  H CO-Me
ll 52A
Reagents and conditions: i, NMM. /-BuOCOCl, (3-Ala-OBn./?-TsOH 70, THF. DMF, -15 
°C->r.t., 12 h. 87%; ii, H2 , 10% Pd/C, EtOH. r.t. 1 2  R 99%; iii, NMM, /-BuOCOCl, 67A. 
THF, DMF, -15 °C->r.t, 12 h, 6 8 %; iv, H ,. 10% Pd/C. EtOH, r.t. 12 h, 99%: v, EDCI. 
CgHjOH, CH2 CI2 , 0 °C->r.t, 12 h, 6 8 %; vi, TFA, CH2 CI2 , r.t., 45 min, quant.; vii, DIPEA, 
CH2 CI2 , r.t., 7 days, 54%.
Scheme 2.9: Synthesis o f  Cyclic Pentapeptide (52A)
The dipeptide 72, was activated using NMM and IBCF, and the resulting mixed 
anhydride treated with the tripeptide hydrochloride 67A and NMM to afford the 
required fully protected pentapeptide 68A in 68% yield, after recrystallisation from 
ethyl acetate and hexane {mp 118-9 °C; [a]o +31.67 (MeOH)}.
In order to activate the peptide for cyclisation, the C-terminal benz>-'l ester of 68A 
was removed through catalytic hydrogenation and was replaced by a 
pentafluorophenyl ester group, using EDCI and pentafluorophenol in 
dichloromethane, to give the ester 74A in 68% yield, after chromatographic 
purification. Deprotection of the N-Boc pentapeptide PFP ester 74A with TFA in 
dichloromethane gave the amine salt which was dried under high vacuum. The
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amine TFA salt was treated with DIPEA in dichloromethane under conditions of 
very high dilution.
The cyclisation reaction was followed by TLC (see experimental section), and after 
seven days at room temperature, the appearance of a new less polar band was 
judged to be complete. Immediately, after concentration of the reaction mixture 
under reduced pressure, the residue was purified by flash chromatography and 
recrystallised from acetone/diethyl ether to afford the desired cyclic isopeptide 52A 
in 52% yield. The macrocycle {mp >220 °C (decomp.)}, was found to be 
insoluble in most organic solvents, but was soluble in DMSO.
The epimer 52B, containing the (2jR)-Pro residue instead of the (25)-Pro was 
prepared in exactly the same manner, and was obtained in 16% overall yield.
Both macrocycles gave satisfactory analytical data. The TOCSY spectrum 
revealed that each macrocycles existed as a mixture of the ti'ans- and cis- 
y-Glu-Pro amide rotomers (see Fig. 2,5 and Fig. 2.6).
In each case the replacement of the Sar residue by Pro allowed us to deduce the 
3-D structures of each conformer to be deduced as required.
Figure 2.5: TOCSY Spectrum 1 o f Macrocycle
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Pro trans
G lu cis
PAJa cis
pAJa tra/js
Phe cis
Asp cis
Asp trans
Figure 2.6: TOCSY Spectrum 2 o f Macrocycle
The three-dimensional structure for the major isomer {trans isomer) in the 
(26)-proline macrocycle was deduced by restrained simulated annealing, using 
twenty H-H distance restraints generated from a ROES Y experiment. Each ROE
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interaction was defined as strong, medium or weak, and energy penalties were 
applied when the corresponding H-H distances lay outside the range: 0.18-0.27 
nm; 0.18-0.33 nm; and 0.18-0.5 nm, respectively (see Appendix 2). Nine of the ten 
initial models converged to a consensus structure. The lowest energy structure 
had a low ROE forcing potential (6.9 kcal/mol), indicating that it was consistent 
with experimental data, and showed close structural similarity with the 
corresponding potion with microcystin-LR (see Fig. 2.7).
Pro
y-Glu
Ala
Asp
Phe
Figure 2.7: Three-Dimensional Structures o f  Macrocycle
2.5 Solid Phase Synthesis for Nodularin Anaiogues
While the synthetic route to the nodularin macrocycle was proving to be fairly 
efficient, the time required to prepare such compounds was too long to employ for 
the preparation of the hundreds o f structural variants needed for a full SAR study.
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One of the most time-consuming steps was the purification of intermediates since 
this usually required a different procedure for each step. Solid phase peptide 
synthesis, on the other hand, unifies the purification of intermediates to simple 
washing procedures.
Two solid phase routes were, therefore, considered in which:
e the entire isopeptide would be prepared and cyclised on the resin; and
« the solid-phase assembled isopentapeptide would be removed from the resin 
prior to cyclisation.
2.5.1 Solid Phase Peptide Synthesis
The idea of solid phase peptide synthesis (SPPS), which uses the attachment of 
one of the reactants of a reaction to an insoluble, solid support with subsequent 
purification by filtration, was first conceived by Merrifield in 1959. In this method 
the carboxy terminal amino acid is covalently achored to an insoluble polymer via a 
linker, and the peptide is grown one residue at a time, on this polymer. Solutions 
containing the appropriate reagents are allowed to contact the polymer with 
shaking. At the conclusion of each step, the polymer containing the peptide is 
simply filtered away from the solution which contains soluble by-products and 
impurities. The completed peptide is then removed from the polymer resin by a 
simple cleavage step (see Scheme 2 .10). The advantage of this method is the ease 
with which the peptide is separated from soluble by-products of the reaction.
Merrifield’s original approach was based on a step-wise strategy starting with the 
C-terminal residue.^°^ About the same time, Letsinger and Komet recommended a 
similar technique in which the N-terminal residue was protected by a polymeric 
form of the benzyloxycarbonyl group, and the chain was lengthened stepwise. 
However, because of the inherent problem of racemization in the elongation of the 
peptide chain fi’om the N-terminal residue, the Merrifield approach remains the 
method of choice.
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Linkei-----
Attachment
Y “ M— Linke
Deprotection
M— Linke
Coupling
Y -M 2'M i—Linker
Repeat De protection and Coupling
Y -M y'M x‘M2*Mi—Linker— u R
Cleavage
Polymer
Scheme 2.10: General outline o f  solid phase synthesis, M, monomer; 
P, polymeric support; Y, protecting group removed during synthesis; 
and S, side-chain protecting group.
The solid phase peptide synthesis method developed by Merrifield utilises a 
Boc-amino blocking g r o u p . T h e  repeated acidolysis required for Boc 
deprotection could lead to alteration of sensitive peptide bonds as well as, acid 
catalysed side reactions, therefore the development of other protecting groups 
became important - the base labile N-a-protecting group, 9-fluorenylmeihoxy- 
carbonyl (Fmoc) group is one such group.
The Fmoc group is rapidly removed by primary (ethanolamine) and some 
secondary amines (piperidine), whilst more slowly by tertiary amines. Removal is
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also more rapid in polar media (DMF). The Fmoc group is most often deprotected 
by 20% piperidine/DMF, although other amines have also been used.
The electron withdrawing ftuorene ring of the Fmoc group renders the lone 
hydrogen on the P-carbon very acidic, and therefore susceptible to removal by 
weak bases. After p-elimination, the Fmoc group proceeds through a carbanion 
intermediate to form dibenzofulvene (see Scheme 2.11).
Scheme 2.11: Deprotection o f the base-labile Fmoc Group
The type of resin used for the synthesis is also of vital importance. There are 
several resins offering use with Fmoc-based strategies. We chose to use Wang 
resin which is the most successful and widely used polyst\Tene-based resin known
to date. 207
HO
Wang (4-Alkoxybenzyl) Resin 75
The resin consists of a polystyrene bead onto which an acid-labile linker has been 
attached.
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2.5.2 Synthesis of the Linear Pentapeptide; P-Allyl (2i9)-N-(9- 
fluorenylmethoxycarbonyi)phenylaianyl-P“alanyi-(2i?)-a-methyl- 
glutamyl~Y“(2i?)-prolyl-(2i?)-aspartate 76
The disconnection of the cyclic pentapeptide gives the linear precursor 
(25)-phenylalanyl-p-alanyl-(2i?)-glutamyI-a-OMe-y-prolyl-(2i?)-aspartate 53, as 
before. This was synthesised sequentially from the C-terminus using Wang resin 
and Fmoc protecting strategy for the N-terminal amino acids.
However, in order to cyclise the linear pentapeptide, a suitable protecting strategy 
for the co-carboxylic acids on aspartic and glutamic acids was required.
The general methodology for SPPS is based on the use of independent classes of 
protecting groups which can be removed by a specific chemical treatment that does 
not affect the protecting groups of other classes. By definition, such classes of 
protecting groups are said to be orthogonal.
The concept of orthogonality has been applied to this synthesis on solid support by 
the use of Fmoc and Me protecting groups for the protection of the N-terminus 
and the side-chains of the growing peptide, respectively. Selective cleavage of the 
allyl group, using a palladium catalyst, for the respective protection of the 
P-carboxylic acid on the aspartic acid allows for a third dimension of 
orthogonality.
2.5.2.1 Synthesis of a-MethyI-(2i?)-7V-(9-fluorenylmethoxycarbonyl) 
glutamate 77
In order to synthesise the a-methyl protected Fmoc-glutamic acid 77 (the starting 
material for one of the intermediates) two methods were tried. The first employed 
protection of the y-carboxyl group as a benzyl ester, which could be removed after 
Fmoc protection by catalytic hydrogenation (see Scheme 2.12). Allyl ester
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protection of the y-carboxyl group of glutamic acid was the second method to be 
considered (see Scheme 2.13).
y-Benzyl-9-fluorenylmethoxycarbonyl (2i?)-glutamate 79 was prepared from 
y-benzyl-(2i?)-glutamate 78 and fluorenylmethoxycarbonyl chloride under basic 
conditions to give the required compound as a white solid in 72% yield {mp 
137-8 °C; [a]o -12.9 (MeOH)}. The resulting compound was treated with 
ethereal diazomethane to give the methyl ester 80. Subsequent catalytic 
hydrogenation, to remove the benzyl ester, failed to give high yields of the required 
acid. This was due to instability of the Fmoc group under such conditions, even 
after addition of a small amount of TFA to the reaction mixture, the yield was still 
very poor.
OH
Reagents and conditions: i, Fmoc-Cl, KCC ,^ dioxane, water, 82%; ii, CH2N; 
EtOAc, Et20, quant.; iii, H2, 5% Pd/C, EtOH, r.t., 12 h, 20%.
Scheme 2.12: Synthesis o f  glutamate (77) using y^benzyl ester protection
Thus, the strategy with allyl ester protection seemed more attractive at this stage 
(see Scheme 2.13).
R eslo-t s  a n d  D isc u ssio n P age 88
The allyl ester group was added to the y-carboxy group of (2JR)-glutamic acid 81, 
under acidic conditions, with allyl alcohol to give the hydrochloride salt in 72% 
yield. The N-terminal was treated with fluorenylmethoxycarbonyl chloride, and 
then the a-carboxyl group protected with diazomethane, to >ield the fully 
protected diester 84 in 82% overall yield {mp 84-5 °C; [a]o 22.14 (MeOH)}.
HO2C H 
H2N O H  I
HO2C H
 ii_
81 O 82 O
O H CO2H
III, IV
O COzMe 
77
Reagents and conditions', i, TMS-Cl Myl-OH, 72%; ii, Fmoc-Cl, KCO3, dioxane 
water, 82%: iii, CH9N2, EtOAc. Et20, quant.; iv. PdfPPh^) .^ PhSiH^. DCM (dn). 
76%.
Scheme 2.13: Synthesis o f glutamate (77) using y-allyl ester protection
In 1950 the allyloxycarbonyl group (Aloe) was introduced by Stevens and 
Watanabe for the protection of amine and alcohol flmctions.^^^ Cleavage of the 
Aloe group was accomplished by catalytic hydrogenolysis using platinum or 
palladium catalysts, the use of metallic sodium in liquid ammonia, or the use of 
phosphonium iodide in glacial acetic acid. Unfortunately, these methods for 
removal of the Aloe group were not straightforward, which limited its use in 
organic synthesis. With the palladium catalysed allyl removal reactions developed 
by TsujP^^ and Trost^^°, the greater potential of the allyl protecting groups was
recognised.
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Allyl carboxylates and allyl carbonates are rapidly cleaved in the presence of 
soluble palladium catalyst [typically Pd(PPh3)4] and a nucleophile acting as an allyl 
scavenger, to regenerate the free unprotected function. Such catalytic 
methodology is of special interest for peptide synthesis because the deprotection 
conditions are usually mild enough to be compatible with the presence of the acid 
labile ‘‘Bu, Boc protections and the base labile Fmoc protections, provided, in the 
latter case, that a nucleophilic allyl group acceptor of sufficiently low basicity is 
used.
A variety of nucleophilic species has been used for intercepting the intermediate 
TC-allyl complexes, which includes carbon nucleophiles, heterophiles (amines, thiols 
and carboxylates), and hydride donors (HCO2H, BusSnH, NaBHU).
A variety of these nucleophiles (pyrrolidine, dimedone) were tried with our amino 
acid 83, however, on work up, the yields were typically very low (5-25%). On 
analysis of the NMR spectra (^H & *‘'C), it appeared that the Fmoc group was 
being removed, as well as the allyl ester.
In 1995, Dessolin et reported the use of a new allyl group scavenger, the 
hydride donor phenyltrihydrosilane (PhSiHs). This cleaves allyl carboxylates to 
silyl derivatives within 5 to 15 mln. [In dichloromethane at room temperature in 
the presence of Pd(PPh3)4 (0.02 molar equivalent) and PhSiH3 (1.2 - 2 molar 
equivalents)]. The silyl derivatives may, in turn, be instantaneously hydrolysed 
upon exposure to water.
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Pd(0 )L RCOO[Si] RCOOH
PdNu ‘OCOR
Scheme 2.14: Allyl Deprotection
The phenyltrihydrosilane reagent was successful in our hands, and gave the desired 
ester 77 {mp 130-1 °C; [a]o +19.5 (MeOH)} in 76% after purification by column 
chromatography.
2.5.2.2 Synthesis of P-AIIyl (2i?)-N-(9-fluorenylmethox>xarbonyl)- 
aspartyl-Wang resin 85
Using the same procedure as for the Fmoc-Glu-y-allyl ester 83, the 
Fmoc-Asp-p-allyl ester 88 (m.p 110 °C, [ajo +3.04 (MeOH)} was prepared in 
86% overall yield and then attached to Wang resin, using a method developed by 
Seiber (see Scheme 2.15).^^" The a-carboxyl group was activated as its 
2,6-dichorobenzoic anhydride, using 2,6-dichorobenzoyl chloride, and then reacted 
with the 4-hydroxymethyl group of Wang resin to give the immobilised diester. 
The remaining hydroxyl groups on the resin were then benzoylated with benzoyl 
chloride and p\Tidine.
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HO.C H O 
86
HO2C H O
87
ni
Reagents and conditions: i, TMSCl, Allyl-OH, 79%; ii. Fmoc-Cl. KCO3 , dioxane, waier. 
92%; iii, Wang Resin (0.84 mmol g' substitution), p\Tidine, 2 ,6 -dichloroben2 oylchloride. 
DMF, then benzoyl chloride, p\Tidine, DMF, 75% loading.
Scheme 2.15: Addition o f the First Residue (Asp) onto Wang Resin
The loading was checked using a method from the technical notes from 
Novabiochem^^^^ (see Appendix 4)
Using the above procedure, loadings between 70-80% were achieved
2.5.2.3 Solid Phase Synthesis of Peptide Sequence 76
The SPPS of the linear pentapeptide was carried out on a Rainin PS3 automated 
peptide synthesiser.
The Fmoc group was removed by a 20% piperidine/DMF solution. A 5% 
NMM/DMF solution was used for the activation of the Fmoc-(25)-Pro 89 by 
PyBOP, which was coupled to the resin bound amino acid. Once again, removal 
of the Fmoc group followed by reaction with PyBOP-activated 
Fmoc-(27^)-Glu-a-OMe 77 gave the immobilised Fmoc-tripeptide triester.
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Removal of the Fmoc group followed by reaction with PyBOP activated 
Fmoc-P-Ala 90 gave the tetrapeptide triester which was deprotected and reacted 
with PyBOP-activated Fmoc-(25)-Phe 91 to give the Fmoc-pentapeptide triester 
76 (see Scheme 2.16).
At this stage, a small amount of peptide (30 mg) was cleaved from the resin using 
a mixture of DCM/TFA/TES/water (53:40:2:5), and subsequently precipitated 
with ether to yield the required pentapeptide 76A in almost quantitative yield {mp 
115-6 °C; [a ]o -13.0 (MeOH)}.
2.5.3 Isopeptide Cyclised On Wang Resin using PyBOP
With the successful synthesis of the linear pentapeptide on the resin, the allyl ester 
was removed, under nearly neutral conditions, with Pd(PPhs)4 in DMSO/THF/0.5 
M HCl (aq.)/morpholine (2:2:1:0.1).^^'^’^ ^^  The ^H NMR spectrum of a sample 
cleaved from the resin by TFA at this stage showed that the allyl group had been 
completely removed. The N-terminal Fmoc group was removed using 20% 
piperidine/DMF to give the free N-amino acid group [monitored by the Kaiser test 
(see Appendix 4)], (see Scheme 2.16).
Once again a small amount of the cleaved peptide displayed the expected NMR 
and mass spectral data.
Cyclisation was carried out using PyBOP and HOBt in the presence of DIPEA in 
DMF.^ '^* A negative Kaiser test (see Appendix 4) showed that no free acid groups 
were present after 7 days. Cleavage from the resin using TFA and subsequent 
ether precipitation gave the crude macrocyclic monoester 93 in 78% overall >,ield. 
Reverse-phase HPLC analysis of the material 93 {ca. 50% of the total) displayed 
one major band and several close running bands which were subsequently removed 
by HPLC (see Fig. 2.8). The pure material (obtained in 30% yield) eluted as a 
single band and gave the expected ES mass spectrum (574 Da, M^).
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Removal of the Fmoc group followed by reaction with PyBOP activated 
Fmoc-P-Ala 90 gave the tetrapeptide triester which was deprotected and reacted 
with PyBOP-activated Fmoc-(25)-Phe 91 to give the Fmoc-pentapeptide triester 
76 (see Scheme 2.16).
At this stage, a small amount of resin (30 mg) was cleaved from the resin using a 
mixture of DCM/TFA/TES/water (53:40:2:5), and subsequently precipitated with 
ether to yield the desired pentapeptide 76A in almost quantitative yield {mp 115-6 
"C; [a ]o -13.0 (MeOH)}.
2.5.3 Isopeptide Cyclised On Wang Resin using PyBOP
With the successful synthesis of the linear pentapeptide on the resin, the allyl ester 
was removed, under nearly neutral conditions, with Pd(PPh3)4 in DMSO/THF/0.5 
M HCl (aq.)/morpholine (2:2:1:0.1).^""^" The ^H NMR spectrum of a sample 
cleaved from the resin by TFA at this stage showed that the allyl group had been 
completely removed. The N-terminal Fmoc group was removed using 20% 
piperidine/DMF to give the free N-amino acid group [monitored by the Kaiser test 
(see Appendix 4)], (see Scheme 2.16).
Once again a small amount of the cleaved peptide displayed the expected XNIR 
and mass spectral data.
Cyclisation was carried out using PyBOP and HOBt in the presence of DIPEA in 
DMF.^ '^  ^ A negative Kaiser test (see Appendix 4) showed that no free acid groups 
were present after 7 days. Cleavage from the resin using TFA and subsequent 
ether precipitation gave the crude macrocyclic monoester 93 in 78% overall weld. 
Reverse-phase HPLC analysis of the material 93 (ca. 50% of the total) displayed 
one major band and several close ruiming bands which were subsequently removed 
by HPLC (see Fig. 2.8). The pure material (obtained in 30% yield) eluted as a 
single band and gave the expected ES mass spectrum (574 Da, Mf).
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H ^  HCO2H 
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Reagents and conditions: i, Pd(Ph3 ) ,^ DMSO: THF; 0.5 M HCl: NMM (2:2:1:0.1). pH 
6 ; ii, 20% piperidine/ DMF; iii, P>BOP, HOBt, DIPEA, DMF; iv, DCM: TFA: H.O: 
TES (50:42:5:3); v, 1 M NaOH, MeOH, overall 78% crude yield.
Scheme 2.16: Cyclisation to give 93 Achieved on Wang Resin
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M in
Figure 2.8; HPLC o f macrocycle, before and after purification (dashed line)
and NMR spectra recorded in DMSO, and subsequently analysis using 
COSY, TOCSY and HSQC experiments, revealed the presence of two major 
conformers, as expected, corresponding to the trans- and cis- Glu-y-Pro rotomers. 
Saponification of the monoester gave a diacid 94A which displayed identical ES 
mass spectrum (560 Da, MT) and HPLC band to that derived from the solution 
phase synthesis.
Treatment of a sample of the crude material with diazomethane gave the crude 
diester 52A which displayed several NMR spectral signals coincident to those for
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the pure solution-phase synthesised material, and further analysis indicated that the 
crude macrocycle was ca. 50% pure, in keeping with the HPLC analysis of the 
precursors.
2.5.4 Isopeptide Cyclised On Wang Resin using pentafluorophenyl 
activation
In an attempt to improve the overall yield of 30% for the macrocycle 93 it was 
decided to cyclise the linear pentapeptide using pentaflurophenyl activation (see 
Scheme 2.17).
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Reagents and conditions:\, Pd(Ph3 ) ,^ DMSO: THF: 0.5 M HCl: NMM (2:2:1:0.1). 
pH 6 ; ii, pfp, EDCI, DCM, 18 h; iii, 20% piperidine/ DMF; iv, DIPEA, DCM: iv. 
DCM; TFA: H2 O: TES (50:42:5:3); v, 1 M NaOH, MeOH, overall 80% crude \idd.
Scheme 2.17: Cyclisation using pentafluorophenyl activation
The allyl protecting group on the linear pentapeptide 76, was removed as before, 
and converted to the pfp ester 95 using pentafluorophenol and EDCI. The pfp 
ester was treated with 20% piperidine in DMF, to remove the Fmoc protection, to 
give the diester 96. A small amount of this material was cleaved from the resin 
using TFA to give the desired compound which gave the expected NMR ‘-'C 
and ^^ F) data. Treatment of the diester 96 with DIPEA in DMF gave the resin-
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bound macrocycle. Removal of the resin then gave crude macrocycle 93 which 
was of similar purity to the material prepared using PyBOP-activation on analysis 
by reverse-phase HPLC (see Fig. 2.9).
_:oo0 . 2 0 .
O. l S.
1500 . 1 0 .
Cyclisation using DIPEA with pfp  activation0 .0 5
0 . 2 0 .
O. l S-
.500 . 10 .
Cyclisation using P yB O P0 .0 5 .
0 . 00 .
.Figure 2.9: HPLC plots o f  Cyclisation using DIPEA and PyBOP
2.5,5 Linear Isopentapeptide Prepared on Wang-Resin, But 
Removed From Resin Prior To Cyclisation
In order to discover the basis of the low purity of the cyclised materials on the 
resin, the linear pentapeptide 76 was removed from the resin, and the free Asp 
ct-car boxy group was methylated with diazomethane. The crude product 97 was
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> 95% pure as judged by NMR and HPLC, and gave the expected analytical and 
spectroscopic data {mp 120-1 °C; [a]o -17.8 (MeOH)}.
The allyl group and Fmoc groups were removed sequentially (see Scheme 2.18) to 
give the amino acid 99 which was then cyclised, through activation of the carboxy 
group with PyBOP to afford the crude macrocycle 52A in almost quantitative 
recovery (see Scheme 2.18).
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Reagents and conditions: i, DCM, TFA, H2 O, TES (50:42:5:3), quant.; ii, CH^Nn, 
DCM, EtsO quant.; iii, Pd(PPh3 ) ,^ PhSiHj, DCM, 70%; iv, Piperidine, DMF, 97%: v, 
PyBOP, DIPEA, DMF, 78%; vL 1 M NaOH, MeOH.
Scheme 2.18: SPPS o f Linear Isopeptide (97) and then Off-resin Cyclisation
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N^ V'ÎR analysis indicated that this material was at least 85% pure and identical to 
the material obtained from the solution-phase synthesis (see Fig. 2.10 and Scheme 
2 .8).
l‘\ Solid/Solution
f'-v._____ _
Phase
Solution Phase
U ll
ppm
Figure 2,10: NMR o f  52Afrom solution phase and solid/solution phase
Although the presence of the resin appears to inhibit the macrolactamisation step 
compared to the situation in solution, this methodology offers sisnincant 
advantages in the construction of the linear isopentapeptide precursor. Therefore,
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a combination of solid and solution phase synthesis offers the best strategy to the 
construction of cyclic isopeptides.
The synthesis can be shortened further by designing the linear isopentapeptide to 
be attached to the Wang resin at the p-carboxy position instead of the a-carbo.\y 
position. This will allow cyclisation to occur immediately after cleavage from the 
resin (see Scheme 2.19).
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Reagents and Conditions: i, 20% Piperidine, DMF; ii, DCM, TFA, HjO, TES 
(50:42:5:3), quant.; iii, P\BOP, DIPEA, DMF, 78%; iv, 1 M NaOH, MeOH.
Scheme 2.19: Synthesis o f  Linear Pentapeptide Attached to the Resin on the fd- 
Carboxylic Acid, then Cyclisation o ff Resin
2 .5.5.1 Synthesis of a-M ethoxy (2i?)-A^-(9-fluorenyimetho.\ycarbonyi) 
aspartyl-W ang resin 104
Using the same procedure as for the Fmoc-Glu-a-OMe ester 77, the
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Fmoc-Asp-a-OMe ester 103 (mp 124-5 °C; [a]o +19.05 (MeOH)} was 
synthesised (see Scheme 2.13). Attachment to Wang resin then gave the 
immobilised diester 104. Loadings were comparable to the aspartic acid attached 
at the a-carboxy position (82%) (see Scheme 2.20).
H
I, II
88
O C02Me Q
OH
III. IV
O  002^6 Q
104
Reagents and conditions: i, C1^ N2, EtOAc, Et20, quant.;ii, Pd(PPh3)4, PhSiHg, 
DCM (dr>), 78%; iii, Wang Resin (0.84 mmol g'  ^ substitution), p\Tidine, 
2,6-dichlorobenzoylchloride, DMF, then benzoyl chloride, p\Tidine, DMF, 82% 
loading.
Scheme 2 .2 0 : First Residue Attached to Wang Resin on p-carboxylic acid
The resin attached Fmoc-Asp-a-OMe is now ready to be used in the peptide 
synthesiser for the synthesis of the linear isopentapeptide. Removal of the Fmoc 
group would then allow cyclisation using PyBOP.
2.6 Introduction of Adda Moiety
Whilst the construction of the cyclic peptide using solid-phase peptide synthesis 
was being carried out, it was important to examine functional groups which could 
be utilised for the incorporation of a rigid lipophilic moiety at the Adda position 
and hence give biological activity.
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Either the Adda moiety could be added before cyclisation or after cyclisation.
2.6.1 Introduction of Adda Moiety After Cyclisation
2.6.1.1 Previous Studies - Diene
Dr A P Mehrotra designed a diene fragment which could be incorporated into the 
macrocycle via a hydroxymethyl analogue, which could undergo subsequent 
oxidation and a Wittig reaction with an appropriate ylide (see Scheme 2.21).
HOtC NH
P P h , Br
I V- V
112
Reagents and conditions: LIBCF, NM \L THE, -30 "C. 30 mins; ii. NaBH^, THE, -15 ’’C to r.L, 8 2 V  iii. Dess .Martin 
periodmane, 15 h, r.t.90%; iv, NaBH.,, EtOH, 40 min, 79%; v, PBr ,^ p>Tidtne. hexane. 0 '^ C to r.t, 85%; vi.
PPh], toluene, 6 h. a; viL, BuLi in hexane, THE, -78 °C to r.t. 30%.
Scheme 2.21: Synthesis o f  Diene Fragment
In order to transfer the chemistry from the model synthesis to the macrocycle, the 
p-alanine was replaced by the hydroxymethyl analogue. The macrocycle 
containing sarcosine was prepared using the same chemistry as for the (3-alanine 
macrocycles 52, however, the desired product was not only found to be unstable, 
but was also obtained in a very low yield.
We attempted to prepare the (25)- and (2R)- proline hydroxymethyl macrocycles 
using solution phase synthesis, however, the linear pentapeptides appeared to be 
unstable and gave a variety of unidentified breakdown products. On completion of 
the synthesis, the macrocycles were obtained in approximately 10% yield, and 
appeared to be as unstable as their linear counterparts.
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We attempted the same strategy using solid phase synthesis, however, the transfer 
of the hydroxymethyl compound for use on the solid phase was also problematic.
The synthesis of (2f?)W-(9-Fluorenylmethoxycarbonyl)-4-hydroxy-l-butyrate (the 
starting material for the hydroxymethyl intermediate for the solid phase), was 
attempted from the Fmoc-|3-allyl-(2i?)-aspartate 88 which was converted to the 
mixed carbonic anhydride and then reduced with sodium borohydride in THF to 
give the alcohol 113 in 84% yield {mp 124-5 °C; [a]o +8.14 (MeOH)}. Removal 
of the allyl ester using Pd(PPh3)4 and PhSiHa, however, led to the formation of a 
y-lactone ring 114 exclusively in 90% yield (HRMS; found [M + H]~, 324.1239. 
C19H 18NO4 requires 324.1236), (see Scheme 2.22).
Reagents and conditions: i, IBCF, NMM, THF, -30 °C, 30 mins; ii, NaBH^, THF, -15 °C to 
r.t., 84%; iii, Pd(PPl^)4 , PhSiHg, DCM, 90%.
114
H
113
Scheme 2,22: Preparation o f Hydroxymethyl Aspartate
In light of the instability of the alcohol pentapeptides, and the problems 
encountered synthesising the hydroxymethyl amino acid for the solid phase 
strategy, a new approach for the synthesis of precursors for the addition of the 
Adda moiety was considered.
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2.6.2 Benzyl Ester Functionality
We proposed, that if a P-alanine was replaced by a-carboxy protected aspartate 
residue, this could be unmasked once cyclisation had taken place and subsequent 
reactions could be achieved on the free carboxylic acid to yield potential inhibitors.
Benzyl ester protection was chosen as it is relatively stable to acidic and basic 
conditions. Whilst Dr A Maude concentrated on the solution phase synthesis, we 
decided to carry out the corresponding synthesis using solid phase chemistry.
The synthesis of the benzyl protected precursor 116 which was required for the 
solid phase synthesis started with P-allyl-9-fluorenylmethoxycarbonyl 
(2i?)-aspartate 88. Reaction of the caesium salt of ester 88 with benzyl bromide 
gave the benzyl ester in 96% yield {mp 82-83 °C; [ajo + 8.7 (MeOH)}. Allyl ester 
deprotection using Pd(PPh3)4 and PhSiHs then gave desired compound 116 in 76% 
yield {mp 96-7 °C; [ œ ] d  -9.17 (MeOH)} (see Scheme 2.23).
115
OH
116
Reagents and condtions: i, CsCOj, MeOH: ii, BnBr, DMF, 96%; iii, Pd(PPh2)^ , PhSiH .^ 
DCM, 76%.
Scheme 2.23: Synthesis o f  Benzyl Protected Precursor (16) fo r  
Solid Phase Synthesis
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This precursor was then used in the peptide synthesiser using the same strategy as 
before (see Section 2.5.2.3) to yield the required pentapeptide 117 in almost 
quantitative yield {mp 102-4 °C; (Found; C, 64.6; H, 5.7; N 6.9. requires 
C53H57N5O14: C, 64.4; H, 5.8; N, 7.1%); [a]o + 17.8 (MeOH)}.
After synthesis of the linear pentapeptide 117, once again the allyl ester was 
removed, under nearly neutral conditions, with Pd(PPh3)4 (see Section 2.5.3). The 
N-terminal Fmoc group was removed to give the free N-amino acid group 118. 
Cyclisation was carried out using PyBOP and HOBt in the presence of DIPEA in 
DMF. A negative Kaiser (ninhydrin) test (see Appendix 4) showed that no free 
amino groups were present after 7 days. Cleavage from the resin using TFA and 
subsequent ether precipitation gave a mixture of products which did not 
correspond to the required macro cycle 119. HPLC analysis showed that the major 
peak, according to mass spectroscopy was a result of the loss of the benzyl ester 
group from the macrocycle. One possible explanation for this is the position of the 
benzyl ester upon cyclisation. On cleavage the benzyl ester is exposed to the TFA 
solvent conditions, whereas before cyclisation the benzyl ester- was masked by the 
linear pentapeptide. A variety of cleavage conditions were tried, however, all 
seemed to give rise to the loss of the benzyl ester.
The parallel synthesis carried out by Dr A Maude on the solution phase only gave 
rise to 44% yield of the required benzyl ester macrocycle from the final coupling 
step.
Therefore, on the basis of both the above results, the possibility of synthesising 
analogues without Adda functionality before cyclisation was deemed unsuitable.
2.6.3 Addition of Adda Functionality Before Cyclisation
Whilst the above work was in progress, both Shreiber and Chamberlin reported the 
synthesis of the natural products, motuporin and microcystin-LA respectively, with 
introduction of the Adda moiety before cyclisation. Solid phase peptide synthesis 
is very suitable for addition of the moiety prior to cyclisation, and opens up 
opportunities for combinatorial chemistry.
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A secondary amine was chosen instead of (3-alanine for the synthesis because 
molecular modelling revealed that the secondary amine should fit into the 
hydrophobic pocket on the enzymes PPl and PP2A. 4-Benzylpiperidine was 
chosen to couple onto the a-carboxyl moiety which could be used in the peptide 
synthesiser.
The a-benzylpiperindo y-allyl (2i?)-iV-(9-fluorenylmethoxycarbonyl)aspartate 120 
was prepared from the reaction of the pre-formed mixed anhydride of 
Fmoc-p-allyl-(2i^)-aspartate 88 using NMM and IBCF to give the mixed anhydride 
which was then reacted with the 4-benzylpiperidine. The resulting product showed 
presence of Fmoc-OH, presumably due to the proton on the P-carbon of the Fmoc 
group being very acidic, and therefore susceptible to removal by weak bases such 
as 4-benzylpiperidine. Therefore, the resulting ester was immediately deprotected 
using Pd(Ph3)4 and PhSiH3 to yield the free acid 121 in 54% overall yield (mp 
79-81 °C; [a]o + 27.3 (MeOH)}.
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OH
120
OH
121
Reagents and conditions: i, IBCF, NMM, 4-benzyl piperidine, THF, DMF. -15 °C 
to r.t., 53%; ii, Pd(PPh3 )4 , PhSiHj, DCM, 6 8 %.
Scheme 2.24: Synthesis o f  
a-benzylpiperindo-(2R)-N-%fluorenylmethoxycarbonyl~aspartate
Using the same methodology as above, two other precursors for use in the peptide 
synthesiser were prepared with benzylamine and benyzlpiperazine moieties; 
a-benzylamido (2i?)-7V-(9-fluorenylmethoxycarbonyl)aspartate 124
(mp 141-2 °C; [a]n + 13.84 (MeOH)} and a-benzylpiperizido (2i^)-iY-(9- 
fluorenylmethoxycarbonyl)aspartate 125 {mp 74-5 °C; [a]o + 9.05 (MeOH)}, 
were prepared in 62% and 56% overall yield, respectively.
OH
122 123
Figure 2.11: Benzylamido and Benzylpiperiùdo Derivatives
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Dr J Wilkie has modelled the cyclic isopeptide 126 interaction with the PPU using 
INSIGHT-11, and found that the 4-benzylpiperidine moiety, which is approximately 
the same length as Adda, fits into the hydrophobic pocket on the enzyme leaving 
the acidic moieties to interact with the metals via water.
Acid Pocket Hydrophobic Pocket
Cys 273
Tyr 272
H o
Figure 2.12: Modelling o f  Cyclic Isopeptide (126)
Thus, the cyclic peptide 126 containing the 4-benzyl piperidine moiety was 
synthesised on the resin using the same methodology as before (see Section 2.5.3). 
Once again the linear pentapeptide 127 was obtained in almost quantitative yield 
and did not require further purification {134-6 °C; [a]o + 30 (MeOH)}. The
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C- and N- terminals were deprotected, and cyclisation was achieved in 7 days. 
The HPLC trace showed three major products, one of which gave rise to the 
desired cyclic pentapeptide 126. The recovered yield was very poor (> 20%). 
This synthesis has subsequently been repeated by Dr A Maude, using the 
combination of solution and solid phase (see Section 2.5.5) and higher yields have 
been obtained.
2.7 Isolation and Purification of Protein Phosphatase 1 
(PP1)
The gene which encodes for PPl, incorporating a 6-His tag (see Section 2.7.1), 
was cloned into pET21a^^ expression vector by Mrs J Sullivan (Zeneca 
Pharmaceuticals). Single colonies were selected and stored as a glycerol stock at 
- 78 °C [for cDNA sequence see Appendix 3].
PPl was expressed from the glycerol stock. The enzyme was purified using the 
Novagen His'Bind Buffer Kit, and dialysed overnight.
An SDS-PAGE mini-gel was performed using the lysate, cell paste and the purified 
enzyme against Perfect Protein^"  ^ markers. The gel was stained for protein with 
Coomassie blue and silver stain.
150
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Figure 2.13: SDS-PAGE mini-gel o f  PPl
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There are several conclusions which can be drawn from the gel;
® approximately 80% of the enzyme appears in the cell paste, which suggests 
the enzyme is insoluble on purification, and would need refolding in order in 
increase the yield; and
® the band fi*om the lysate, at 37 kDa, which correlates to PPl was judged to 
be 90% pure.
Protein determinations were performed using the Biorad reagent (based on the 
Bradford assay) using BSA as standard. The quantity of PPl purified from 40 cm  ^
cultures, following correction for purity, was 140 pg. This equates to 3.5 mg/litre 
culture (previously published by Zhang et a i as 10 mg/litre^^^).
2.7.1 Nickel chelation theory
Genes which are cloned into pET21a™ vectors carry a His®Tag sequence, stretch 
of either 6 or 10 consecutive histidine residues that can be expressed at the 
N-terminal or C-terminal of the target protein. The His*Tag sequence binds to 
divalent cation (NP^) immobilised on the His*Bind metal chelation resin. After 
unbound proteins are washed away, the target protein is recovered by elution with 
imidazole. Columns can be regenerated and reused many times. The versatile 
system provides a convenient, economical means of purification without the need 
to develop new protocols for each protein. It also allows the purification of target 
proteins under gentle, native conditions necessary for maintaining activity of 
soluble proteins.
2.7.2 Biochemical Characteristics of Recombinant P P l
Work carried out by Mrs J Sullivan showed that the activity o f recombinant PPl 
against pNPP is dependent on the inclusion of Mh^  ^ during the induction period. 
Removal of Mn^^ resulted in a 50% loss of activity, this was previously 
reported.^^^ To date, the enzyme preparations have retained full activity (12 weeks 
maximum).
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2.8 Assay of Ser/Thr Protein Phosphatases
2.8.1 Methods Available
The two methods used most commonly to measure protein phosphatase activity 
are:
>  a continuous or single time-point spectrophotometric assay of hydrolysis of 
a non-proteinaceous compound such as p-nitrophenylphosphate (f>NPP): 
and
> a single-time point assay of inorganic phosphate released from a 
phosphorylated substrate (either a phosphorylated protein or a synthetic 
peptide).
2.8.2 Measurement of Protein Phosphatase Activity using 
/?-Nitrophenylphosphate
Phosphatases are often assayed with the non-specific substrate, 
/7-nitrophenolphosphate (pNPP), however, /?NPP is not applicable to all phosphate 
releasing enzymes -  indeed in our system there was no activity with native 
e n z y m e . p N P P  cannot be employed when one wishes to explore the 
phosphoprotein substrate selectivity of a phosphatase. It, however, does have 
advantages in that it is a freely available substrate and can be used in a continuous 
spectrophotometric assay.^ '^^
2.8.3 Measurement of Protein Phosphatase Activity using 
Phosphorylated Synthetic Peptides
Pimma and co-workers have used peptides as model substrates for Ser/Thr protein 
phosphatases.^^^’^ '  ^ There studies show that PPl is almost inactive towards all 
small phosphopeptides tested so far. PP2A, PP2B and PP2C, however, are able to 
use small phosphopeptide substrates, although there are differences in specificity.
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In general, PP2B requires longer peptides of around 20 residues, whereas this is 
not the case for PP2A or PP2C. Some of these peptides are unrelated to any 
known physiological substrate. Other observations that have been extrapolated 
thus far include; PPl, PP2A and PP2C, by far prefer p-Thr over p-Ser,“^^ and 
unlike PP2 and PP2B, PPl activity towards peptides is not abolished by an acid 
cluster C-terminal to the phosphorylated residue, and seems to be substantially 
increased by multiple basic residues on the N-terminal.
Two synthetic phosphorylated substrates were tested and characterised on both 
recombinant PPl (purified at Zeneca), and native PPl (purified from rabbit skeletal 
muscle, and bought from TCS Biologicals);
RRATpVA (128): and
KRTpIRR (129)
In order to carry out any meaningful studies on either recombinant or native PPl, 
for example, phosphoprotein selectivity of a phosphatase, and characterisation of 
the enzyme itself, it was important to develop an accurate and sensitive assay for 
the dephosphorylation reaction carried out by PPl.
The ■’^ P labelled substrate, phosphorylase, has been used as the substrate of choice 
in most purifications and kinetic studies. However, this, not only, has the major 
disadvantage that it has a short half life (14 days), but relies on costly and 
hazardous radiolabelled substrates. A colourimetric assay, on the other hand, 
offers similar sensitivity to that achieved with a radiolabelled assay, but without the 
hazards and disposal liabilities.^^ The colourimetric assay which was employed 
was the Malachite green assay.^^^’ ^
The synthetic phosphopeptide RRATpVA 128 has been found to be the most 
effective substrate for PP2C so far identified. As it is also a common synthetic 
substrate for PP2A it appeared as an ideal substrate to try with our recombinant 
and native PP1.
The hexapeptide, KRTpIRR 129, has been implicated as a substrate for Ser/Thr 
protein phosphatases by TCS Biologicals. However, the kinetic parameters for
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PP 1 have not been published, therefore, this seemed a suitable substrate for testing 
with both the recombinant and native PP 1.
2.8.4 Summary of Substrate Selectivity’ with Recombinant PPl 
and Native
All assays were carried out under steady state conditions. A summary of the 
results are documented below (see Table 2.3).
Table 2.3: Summary o f Substrate Selectivity
R e c o m b in a n t  PPl N a t iv e  PPl
Substrate kcat kca/K„ Krn kcat kca/K„
(mM) (s') ( M 's ' ) (mM) (s ') ( M 's ' )
pN P P 21 °C 37.56 1.68 45.33 - - -
25 °C 53.04 2.78 52.41 - - -
RRATpVA 21 °C 1.04 6.58 6 299 - - -
25 °C 0.42 6.97 16 787 -
“
1 102
KRTpIRR 21 °C 0.17 3.87 23 081 - _ _
25 °C 0.09 4.12 45 382 0.24 3.73 15 528
Because KRTpIRR 129 was the better substrate with both Native PPl and 
recombinant enzymes, it was decided to use this as a substrate with any subsequent 
assays.
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2.8.5 Inhibition of Native and Recombinant P P l with Nodularin 
and Okadaic Acid
Having established the kinetic parameters of both enzymes with the hexapeptide 
substrate 129, it was important to test inhibitors in order to ensure that our assay 
was reliable and accurate.
Nodularin and okadaic acid, are both tight binding inhibitors that have been well 
characterised with PP 1.
Using Native PPl and KRTpIRR as a substrate under steady state conditions, both 
of these inhibitors gave IC50 values which were comparable to literature .(see Table 
2.4).
Table 2.4: Enzyme inhibition using KRTpIRR as substrate. carried out
at 25 °C with 2 0  min incubation time
NATIVE PPl
Inhibitor IC50 (nM) IC50 (nM)
Nodularin 0.1 0.14
Okadaic Acid 10-50 22.4
Because nodularin showed tight binding ch arac te ris tic s ,w e  were able to 
establish the purity and activity of the native enzyme (bought from TCS).
It was found, using Grqfit, that each assay contained 1.97 nM native PPl, which 
correlates to 2.5% pure/active protein to the published data. To check this result, 
an SDS-PAGE mini-gel was performed using the native PPl against the 
recombinant PP 1 and Perfect Protein™ markers. No protein, at the expected band 
of 37 kDa, was observed on the gel, and hence, this finding reinforced the original 
result.
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From this result, the kcat and specificity constants were calculated for the substrates 
RRATpVA and KRTpIRR respectively.
When testing the recombinant enzyme under steady state conditions, it was 
obvious that it had different characteristics to the native PP 1. Nodularin was not a 
tight binding inhibitor, instead it seem to possess biphasic kinetics (see Table 2.5).
Table 2.5: Recombinant PPl with Inhibitor - Nodularin
RECOMBIN.ANT PPl\
Inhibitor Ref. (nM) Ki 1 (nM) Ki 2 (nM)
Nodularin 0.1 86.34 0.59
135.43 1.4
It is difficult to offer an explanation as to why the recombinant enzyme is so 
different from the native enzyme, however, there is some precedent for 
recombinant forms of PPl exhibiting altered activity towards inhibitors.""^ It is 
believed that the recombinant PP I does not fold correctly, and hence has altered 
sensitivity towards inhibitors.
In our case, the recombinant PP 1 seems to have two different isoforms of the same 
enzyme, one which displays a Ki value which is comparable to the literature result 
(Ki2 ), and one which has decreased sensitivity towards inhibitors {Ki 1).
PPl has been shown to be refolded in the presence of inhibitor-2,^^^ which acts like 
a chaperone, to yield the correctly folded PPl. This is currently under 
investigation at Zeneca Pharmaceuticals.
2,8.6 Synthetic Inhibitors
Due to the problems encountered with the recombinant PPl, all dose response 
assays were carried out using the native PP 1 under steady state conditions, using
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KRTpIRR as substrate at 25 °C.
The synthetic inhibitors tested with native PPl are shown in Figure 2.14.
o H CO2H O HCO2H
NH
94A
O H CO2 H
• O
NH ^ ° 0 ^  H
94 B
130
Ç H CO^H f(/|e
NH H 0 :
H 0  H CO2 H
131
Figure 2.14: Synthetic Inhibitors
These were all prepared by the hydrolysis (1 M NaOH for 1 h at it) of the methyl 
esters.
A summary of the results are shown in Table 2.6.
Table 2.6: IC50 Values o f  Synthetic Inhibitors
NATRŒ PPl
Inhibitor IC50 (mh/I)
94A Undetectable
94B Undetectable
130 2.89
131 2.72
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Although, the above results are disappointing, it is clear that a hydrophobic residue 
at the Adda position is of vital importance for a compound to be an effective 
inhibitor. This was not an unexpected result, as crystallographic studies have 
indicated that the hydrophobic interaction of the Adda residue with PPl is the first 
interaction.
Subsequent modelling, has suggested the amide bond between the 4-benzyl 
piperidine and the carboxylic acid may be at the wrong angle to adopt the correct 
conformation to fulfil binding in the hydrophobic pocket.
2.9 Conclusions and Future Work
2.9.1 Inhibitors
The aim of this study was to synthesise cyclic isopeptides based on the natural 
product, nodularin, as potential inhibitors of PPl and/or PP2A. Initial work 
concentrated on the synthesis of the cyclic wopeptide portion of the inhibitor so 
that the basic chemistry could be sorted out without the added .complication of the 
Adda residue.
VVe began by disconnecting the cyclic Aopeptide between the sarcosine and 
aspartic acid residues, however, the linear pentapeptide did not undergo cyclisation 
to give the desired compound. Molecular modelling suggested that the linear 
pentapeptide did not adopt the correct conformation to achieve cyclisation.
However, cyclisation was successfully accomplished when the Aopeptide was 
disconnected between the aspartic acid and phenylalanine residues, 
pentaflurophenyl activation was used and the synthesis of the linear peptide was 
carried out using solution phase peptide synthesis.
Whilst acceptable yields were obtained using standard solution phase synthesis, the 
synthesis was very time consuming. Therefore, in an effort to shorten the synthesis 
solid phase peptide synthesis, using PyBOP activation and Fmoc and aliyl 
protection was considered.
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Although we had hoped to carry out both the synthesis of the linear Acpeptide and 
its subsequent cyclisation on the solid phase, yields were low for the cyclisation 
step.
To overcome this problem, the linear pentapeptide was synthesised on the resin, 
and then subsequently removed from the resin. The free carboxyl group was 
protected, and the protecting groups on the C- and N- terminal were removed 
prior to cyclisation. Subsequently, the synthesis was further shortened by 
attachment of the Wang resin to the (3-carboxylic acid of aspartic acid instead of 
the original a-carboxylic acid.
Although cyclisation was initially achieved using PyBOP, problems encountered 
with the removal of by-products has now led to the use of BOP-Cl instead.
Introduction of a hydrophobic moiety was achieved using the synthesis outlined 
previously (see Section 2.5.5), The synthesis of inhibitors that incorporate more 
elaborate hydrophobic moieties are currently being synthesised by Dr M O’Donnell 
in order to carry out a detailed SAR study with both PPl and PP2A enzymes.
2.9.2 Assays
Although a successful assay procedure for PPlo has been developed, there are still 
problems associated with the availability of the substrate and enzyme.
Because KRTpIRR is a veiy good substrate with PPL the synthesis of this 
hexapeptide would prove to be useful. This, coupled with RRA.TpVA, the 
excellent substrate for PP2Ac which has been synthesised previously, would enable 
studies to be carried out on both PPl and PP2A in order to find a selective 
inhibitor.
Once the folding problems with the recombinant enzyme has been overcome, this 
enzyme could become a reliable and inexpensive source of PPL. This would then 
allow enzyme assays and kinetic studies to be carried out in house.
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3. Experimental
Elemental microanalyses were performed in the departmental micro analytical 
laboratory.
ISIMR spectra were recorded on a Bruker AM-300 spectrometer (^H, 300 MHz;
75.4 MHz), a Varian Gemini 200 (^H, 200 MHz; 50.3 MHz), a Varian. 
Gemini-300BB (^H, 300 MHz; 75.4 MHz) and a Varian Unity Plus 500 
spectrometer (^H, 500 MHz; 125.6 MHz). Chemical shifts are described in 
parts per million downfield shift from SiMe4 and are reported consecutively as 
position ( 5 h  or Ôc), relative integral, multiplicity (s -singlet, d -doublet, t -triplet, q 
-quartet, quin -quintet, dd -doublet of doublets, sep -septet, m -multiplet, and br 
-broad), coupling constant (//Hz) and assignment (numbering according to the 
lUPAC nomenclature for the compound). ^H-NMR spectra were referenced 
internally on "HzO (Ô 4.68), C^HClg (6 7.27) or (% C )2S0 (6 2.47). ^^C-lSnMR were 
referenced on C^HCh (6 77.5) or (^H3C)2SO (Ô 39.70).
Pyrrolidine ring carbon and hydrogen’s are assigned in NMR spectra as a , (3, y, 5, 
going anticlockwise from the ring nitrogen, according to normal convention. 
Where more than one conformational isomer can be detected in the NMR spectrum 
due to the presence of a tertiary amide bond, these are assigned as c (cis) or t 
(trans), according to the isomeric state of the amide bond.
IR spectra were recorded on a Perkin-Elmer 1710 FT IR spectrometer. The 
samples were prepared as Nujol mulls or thin films between sodium chloride discs. 
The frequencies (u) as absorption maxima are given in wavenumbers (cm'^) relative 
to a polystyrene standard. Mass spectra and accurate mass measurements were 
recorded on a VG 70-250 SE. Major fragments were given as percentages of the 
base peak intensity (100%). UY spectra were recorded on Pye-Unicam SP8-500 or 
SP8-100 spectrophotometers.
Flash chromatography was performed according to the method of Still et 
using Sorbisil C 60 (40-60 pm mesh) silica gel. Analytical thin layer 
chromatography was carried out on 0.25 mm precoated silica gel plates
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chromatography was carried out on 0.25 mm precoated silica gel plates 
(L'lacherey-Nagel SIL g/XJY254) and compounds were visualised using UV' 
fluorescence, iodine vapour, ethanolic phosphomolybdic acid, or ninhydrin.
Melting points were taken on an Electrothermal melting point apparatus and are 
uncorrected. Optical rotations were measured at 23 °C on an Optical Activity 
AA-1000 polarimeter using 10 or 20 cm path length cells and are given in 
10'  ^ deg cm  ^g '\
The solvents used were either distilled or of analar quality and light petroleum 
refers to that portion boiling between 40 and 60 °C. Solvents were dried according 
to literature procedures. Ethanol and methanol were dried using magnesium 
turnings. Propan-2-ol, DMF, toluene, CH2CI2, acetonitrile, diAopropylethylamine, 
p>Tidine and triethylamine were distilled over CaHz. THF and diethyl ether were 
dried over sodium/benzophenone and distilled under nitrogen. Thionyl chloride was 
distilled over sulfur and the initial fractions were always discarded. A-Methyl 
morpholine was distilled over ninhydrin.
SDS-PAGE was performed following the procedure of Laemmli on a discontinuous 
medium. A Mini-Protean II Dual Slab Cell apparatus was used.^^*
Centrifugations were carried out on a CENTRIKON C-124 centrifuge. Pooled 
fractions from various steps were concentrated by ultrafiltration using an AMICON 
apparatus (43 or 76 mm diameter), through YMIO or a YM30 membrane, under 
Nz-
Protein purifications were determined by the method of Lowry et 
Approximately diluted samples of the protein solution were mixed with Coomasie 
blue dye reagent (100 mg of Coomasie brilliant blue dissolved in 50 cm"* of 95% 
ethanol to which 100 cm"* of 85% of phosphoric acid has been added and the whole 
diluted to 1 1 with water). After 5 min the absorbance was measured at 595 nm. 
Standard curves were prepared by using bovine serum albumin.
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Diazomethane:
Potassium hydroxide (6.0 g) was dissolved in water (10 cm’'), isopropanol (35 cm') 
and diethyl ether were added. The solution was heated and maintained at 50 °C 
using a water bath. Diazald (21.4 g), dissolved in diethyl ether (130 cm'), was 
added to the solution over 45 min. The yellow distillate was collected in a flask 
immersed in an ice bath and the whole system was fitted with a drying tube. An 
additional amount of ether (100 cm^) was added until the ether distilling over was 
colourless. The ethereal solution in the receiver (-200 cm'’) contained 
approximately 4 g of diazomethane.
General Cyclisation Procedure using DIPEA and pfp Activation
To a stirred solution of the pentapeptide activated ester (75 mg, 0.087 mmol) in 
DCM (3 cm^), was added trifluroacetic acid (3 cm )^. The reaction was allowed to 
stir at room temperature for 1 h., after which time no starting material was observed 
by TLC. The reaction mixture was concentrated under reduced pressure to yield a 
colourless oil.
The residue was dissolved in DCM (200 cm^), treated with DIPEA (210 mm''), and 
stirred at room temperature for 7 days. The reaction mixture was concentrated 
under reduced pressure, redissolved in ethyl acetate (30 cm''), and washed with IM 
HCl (3 X 20 cm’), 5% NaHCOs (2 x 20 cm"*), water (2 x 20 cm'') and brine (1 x 20 
cm'). The organic phase was dried (MgSOa) and the solvent removed under 
reduced pressure to give a colourless oil.
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General Solid Phase Synthesis and Peptide Removal from Wang Resin
Solid phase synthesis of the pentapeptides described below were carried out using 
the Rainin PPS automated peptide synthesiser. The synthesis employed Fmoc 
chemistry and the C-terminal end amino acids were linked to (3-allyl (2R)-iY-{9~ 
fluorenylmethoxycarbonyl)aspartyl-Wang resin 85. Amino acids and the activating 
agent PyBOP were purchased from Novabiochem chemicals, solvents DMF, 
piperidine and V-methylmorpholine from Sigma-Aldrich. A four fold excess of the 
amino acid was used for each coupling procedure. The N-a-Fmoc group was 
deprotected using a 20% piperidine/DMF solution and the activation was achieved 
using a 5% NMM/DMF solution.
The peptides were cleaved from the resin using a mixture of TFA/TES/H2O/DCM.
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a-M ethyl y-benzyl (2i?)-A-(ter?-butoxycarbonyl)glutamate diester 36
To a stirred solution of the y-benzyl (2i^)-iV-(/er/-butoxycarbonyl)glutamate 
(1.00 g, 2.96 mmol) in diethyl ether (15 cm') at 0 °C was added diazomethane 
(10 cm^) dropwise. After 30 min, the solution was purged with nitrogen to remove 
excess diazomethane and was then concentrated under reduced pressure to give the 
ester as a colourless oil. Upon storage the oil solidified to give the diester as an 
white amorphous solid in almost quantitative recovery, mp 33-34 °C; [a]o ^10.46 
(c 1 in MeOH) {lit.,^'° -18.0 (c 5.2 in MeOH)(for the 6"-isomer)}; 
u„ux(CH2Cl2)/cm'‘ 3373 (NH), 2879 (CH), 1758 (CO, urethane) and 1715 (CO, 
ester); 8H(200 Hz; C^ ^HCls) 1.45 [9 H, s, (CHs);], 1.85-2.30 (2 H, m, ^-CHz), 
2.40-2.55 (2 H, m, y-CHz), 3.75 (3 H, s, CH3), 4.37 (1 H, q, /  5.1 a-H ), 5.10-5.20 
(3 H, m, PhCFfz and NH) and 7.35 (5 H, s, Ph); 5c(50.3 MHz; C'HCb) 28.73 
(P-CH2), 28.89 [(CHs))], 32.52 (y-CHz), 52.83 (a-C ), 53.47 (CH3), 67.48 
(PhCHz), 80.35 [C(CH3)3], 128.60 and 129.04 (Ar-CH), 135.69 (Ar-C quaternary), 
135.69 (CO, urethane) and 170.41 and 173.33 (CO, esters); m/z (El) 292 (10«/o, [M 
-  COzCHsli, 236 (16, [M -  C4H9 -  CO2CH3 + H]’), 192 (47, [M -  Boc -  CO2CH3 
+ H]3, 108 (12, PhCHzOH") and 91 (1 0 0 , PhCHz).
a-M ethyl (2R)-7V-(fert-butoxycarbonyl)glutamate 37
To a stirred solution of benzyl ester 36 (1.02 g, 2.9 mmol) in ethanol (30 cm') was 
added 10% palladium on carbon (100 mg) and the mixture was stirred under an 
atmosphere of hydrogen for 3 h. The catalyst was removed by filtration through a 
pre-washed celite pad and the filtrate was concentrated under reduced pressure to 
give a colourless oil in quantitative recovery which was refractory to crystallisation, 
[a]D+27.14 (c 5.0 in MeOH) -27.7 (c 4.8 in MeOH) (for the 5-isomer)};
UaitCCHiCy/cm'* 3375 (NH), 1720 (CO, urethane) and 1700 (CO, ester); 5h (300 
MHz; C^HCls) 1.45 [9 H. s, (CH3)3], 1.82-2.23 (2 H. m. p-CHj), 2.38-2.57 (2 H,
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m, V-CH2). 3.78 (3 H. s, CH;). 4.38 (1 H, q. J  5.3. a -H ), 5.20 (1 H. d, J  S. 
urethane) and 6.69-7.31 (1 H, br s, COjH); 6c(50.3 MHz; C^HCb) 27.78 (P-CH,). 
28.64 [(CH;);], 30.47 (y-CHz), 52.89 (a-C ), 53.47 (CH-,), 80.62 [QCH;);], 
156.13 (CO, urethane), 176.74 (CO, ester) and 176.84 (CO, acid); nVz (Cl) 262 
(4%, [M + H]'), 206 (100, [M + 2H -  C4H9 + H]"), 162 (49, [M + H C5H9O2 + 
H]1 and 144 (64, CsHioNOs").
Benzyl sarcosinate /7-toluenesuIfonate 38
To a stirred suspension of sarcosine (9.98 g, 110 mmol) in toluene (200 cm') was 
added benzyl alcohol (120 cm', 55.6 mmol) followed by /7-toluene sulfonic acid 
(25.61 g, 120 mmol). The mixture was refluxed under Dean-Stark conditions for 6 
h. On cooling white crystals formed which were filtered at the pump, washed with 
ether and recrystallised using methanol/ether to give the benzyl ester 38 as white 
crystals (30 g, 80%) mp 91-92 °C, u„«,,(CH2Cl2)/cm-‘ 3436 (NH), 1751 (CO, ester) 
and 1660 (NH, amide); 5h(200 MHz (% C )2S0 ) 2.32 (3 H, s.CH;), 2.65 (3 H, s. 
N-CH;), 4.07 (2 H, s, CH;), 5.27 (2 H, br, PhCft), 7.10-7.60 (9 H, m, Ph) and 
9.00 (3 H. s, NH;); 5c(50.3 MHz (%C)zSO) 21.09 (CH;), 32.98 (CH;), 48.43 
(N-CH;), 67.18 (PhCHj), 125.80, 126.14, 128.34, 128.54, 128.70 and 128.76 
(Ar-CH), 135.35 (Ar-C quaternary) and 166.99 (CO, ester); m/z (Cl) 180 (100%, 
[ M A H -  TsOH]*) and 90 (62, [CsHsNOz]").
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Benzyl [(2i?)-iY-(tert-butoxycarbonyl)-a-methyl-glutamyl]-Y-sarcosinate 
diester 39
To a stirred solution of the a-methyl (2R)-iV-(/er/-butoxycarbonyl)glutamate 37 
(1.45 g, 6.22 mmol) in dry THF (25 cm') at - 15 °C was added 
A-methylmorpholine (678 mm', 6.22 mmol). Isobutylchloroformate (843 mm',
6.22 mmol) was added and the suspension was stirred at - 15 °C for a further 5 min. 
A mixture of benzyl sarcosinate /7-toluenesulfonate 38 (2.09 g, 6.22 mmol) and 
iV-methylmorpholine (678 mm', 6.22 mmol) in dry DMF (10 cm') and THF (25 
cm') was added and was left to stir over night. The hydrochloride salts were 
removed by filtration and the solution concentrated under reduced pressure to give 
a pale yellow oil which was redissolved in ethyl acetate (15 cm'), washed 
successively with water (10 cm'), 5% aqueous NaHCOj (15 cm'), 10% citric acid 
(15 cm^) and brine (15 cm'), and then dried (MgS04), and concentrated under 
reduced pressure to give a colourless oil which crystallised on standing to give the 
required compound (2.21 g, 84%), mp 76-77 °C (lit., '^^ 75-77 °C) (Found: C  59.6; 
H, 7.1; N, 6.5. C21H30N2O7 requires C, 59.6; H, 7.2; N, 6.6%); M o+13.4 (c 1.51 
in MeOH) (Ut.,^^ +13.4 (c 1.5 in MeOH)}; u„^,(CH2Cl2)/cm'' 3341 (NH), 2975 
(CH), 1747 (CO, urethane), 1713 (CO, esters) and 1651 (CO, amide); 5h(200 
MHz; C^HCb, mixture of rotomers) 1.40 [9 H, s, (CHzOs], 1.90-2.35 (2 H, m, 
P-CH2), 2.45-2.80 (2 H, m, y-CHz), 3.03 and 3.10 (3 H, s, N-CH5), 3.80 (3 H, s, 
CH:0, 4.00-4.60 (3 H, m, CHz (Sar) and a -H ), 5.15 (2 H, br, PhCi/z), 5.35 (1 H, s, 
NH), 6.65 (1 H, br, NH) and 7.30-7.40 (5 H, m, Ph); 8c(50.3 MHz; C'HCb, 
mixture of rotomers) 28.12 (p-CHz), 28.79 [CHg)]], 29.75 (y-CH?), 35.57 and 
36.94 (N-CH3), 50.06 [CH2 (Sar)] 52.89 (CH3), 53.54 (a-C ), 67.44 (PhCHz), 
78.21 [C(CH3)s], 128.83, 128.94, 129.12 and 129.22 (Ar-CH), 135.83 (Ar-C
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quaternary), 156.84 (CO, urethane) and 173.10 (CO, ester); m/z (Cl) 423 (10%, [M 
+ H]"), 367 (24, [M + H -  C4H9 + H]"), 323 (100, [M + H -  C5H9O2 + and 
144 (61, CgHioNOsl.
Benzyl [a-methyl (2i?)-glutamyl]-Y-sarcosinate hydrochloride 40
Hydrogen chloride gas was bubble into dry ethyl acetate (50 cm') at 0 °C and 
stirred for 1 h. To this was added a solution of the glutamyl-sarcosyl dipeptide 39 
(2.21 g, 5.23 mmol) dissolved in ethyl acetate (20 cm') and the mixture was stirred 
for 1.5 h at room temperature. The solution was concentrated under reduced 
pressure to give the required salt as an essentially pure hydroscopic solid (1.78 g, 
95%) (HRMS; found [M + H -  H Clf, 323.1615. C16H22NO5 requires 323.1607); 
[a]D +13.50 (c 0.64 in MeOH); u„„(CH2Cl2)/cm‘‘ 3323 (NH), 1759 (CO, ester) 
and 1633 (CO, amide); 5h (200 MHz; ^H20, mixture of rotomers) 2.02-2.20 (2 H, 
m, P-CH;), 2.38-2.69 (2 H, m, y-CH;), 2.85 and 3.02 (3 H, 2 x s, N-CH;), 3.73 (3 
H, s. CH;), 4.02-4.18 [3 H, m, CH; (Sar) and a-H ], 5.11 (2 H, s. PhCft) and 7.35 
(5 H, s. Ph); 5c(50.3 MHz; % 0 )  27.74 (P-CH;), 31.25 (y-CH;), 39.51 (N-CH;),
53.03 [CH; (Sar)], 54.97 (CH;), 56.43 (a-C ), 70.32 (PhCH;), 131.12, 131.2,
131.53 and 131.63 (Ar-CH), 137.97 (Ar-C quaternary), 172.97, 173.83 and 176.95 
(CO. amide and esters); m/z (Cl) 323 (13%, [M + H -  HCl]"), 263 (31, [M -  
CO;Me]"), 91 (94, PhCH;"), 84 (100, CH2CHC0 ;Me") and 56 (52, CH2CH2CO").
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Benzyl A-(rert-butoxycarbonyI)-p-aianyl-[a-methyl (2i?)-giutamyl] 
-y-sarcosinate diester 41
O
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39 using V-(/er/-butoxycarbonyl)-P-alanine (554 mg, 2.93 mmol), 
and the hydrochloride 40 (1,05 g, 2.93 mmol), to give the required product as an 
oil, which upon trituration with diethyl ether afforded a white solid (1.19 g, 82%), 
mp 78-79 °C (Found: C, 58.2; H, 7.0; N, 8.5. Cza^NsOg requires C, 58.4; H, 7.2; 
N. S.5%); [a]o +26.0 (c 0.25 in MeOH); u„„(CH2Cl2)/cm-‘ 2928 (CH). 1746 (CO. 
urethane) and 1655 and 1634 (CO. amides); 5h(200 MHz; C^HCb, mixture of 
rotomers) 1.40 [9 H. s, (CH;);], 2.01-2.23 [2 H, m, p-CH, (Olu)], 2.39-2.40 [2 H, 
m, y-CH; (Glu)], 2.49-2.56 [2 H, m, p-CH; (p-Aia)], 2.97 and 3.07 (3 H, 2 x s, 
N-CH;), 3.39 [2 H, q, J  5.8, a -C H ; (P-Ala)], 3.7 (3 H, s. CH;), 4.19 [2 H, dd, J
12.1 and 17.8 CH; (Sar)], 4.45 [1 H, q, /  5.3, a -H  (Glu)], 5.10-5.35 [3 H, m, 
PhCTf; and NH (urethane)], 6.90 [1 H, d, /  7.3, NH (amide)] and 7.25-7.40 [5 H, 
m, Ph]; 5c(50.3 MHz; C^HCl;, mixture of rotomers) 28.73 [p-CH; (Glu)], 28.89 
[(CH;);], 32.52 [y-CH; (Glu)], 36.20 and 37.32 [2 x CH; (P-Ala)], 41.81 (N-CH;),
48.53 [CH; (Sar)], 52.83 [a -C  (Glu)], 53.47 (CH;), 67.48 (PhCH;), 80.35 
[C(CH;);], 128.50, 128.58 and 129.09 (Ar-CH), 135.69 (Ar-C, quaternary), 155.69 
(CO, urethane), 170.10 and 172.89 (CO, amides) and 173.25 and 173.56 (CO, 
esters); m/z (Cl) 494 (25%, [M + H ])l, 393 (34, [M + H -  CÆ O;]"), 91 (56, 
PhCH;") and 59 ( 100, CO;Me").
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Benzyl p-alanyl-[a-methyl (2R)-glutamyl]-y-sarcosinate hydrochloride 42
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using the tripeptide 41 (0.98 g, 1.99 mmol) to give the required 
product as a white hydroscopic solid (821 mg, 96%), [a]o +8.53 (c 0.95 in MeOH); 
Um,x(CH2Cl2)/crn-  ^ 3327 (NH), 2972 (CH), 1752 (CO, ester) and 1653 (CO, 
amides); 5h(200 MHz; % 0 ,  mixture of rotomers) 1.72-2.14 [2 H, m, Y-CH2 
(Glu)], 2.39-2.52 [2 H, m, P-CH2 (Glu)], 2.53-2.68 [2 H, m, a-CHz (P-Ala)], 2.82 
and 2.98 (3 H, 2 x s, N-CH3), 3.07-3.18 [2 H, m, p-CH. (P-Ala)], 3.62 (3 H, s, 
CH3), 4.18-4.38 [3 H, m, a-H  (Glu) and CH2 (Sar)], 5.11 (2 H, s, PhCT/:) and 
7.32 (5 H, s, Ph); 5c(50.3 MHz; ^H20, mixture of rotomers) 28.48 [P-CH2 (Glu)], 
31.58 [y-CHz (Glu)], 34.41 and 38.26 [2 x CH2 (p-Aa)], 39.66 (N-CH3), 52.81 
[CH2 (Sar)], 53.22 [a-C (Glu)], 55.02 (CH3), 70.43 (PhCHi), 130.35, 131.57 and
131.82 (Ar-CH) and 173.93 and 178.09 (CO, ester and amide); m/z (Cl) 394 (45%, 
[M + H - HC1]1 , 318 (97, [M + H - H C l - PhCH] + H]"), and 180(100, [M + H -  
HCl -  C9H 14N2O4]").
a-M ethyl p-benzyl (2i?)-A-(ferr-butoxycarbonyl)aspartate 44
This compound was prepared in a manner identical to a-methyl y-benzyl 
(2i?)-A’-(/er/-butoxycarbonyl)glutamate 36 using p-benzyl
(2i^)-iV-(/er?-butoxycarbonyl)aspartate 43, (1 g, 3.09 mmol) to give the required 
compound as a white crystalline solid in quantitative yield, which did not require 
further purification, mp 65-66 °C {lit.,^^ 67-68 °C (for the (25)-isomer)}; [a]o 
+8.13 (c 1.04 in MeOH) {lit.,^^ -7.1 {c 1.0 in acetone) (for the (25)-isomer)}; 
Unrn(CH2Cl2)/cm-  ^ 3401 (NH), 2977 (CH), 1737 (CO, urethane) and 1500 (CO, 
amide); 0h (200 MHz; C^HCb) 1.44 [9 H, s, (CHs)]], 2.82-3.12 (2 H, m, p-CH]), 
3.71 (3 H, s, CH]), 4.55-4.62 (1 H, m, a-H ), 5.13 (2 H, s, PhCTT]), 5.49 (1 H, br.
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NH) and 6.94-7.75 (5 H. m, Ph); 5c(50.3 MHz; C^HCb) 28.78 [(CH;);], 38.39 
(P-CH;), 50.3 (a-C ), 53.81 (CH;). 6J.90 (PhCH;), 80.51 [C(CH;);], 128.12,
128.56 and 129.09 (A-CH), 136.2 (A -C  quaternary), 156.31 (CO, ester) and
171.29 and 171.98 (CO, esters); m/z (Cl) 338 (4%, [M + H]"), 282 (22, [M + H -  
C4H9 + H D , 238 (8, [M + H -  C5H9O2 + H]'), 91 (100, VhC Rf) and 57 (90,
ca l^.
a-M ethyl (2i?)-A-(rerf-butoxycarbonyl)aspartate ester 45
This compound was prepared in a manner identical to a-methyl 
(27^)-A(re/V-butoxycarbonyl) glutamate 37, using a-methyl p-benzyl (2i?)-A 
(/er/-butoxycarbonyl)aspartate 44 (1 g, 3.07 mmol) to give the required compound 
as a white crystalline solid in quantitative yield, which did not require further 
purification, mp 98-99 °C Uma.x(CH2Cl2)/cm‘  ^ 3510-2840 br (OH and NH) 2927 
(CH), 1745 (CO, urethane), 1662 (CO, amide) and 1611 (CO, amide); 6 h ( 3 0 0  
MHz; C^HCl;) 1.44 [9 H, s, (CH;);], 2.86 (1 H, dd, J  17.7 and 4.1, 1 H of p-CH;),
3.04 (1 H, dd, J  17.1 and 4.1, 1 H of P-CPI;), 3.74 (3 H, s, CH;). 4.58 (1 H, t, J  
4.2, a-H ), 5.55 (1 H, d, J8 .3 , NH) and 8.30 (1 H, br, OH); 6c(75.4 MHz; C-HCl;)
28.35 [(CH;);], 36.73 (p-CH;), 49.78 (a-C ), 53.92 (CH;), 80.54 [C(CH;);)], 
155.62 (CO, urethane), 171.66 (CO, ester) and 176.24 (CO, acid); m/z (El) 247 
(1%, M*), 188 (30, [M -  CO;Me]*) and 57 (100, C a / ) .
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Benzyl [(2i?)-iY-(rer/-butoxycarbonyl)-a-methyl-aspartyi]-p-(25)- 
phenylalaninate diester 47
COoMa
This compound was prepared in a manner identical to that described for 
glutamyl-sarcosyl diester 39 using a-methyl-(27^)-Y-(/g/V-butoxycarbonyl) 
aspartate 45 (910 mg, 3.68 mmol) and benzyl (26)-phenylalaninate
/7-toluenesulfonate 46 (1.52 g, 3.68 mmol), to give the required product as an oil 
which upon trituration with diethyl ether afforded a white solid, which was not 
purified further (1.94 g, 99%), mp 132-133 °C (Found: C, 64.8; H, 6.5; N 5.5. 
C26H32N2O7 requires C, 64.5; H, 6.6; N, 5.8%); (HRMS: found: [M + H ]\ 
485.2282. C26H33N2O7 requires 485.2293); [a]o -4.4 (c 1.1 in MeOH); 
u««(CH;CW/cm-' 3350 (NH), 2983 (CH), 1746 (CO, urethane), 1720 (CO. esters) 
and 1675 (CO, amide); 5h(300 MHz; C-HCU) 1.49 [9 H, s, (CH;);], 2.66 [1 H, dd. 
J  15.9 and 4.6, 1 H of p-CH; (Asp)], 2.91 [1 H, dd, J  17.1 and 16.1, 1 H of p-CH; 
(Asp)]. 3.03-3.16 [2 H, m, p-CH; (Phe)], 3.73 (3 H, s, CH;), 4.49 [1 H, q, J4 .2 , 
a -H  (Asp)], 4.88 [1 H, q, J  5.7, a -H , (Phe)], 5.14 (2 H, AB, J  12.3 and 6, 
PhC77;), 5.62 [1 H, d, y  6, NH (urethane)], 6.04 [1 H, d, J  7.8, NH (amide)] and 
6.96-7.42 (10 H, m. Ph); 5c(75.4 MHz; C^HCIj) 28.42 [(CH;);], 37.93 [P-CH; 
(Asp and Phe)], 50.32 [a -C  (Phe)], 52.74 [a-C  (Asp)], 53.29 (CH;), 67.49 
(PhCH;), 80.1 [C(CH;);], 127.26, 128.71, 128.77 and 129.41 (Ar-CH), 135.05 
and 135.62 (Ar-C quaternary), 155.74 (CO, urethane) and 169.52, 171.27 and
171.91 (CO. esters); m/z (Cl) 485 (12%, [M + H]'), 429 (30, [M + H -  C4H9 + 
H]'), 385 (38, [M + H -  C5H9O2 + H ]!, 356 (100, [M -  C5H7NO;]"), 256 (22, 
CifiHisNO;"), 91 (20, PhCH;") and 57 (32. CÆ ").
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[(2R)-A-(i‘err-ButoxycarbonyI)-a-raethyl-aspartyI]-P-(26)-phenylaIanine 48
This compound was prepared, through catalytic hydrogenolysis, in a manner 
identical to that described for a-methyl (2i?)-A-(/e/-/-butoxycarbonyl) glutamate 37 
using benzyl [a-methyl (27^)-A-(/er/-butoxycarbonyl)aspartyl]-P-(2iS)- 
phenylalaninate diester 47 (I g, 2.14 mmol) to give a white solid in quantitative 
recovery (810 mg), mp 64-65 °C (HRMS: found: [M + H]’, 395.1814. C19H27N2O7 
requires 395.1822); [a ]o +21.25 (c 1.2 in MeOH); Um«(CH;CI;)/cm ' 3333 (NH), 
2926 (CH), 1749 (CO, urethane), 1710 br (CO, ester and acid) and 1664 (CO, 
amide); 5h(300 MHz; C^HCb) 1.37 [9 H, s, (CH,);], 2.61-3.60 (4 H, m, 2 x 
P-CH;), 3.60 (3 H, s, CH;). 4.37 [1 H, br, a -H  (Phe)], 4.71 [1 H, br. a-C H , 
(Asp)], 5.62 [1 H, d, J  8.3, NH (urethane)], 6.74 [1 H, br, NH (amide)] and 
7.06-7.17 (5 H, m, Ph); 5c(50.3 MHz; C^HCl;) 28.33 [(CH;);], 38.01 [P-CH; 
(Asp) and p-CH; (Phe)], 50.81 [a -C  (Asp)], 52.99 (CH;), 53.86 [a -C  (Phe)],
80.56 [C(CH;);], 127.32, 128.82 and 129.81 (Ar-CH), 136.71 (Ar-C quaternary), 
156.35 (CO, urethane), 170.43 and 172.60 (CO, ester and amide) and 174.10 (CO, 
acid); m/z (Cl) 485 (5%, [M + H]*), 339 (15, [M + H -  C4H9 + H]"), 295 (17, [M + 
H -  C5H9O; + H]"), 266 (100, [M -  C;H;NO;]") and 57(14, C4H9").
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Benzyl [(2i^)-iY-(^er^-butoxycarbonyI)-a-methyl-aspart>'l]-P-(2iS)- 
phenyialanyi-P-alanyl [a-methyl(2i?)-gIutamyl]-Y-sarcosinate triester 34
o
Me U
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using [a-methyl (2i?)-iV-(re/7-butoxycarbonyl)aspartyl] 
-P-(26)-phenylalanine 48, (583 mg, 1.36 mmol) and benzyl p-alanyl-[a-methyl 
(2jR)-glutamyl]-y-sarcosinate hydrochloride 42 (513 mg, 1.36 mmol) to give the 
required compound as a white crystalline solid. Purification by silica 
chromatography (94% CHzClz-MeOH) gave compound 34 as a white ciy’Stalline 
solid (750 mg, 72%), mp 82-83 °C (Found: C, 59.2; H, 6.5; N 8.9. CsgHsiNjOn 
requires: C, 59.3; H, 6.7; N, 9.1%); [a]o +6.22 (c 1.24 in 1.45 MeOH); 
UnuxCCHîCy/cm'' 3316 (NH). 2955 (CH). 1756 (CO, urethane) and 1658 (CO, 
amides); 5h (500 IMHz; C^HCU, mixture of rotomers) 1.37 and 1.39 [9 H, 2 x s. 
(CHs)3], 1.96-2.03 [1 H, m, 1 H o fy -C %  (Glu)], 2.11-2.53 [6 H, m. 1 H of p-CHj 
(Glu), y-CHj (Glu) and 1 H of p-CHj (Asp) and CH; (p-Ala)], 2.75-3.04 [3 H. m, 
1 H of p-CH; (Asp) and p-CH; (Phe)], 3.04 and 3.06 (3 H, 2 x s, N-CHj),
3.35-3.48 [2 H, m, CH; (p-Ala)], 3.63, 3.65, 3.67 and 3.69 [6 H, 4 x s, CH; (Asp 
and Glu)], 3.97-4.12 [2 H, m, CH; (Sar)], 4.10-4.44 [2 H, m, 2 x a -H  (Glu and 
Asp) 4.57 (1 H, br, a -H  (Phe)], 5.08 and 5.13 (2 H, 2 x s. PhC%), 5.66 [1 H  d, J  
8.36, NH (urethane)], 6.61-6.91 [3 H, m, 3 x NH (amide)] and 7.11-7.30 (10 H, m, 
Ph); 5c(75.4 MHz; C^HCl;,, mixture of rotomers) 27.98 [p-CH; (Glu)], 28.32 
[(CH;);]. 29.46 [y-CH; (Glu)], 35.24 (N-CH;), 35.52 and 35.92 [2 x CH; 
(P-Ala)], 36.67 (N-CH;), 37.60 [P-CH; (Asp)], 38.22 [p-CH; (Phe)], 49.77 [a-C
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(Asp)], 50.38 [CH; (Sar)], 51.62 [a-C  (Glu)], 52.46 and 52.55 (2 x CH;), 54.53 
[a-C  (Phe)], 67.09 (PhCH;), 79.88 [qC H ;);]. 126.91, 128.36, 128.57, 128,73, 
128.84 and 129.39 (Ar-CH), 135.41 and 136.94 (Ar-C quaternary) and 155.72 
(CO, urethane), 169.22, 170.21, 171,21, 171.83, 172.47 and 173.28 (CO, amides 
and esters); m z  (FAB) 792 (5%, [M f  Na]"), 770 (1. M '). and 120 (100, [C A N  + 
H]-).
[(2jR)-A^-(^err-Butoxycarbonyl)-a-methyl-aspartyl]-|3-(26)-phenylaIanyl 
-p-alanyl-[a-methyi(2i?)-glutamyI]-Y-sarcosinate diester 48
This compound was prepared in a manner identical to a-methyl 
(2i^)-A^-(/er/-butoxycarbonyl)glutamate 37, using triester 34 (250 mg, 0.325 mmol) 
to give the required compound as a white crystalline solid in quantitative recovery, 
which was not purified further, mp 55-56 °C (HRJ/IS: found [M + Na]", 702.2975. 
CsiHjsNjOnNa requires 702.2962); Uma.,(CH;CI;)/cm'' 3296 (NH). 1745 (CO, 
ester) and 1649 (CO, amides); 5h(300 MHz; C^HCI;, mixture of rotomers) 1.35 [9 
H, s, (CH;);], 1.91-2.14 [2 H, m, y-CH; (Glu)], 2.21-2.59 [6 H, m, P-CH; (Glu), 
P-CH; (Asp) and a-C H ; (P-Ala)], 2.76-2.82 [2 H, m, p-CH; (Phe)], 2.82 and 
2.99 (3 H; 2 X s, N-CH;), 2.37 [2 H. br, p-CH; (P-Ala)], 3.60, 3.61, 3.62 and 3.63 
[6 H, 4 X s, CH; (Asp and Glu)], 3.93-4.18 [2 H, m, CH; (Sar)], 4.40 [2 H, br. 2 x 
a -H  (Glu and Asp)] 4.57 [1 H, br, a -H  (Phe)], 5.71 [1 H, d, J 7 ,  NH (urethane)] 
and 7.03-7.58 [8 H, m, Ph and 3 x NH (amides)]; 5c(75.4 MHz; C^HCl;, mixture of 
rotomers) 26.19 [p-CH; (Glu)], 28.36 [C(CH;);], 29.58 [y-CH; (Glu)], 35.29 
(N-CH;), 35.96 and 36.83 [2 x CH; (P-Ala)], 37.64 [p-CH; (Asp)], 38.26 [P-CH; 
(Phe)], 50.08 [a -C  (Asp))] 50.38 [CH; (Sar)], 52.52 [a -C  (Glu)], 52.58 and 54.62 
(2 X CH;), 57.96 [a -C  (Phe)], 80.00 [(CH;);], 126.85, 127.12, 128.51, 128.58, 
129.31 and 129.38 (Ar-CH), 136.66 (Ar-C quaternary), 155.81 (CO urethane), 
170.41, 171.50, 171.67, 171.99, 172.40 and 172.57 (CO. esters and amides) and 
173.50 (CO, add); m/z (FAB) 702 (40%, [M + Na]*), 680 (12, [M -f H ]l, 580 
(45. [M + H -  C A O ; + H]*) and 120 (100, [C A N + H ]! .
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(3-Pentafluorophenyl [(2i?)-A'-(/ert-butoxycarbonyl)-a-methyI-aspartyl]-P- 
(25)-phenyiaIanyI-p-alanyl-[a-methyl (2i?)-glutamyi]-y- sarcosinate triester 49
To a stirred solution of the pentapeptide carboxylic acid 48 (160 mg, 0.22 mmol) in 
CH2CI2 (20 cm^) at 0 °C was added pentafluorophenol (122 mg, 6.63 mmol) 
followed by EDCI (99 mg, 0.33 mmol). The reaction mixture was allowed to warm 
to room temperature and stirred over night. The solution was concentrated under 
reduced pressure to yield a colourless oil which was purified by flash 
chromatography on silica eluting with 95% CHzCE-MeOH to give triester 49 as a 
white crystalline solid (119 mg, 63%), mp 109-110 °C; Umax(CH:Cl2)/cm'^ 3322 
(NH), 2969 (CH), 1757 (CO, urethane) and 1656 (CO, amides); 0h(300 YH z; 
C-HCI3, mixture of rotomers) 1.41 [9 H, s, (CHg)]], 2.02-2.61 [8 H, m, y-CHz 
(Glu), P-CH2 (Glu), P-CH2 (Asp) and CH2 (p-Ala)], 2.79-3.04 [2 H, m, P-CH2 
(Phe)], 3.12 (3 H, s, N-CH3), 3.14-3.59 [2 H, m, CH2 (P-Ala)], 3.67 and 3.68 [6 H, 
2 x s, CH3 (Asp and Glu)], 4.09-4.62 [5 H, m, CH2 (Sar), 2 x a -H  (Glu and Asp) 
and a -H  (Phe)], 5.78 [1 H, d, J7 .2 , NH (urethane)], 6.58, 6.75 and 6.90 [3 H, 3 x 
br, NH (amides)] and 7.08-7 .34  (5 H, m, Ar-H); 5c(75.4 MHz; C^HCb, mixture of 
rotomers) 26.77 [p-CHz (Glu)], 28.75 [(CHs)!], 29.92 [y-CH: (Glu)], 35.97 
(N-CHs), 36.20 and 37.08 [2 x CH2 (P~Ala)], 38.01 [P-CH: (Asp)], 38.59 [P-CH: 
(Phe)], 50.07 [a -C  (Asp)], 50.71 [CH: (Sar)], 51.87 [a -C  (Glu)], 52.11 and 52.75 
(2 X CH3), 54.78 [a-C H  (Phe)], 80.30 [C(CH3)3], 127.30, 128.99 and 129.69 
(Ar-CH), 137.20 (Ar-C quaternary), 156.01 (CO, urethane), 171.28, 171.98 and 
172.73 (CO, esters and amides) and 173.61 (CO, acid); nt'z (ES) 884 (2%, [M + 
K]3, 868 (4, [M + N aH , 846 (7, [M + H]"), 213 (100, C7H2O2F53, 157 (57, 
C6H7NO4']  and 101 (25, CgHgO:").
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Benzyl [(2i?)-A-(^e'r/-butoxycarbonyi)-a“methyl-glutamyi]-(25)-prolinate 
diester 58A
COjMe
This compound was prepared in a manner identical to that described for 
glutamyl-sarcosyl diester 39 using a-methyl (2i^)-iV-(/e/7-butoxycarbonyl)glutamate 
37, (2.03 g, 5.78 mmol) and benzyl (26)-prolinate /?-toluenesulfonate (2.09 g,
6.22 mmol), to give the required compound as colourless oil, which was 
contaminated with 50% benzyl alcohol (2.0 g, 77%), (HRMS; found [M + H]~, 
449.2279, C23H33N2O7 requires 449.2288); u^^CCHiCy/ciri'' 3362 (NH). 2976 
(CH), 1744 (CO. urethane) and 1720 and 1699 (CO, esters); 5h(300 MHz; C^HClj, 
mixture of isomers) 1.40 [9 H, s, (CH;);], 1.81-2.54 [8 H  m, y-CH; and P-CH; 
(Pro and Glu)], 3.36-3.51 [2 H. m, 5-CH; (Pro)], 3.67 and 3.69 (3 H, s, CH;), 
4.05-4.58 (2H. m, 2 X a-H ), 5.04-5.19 (2 H, AB, J  12, PhC%), 5.45 [1 H, d 7  
8.1, NH (urethane)] and 7.20-7.30 (5 H, m, Ph); 5c(75.4 MHz; C^HCl;) 22.51 [c, 
y-CH; (Pro)], 24.64 [/, y-CH; (Pro)], 27.06 [/, p-CH; (Glu)], 27.56 [c, p-CH; 
(Glu)], 28.26 [r, (CH;);], 29.11 [c, (CH;);], 29.99 27.06 [y-CH; (Glu)], 30:62 [t, 
P-CH; (Pro)], 31.29 [c. p-CH; (Pro)], 46.57 [c, 5-CH; (Pro)], 46.99 [/, 5-CH; 
(Pro)], 52.31 (r, CH;), 52.54 (J, CH;), 53.40 [/, a -C  (Glu)], 53.52 [c, a -C  (Glu)], 
58.89 [/, a -C  (Pro)], 59.50 [c, a -C  (Pro)], 66.85 (t, PhCH;), 67.34 (c, PhCH;), 
79.88 [C(CH;);], 127.76, 127.76, 127.91 and 128.86 (Ar-CH), 135.86 (Ar-C 
quaternary), 155.86 (CO, urethane) and 171.23, 172.28 and 173.07 (CO, esters); 
m/z (Cl) 449 (55%. [M + H]*), 349 (20, [M + H -  C A O ;+  H]*) and 206 (100 [M 
+ 2 H -C ,iH ,;N 0 ;n .
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a-M ethyl P-benzyl (2i?)-aspartate diester hydrochloride 59
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using a-methyl p-benzyl (2i?)-iY-(fôrt-butoxycarbonyl)aspartate 
diester 62 (1.0 g, 3.07 mmol), to yield a white hydroscopic solid which was not 
purified any further (820 mg, 98%), mp 139-140 °C {lit.,“ " 137.8-138 °C (for the 
6"-isomer)}; [ajo +17.9 (c 2.0 in MeOH), {lit.,”’" +19.2 {c 4.2 in water) (for the 
5-isomer)}; 3405 (NH), 2967 (CH), 1739 (CO. ester) and 1634
(CO, amide); Sh(200 MHz; C^HCU) 3.35 (2 H, br, p-CHj), 3.65 (3 H, s, CH;), 
4.65 (1 H, br, a -H ), 5.14 (2 H, s, PhC ft), 7.32 (5 H, br, Ph) and 8.86 (1 H, br, 
OH); 5c (50.3 MHz; C^HCb) 34.82 (g-CHi), 50.01 (a-C), 54.12 (CH;), 67.97 
(PhCHj), 128.54, 128.96 and 129.03 (Ar-CH), 137.96 (Ar-C quaternary) and 
168.55 and 170.67 (CO, esters); m/z (Cl) 238 ( 100%, [M -  H -  Cl]').
p-Benzyl [(25)-A^-(^err-butoxycarbonyl)prolyI]-a-methyl (2i?)-aspartate diester 
64A
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using 7/-(?er/-butoxycarbonyl)-(25)-proline, (215 mg, 1 mmol) 
and a-methyl p-benzyl (2i^)-aspartyl diester hydrochloride 59 (273 mg, 1 mmol), to 
give the required compound as colourless oil which was refractory to crystallisation 
(343 mg, 78%) (Found; C, 61.1; H, 7.3; N 6.2. C22H50N2O7 requires: C, 60.8; 
H, 7.0; N, 6.4%) (HRMS: found [M + H]% 435.2124. C22H31N2O7 requires
435.2131); [a]o -5.41 (c 1.21 in MeOH); Um^;(CH;Cl2)/cm ' 3323 (NH). 2976 
(CH), 1739 (CO. urethane) and 1699 (CO, esters); 5h (300 MHz; C’HCI;) 1.43 [9
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H, s, (CH;);]. 1.82-2.22 [4 H, m. y -C H  and g -C H  (Pro)], 2.85 [1 H, dd, J  17.1 
and 4.8, 1 H of p-CH; (Asp)], 3.06 [1 H. dd, J  14.1 and 4.7, 1 H of p-CH; (Asp)], 
3.09-3.45 [2 H, m. 5-CH; (Pro)], 3.66 (3 H, s. CH;), 4.18-4.37 [1 H, m, a -H  
(Pro)], 4.87 [1 H, q, J4 .5 , a -H , (Asp)], 5.09 (2 H  s, PhCff;), 7.28-7.34 (5 H, m. 
Ph) and 7.37 (1 H. br, NH); 5c(75.4 MHz; C^HCl;) 24.14 [c, y-CH; (Pro)], 24.27 
[t, y-CH; (Pro)], 28.40 [t, (CH;);], 28.75 [c, (CH;);]. 28.97 [/, g-CH; (Pro)], 
29.08 [c, p-CH; (Pro)], 36.78 [g-CH; (Asp)], 47.25 [r, 5-CH; (Pro)], 48.49 [c, 
5-CH; (Pro)], 48.68 [a -C  (Asp)], 53.13 (CH;), 60.65 [c, a -C  (Pro)], 60.74 [/, 
a -C  (Pro)], 67.29 (PhCH;), 80.81 [C(CH;);], 128.61, 128.81 and 129.04 (Ar-CH), 
136.20 (Ar-C quaternary), 156.04 (CO, urethane) and 171.06, 171.11 and 171.38 
(CO, esters); m/z (Cl) 435 (100%, [M -!■ H]*), 379 (55. [M + H -  CjH, + H]") and 
335 (97, [ M 4 - H - C 3H5O2+ H]*).
g-Benzyl [(2iî)-A-(rert-butoxycarbonyl)-prolyl]-a-methyl (2A)-aspartate 
diester 64B
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using iV-(/ert-butoxycarbonyl)-(27^)-proline (215 mg, 1 mmol) 
and a-methyl p-benzyl (27^)-aspartyl diester hydrochloride 59 (273 mg, 1 mmol), to 
give the required compound as colourless oil which was refractory to crystallisation 
(321 mg, 74%), (HRMS: found [M + H]% 435.2124. C22H31N2O7 requires
435.2131); [a]o+40.6 (c 1.4 in MeOH); Um«(CH;Ct;)/crn-' 3296 (NH), 2974 (CH), 
1756 (CO, urethane), 1712 (CO, esters) and 1527 (CO, amides); 5h(300 MHz; 
C^HCl;) 1.20 [9 H, s, (CH;);], 1.77-2.02 [4 H, m, y-CH; and g-CH; (Pro)], 2.87 
[1 H. dd, J  17.1 and 4.2, 1 H of g-CH; (Asp)], 3.03 [1 H, dd, J  17.1 and 4.2. 1 H 
of g-CH; (Asp)], 3.36-3.49 [2 H. m. 5-CH; (Pro)], 3.68 (3 H, s, CH;), 4.08 [1 H, 
br, a -H  (Pro)], 4.83 [1 H, q, J  4.5. a -H , (Asp)], 5.09 (2 H. s, PhC%), 6.93 (1 H, 
br, NH amide) and 7.35 (5 H, s, Ph); 5c(75.4 MHz; C^HCl;) 21.05 [c. y-CH; 
(Pro)], 23.7 [r, y-CH; (Pro)], 28.33 [(CH;);], 31.01 [t atui c, g-CH; (Pro)], 36.49 
[p-CH; (Asp)] 46.99 [1 and c, 5-CH; (Pro)], 48.62 [a -C  (Asp)], 52.72 (CH;),
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60.24 [r (ZMüf c, a -C  (Pro)], 66.85 (PI1CH2), 80.58 [C(CH3)3], 128.4, 128.71 and
129.03 (Ar-CH), 135.55 (Ar-C quaternary) and 170.62 (CO, esters and amides); 
m/z (CI) 435 (100%, [M + H ]l, 379 (14, [M + 2 H -  C4H9]") and 335 (23, [M + 2 
H -  C3H9O2]-).
p-Benzyl [(2»5)-prolyl]-a-methyl (2i?)-aspartate diester hydrochloride 65A
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using the prolyl-aspartyl diester 64A, (750 mg, 1.73 mmol), to 
yield a white hydroscopic solid which was not purified any further (590 mg, 93%), 
mp 101-102 =C (Found: C, 55.0; H, 6.3; N 7.4. requires C17H22N2O5CI. 0.2 H.O: 
C, 54.7; H, 6.1; N, 7.5%); (HRMS: found [M + H -  HCl]', 335.1600. C.7H23N2O5 
requires 335,1607); [a]o -28.28 (c 1.32 in MeOH); Um«(CH;Cl2)/cm'' 3189 (NH). 
2959 (CH). 1739 (CO. ester) and 1684 (CO, amide); 5h(300 MHz; C-HCb) 
1.89-1.99 [3 H. m, y-CH;, 1 H of g-CH; (Pro)]. 2.38-2.58 [1 H, m. 1 H of g-CH; 
(Pro)], 2.94 [2 H, d. J  5.7. g-CH; (Asp)], 3.43 [2 H, br, 5-CH;(Pro)], 3.6 (3 H, s, 
CH;), 4.62-4.86 [2 H, m, a -H  (Pro) and a -H , (Asp)]. 5.07 [2 H, q, V 12.3, 
PhC%], 7.27 (5 H, s, Ph), 7.84 (1 H, br, NH) and 9.10 (1 H, d, J  7.5, NH"); 
5c(75.4 MHz; C^HClj) 24,26 [y-CH; (Pro)], 30.39 [g-CH; (Pro)], 36.02 [g-CH; 
(Asp)], 46.74 [5-CH; (Pro)], 49.45 [a-C H  (Asp)], 52.84 (CH;). 59.70 [a-C  
(Pro)], 66.85 (PhCH;), 128.17, 128.3, 128,35 and 128.49 (Ar-CH), 135.45 (Ar-C 
quaternary) and 169.04, 170.11 and 170.86 (3 x CO, esters and amides); m 'z (Cl) 
335 (39%, [M + H -  HCl]'), 303 (82, [M -  HCl -  CH;]") and 213 ( 100,
C 1 Û H 1 5 N O 4 ' ) .
g-Benzyl [(2i?)-prolyl]-a-methyl (2iî)-aspartate diester hydrochloride 65B
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using the prolyl-aspartyl diester 64B (200 mg, 0.46 mmol), to 
give the required compound a colourless oil which was refractory' to crystallisation
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(155 mg. 91%) (HRMS: found [M + H - HCl]', 335.1612. C17H23N2O5 requires 
335.1607); [a]n +24.65 (c 0.43 in MeOH); ^^«(CHzCW/cm-^ 2955 (CH), 1740 
(CO, esters) and 1683 (CO, amide); 5h(300 MHz; C^HCI;) 1.83-2.12 [3 H. m, 
y-CH2 and 1 H of P-CH2 (Pro)], 2.41-2.57 [1 H, m, 1 H of g-CH; (Pro)], 2.95 [2 
H, m, p-CH: (Asp)], 3.41 [2 H, d, 7  7.2, 6-C H 2(Pro)], 3.56 (3 H, s, CHs), 4.70 [1 
H, br, a -H  (Pro)], 4.83 [1 H. q, J4 .5 , a -H , (Asp)], 5.07 (2 H, s, PhC//:), 7.27 (5 
H, s, Ph), 8.00 (1 H, br, NH) and 8.71 (1 H, d, J7.S, NH); Sc (50.3 MHz; C^HCh) 
24.85 [y-CH: (Pro)], 30.80 [p-CH: (Pro)], 36.23 [p-CH: (Asp)], 47.20 [S-CHz 
(Pro)], 49.74 [a -C  (Asp)], 53.34 (CHj), 60.06 [a -C  (Pro)], 67.59 (PhCH:),
128.91 and 129.08 (Ar-CH). 135.80 (Ar-C quaternary) and 169.27, 170.98 and 
171.09 (3 X CO, esters and amide); m i  (Cl) 335 (100%, [M + H -  HCl]'), 303 (1 1, 
[M -  HCl -  CH:]*) and 144 (32, CsHioNO:').
P-Benzyl [a-m ethy l (2jR)-?/-(/ert-butoxycarbonyl)gIutamYl]-Y-(25)-prolyI 
-[a-m ethy l (2i?)-aspartate] triester 66A
NH
OMe
This compound was prepared in a manner identical to that described for the 
glutamyl-sarcosyl diester 39, using a-methyl (2i?)-iV-(fôr/-butoxycarbonyl) 
glutamate 37, (277 mg, 1.19 mmol) and the hydrochloride triester 65A, (440 mg,
1.19 mmol) to give the required compound as a colourless oil which was 
recrystallised using ethyl acetate/hexane to give a white solid (566 mg, 82%), mp 
92-93 °C (Found: C, 57.9; H, 6.8; N 7.2. C28H39N3O10 requires: C, 58.2; H, 6.8; N, 
7.3%); (HRMS: found [M + H ]\ 578.2702. C28H40N3O10 requires 578.2714); [a]o
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-19.2 (c 1.25 in MeOH); u„a,(CH2Cl2)/cm'‘ 3354 (NH), 2956 (CH) and 1742 (CO. 
esters); 5h (300 MHz; C^HCb) 1.46 [9 H, s, (CH,):], 1.64-2.69 [8 H, m, y-CH: and 
P-CH: (Pro and Glu)], 2.87-2.98 [2 H, m, P-CH: (Asp)], 3.37-3.40 [5-CH: 
(Pro)], 3.52 and 3.58 [6 H, s, 2 x CHj], 4,08 [1 H. br, a -H  (Pro)], 4.28-4.38 [1 H, 
br, a -H  (Glu)], 4.83 [1 H, q, J4 .5 , a -H , (Asp)], 5.13 (2 H, s. PhC77:), 5.10 [1 H, 
d, J  5.7 NH (urethane)], 7.29 (5 H, s, Ph) and 7.68 (1 H, d J  5.7, NH); 6c(75.4 
MHz; C^HCh) 22.60 [c, y-CH: (Pro)], 24.56 [1, y-CH: (Pro)], 28.03 [p-CH: 
(Glu)], 28.35 [(CH:):], 28.97 [y-CH: (Glu)], 30.17 [/, p-CH: (Pro)], 32.13 [c, 
p-CH: (Pro)]. 36.87 [P-CH: (Asp)], 46.94 [t, 5-CH: (Pro)], 47.39 [c. 5-CH: 
(Pro)], 48.71 [a -C  (Asp)], 52.56 [a-C  (Glu)], 52.76 [CH: (Asp)], 52.77 [CH: 
(Glu)], 60.23 [a -C  (Pro)], 66.74 (PhCH:), 80.8 [C(CH:):], 128.31, 128.38, 128.59 
and 128.69 (Ar-CH), 135.80 (Ar-C quaternary), 135.91 (CO, urethane) and 
170.31, 170.66, 171.27, 171.51 and 171.62 (CO, esters and amides); m/z (Cl) 578 
(76%, [M + H ] i  and 478 (100, [M + H -  C5H9O2 + H]T
P-Benzyl (a-m ethyl (2if)“AA*(^er^-butoxycarbonyi)g!utamyl]-Y-(2jR)-prolyI 
-[a-m ethy l (2i?)aspartate] triester 66B
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using a-methyl (27?)-A/'-(^erf-butox\'carbonyl)glutamate ester 
37, (144 mg, 0.62 mmol) and the hydrochloride triester 65B, (229 mg, 0.62 mmol) 
to give the required compound as a colourless oil which was refractory to 
crystallisation (250 mg, 70%), (Found; C, 58.4; H, 7.1; N 7.3. C28H39N3O10 
requires: C, 58.2; H, 6.8; N, 7.3%); (HRMS: found [M 4-H]", 578.2707. 
C28H40N3O10 requires 578.2714); [a]o ^ 46.04 (c 1.56 in MeOH); Untax(CH2Cl2)/cm‘^  
3324 (NH), 2956 (CH) and 1742 (CO, esters); 6h(300 MHz; C^HCb) 1.40 [9 H, s, 
(CHs)]], 1.83-2.59 [8 H, m, y-CH] and P-CH2 (Pro and Glu)], 2.87 [1 H, dd, J
17.1 and 4.2, 1 H of P-CH2 (Asp)], 3.01 [1 H, dd, J  17.1 and 4.2, 1 H of p-CH] 
(Asp)], 3.38-3.59 [2 H, m, (6-CH2 Pro)], 3.64-3.70 (6 H, m, 2 x CH3), 4.30 [1 H, 
br, a -H  (Pro)], 4.51 [1 H, d, J5 .1 , a -H  (Glu)], 4.82 [1 H, q, J4 .S , a -H , (Asp)],
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5.11 (2 H, s, PhC%. 5.34 [1 H, br, NH (urethane)], 7.29 (5 H, s, Ph) and 7.43 
[1 H. d J 5 , NH (amide)]; 5c(74.4 MHz; C^HCb) 24.01 [c, y-CH: (Pro)], 24.95 [/, 
y-CH: (Pro)], 27.48 [c. g-CH: (Glu)], 27.93 [(, p-CH: (Glu)], 28.05 [c. (CH;);], 
28.40 [t, C(CH:)3], 30.46 [I, P-CH: (Pro)], 32.07 [c, p-CH: (Pro)], 36.11 [y-CH: 
(Glu)], 36.48 [p-CH: (Asp)], 46.94 [1, 5-CH: (Pro)], 47.39 [c. 5-CH: (Pro)], 
48.76 [c, a -C  (Asp)], 48.83 [t, a -C  (Asp)], 52.43 [a -C  (Glu)], 52.74 [CH; 
(Asp)], 52.81 [CH: (Glu)], 60.48 [t, a -C  (Pro)], 61.33 [c, a -C  (Pro)], 66,91 (/, 
PhCH:), 67.11 (c, PhCH:), 80.81 [C(CH:)3], 128.47, 128.77 and 128.67 (Ar-CH),
135.59 (Ar-C quaternary), 135.73 (CO, urethane) and 170.63, 171.11, 171.23, 
171.38, 171.90 and 173.04 (CO, esters and amides); m/z (Cl) 579(14%, [h.1 + 2 
H ]l, 478 (22, [M + 2 H - C5H9NO2]* and 435 (100, [M + H -  CsHpNO:]*.
P-Benzyl [a-m ethyl (2i?)-glutam yl]-y-(25)-prolyl-[a-m ethyl (27?)-aspartate] 
triester hydrochloride 67A
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using the glutamyl-proiyl-aspartyl triester 66A, (310 mg, 
0.54 mmol) as a starting material, to yield a white hydroscopic solid which was not 
further purified (262 mg, 95%), mp 84-85 °C (HRMS: found [M 4- H -  HCl]i 
478.2182. C23H32N3O8 requires 478.2189); [a]o -41.07 (c 1.34 in MeOH); 
u„™,(CH:Cl2)/cm-‘ 3316 (NH), 2977 (CH) and 1685 (CO, amides); 0h (300 MHz; 
C^HCb) 1.80-2.80 [8 H, m, y-CH: and p-CH: (Pro and Glu)], 2.86-3.04 [2 H, m, 
p-CH: (Asp)]. 3.4-3.59 [6-CH: (Pro)], 3.64, 3.67 and 3.78 [c and l, 6 H, s, 2 x 
CH:)]. 4.26 [1 H, br, a -H  (Pro)], 4.7 [1 H, br, a -H  (Glu)], 4.86 [1 H, q, J 6 , a -H  
(Pro)], 5.11 (2 H, s, PhC%), 7.33 (5 H, s, Ph), 8.15 (1 H, d J7 .8 , NH) and 8.65 (1 
H, br, NH:); ôc(75.4 MHz; C^HCl;) 24.76 [y-CH: (Pro)], 24.91 [P-CH: (Glu)],
29.29 [y-CH: (Glu)], 30.53 [p-CH: (Pro)], 36.37 [p-CH: (Asp)], 47.89 [5-CH: 
(Pro)], 48.94 [a -C  (Asp)], 52.71 [a -C  (Glu)], 52.92 [CH: (Asp)], 53.53 [CH: 
(Glu)], 60.36 [a -C  (Pro)], 67.02 (PhCH:), 128.43, 128.49 and 128.66 (Ar-CH), 
135.67 (Ar-C quaternary) and 169.91, 170.67, 171.61, 172.01 and 172.06 (CO,
EXPERIMENTAL PAGE 144
esters, amides and acid); m/z (Cl) 478 (42%, [M + H -  HCl]"), 460 (88, [M -  2 H
-  Me -  HCl]" and 144 (100, CgHioNO]").
p-Benzyl [a-methyl (2jR)-glutamyl]-y-(2i?)-prolyl-[a-methyI (2i?)-aspartate] 
triester hydrochloride 67B
This compound was prepared in a manner identical to that described for the 
hydrochloride 40 using the glutamyl-proiyl-aspartyl triester 66B, (210 mg, 0.54 
mmol) as a starting material, to yield a white hydroscopic solid which was not 
further purified (164 mg, 88%) mp 87-88 °C (HRMS: found [M 4- H -  HCl]', 
478.2198. C23H32N3O8 requires 478.2189); [a]o +16.4 (c 0.7 in MeOH); 
u«L,(CH:Cl2)/cm'' 2966 (CH). 1750 (CO, esters) and 1636 (CO, amide); 5h(300 
MHz; C^HCb) 1.78-3.11 [10 H. m, y-CH: and p-CH, (Pro and Glu), p-CH: 
(Asp)], 3.39-3.50 [5-CH: (Pro)], 3.63 [3 H. s, CH: (Asp)], 3.77 [3 H, s, CH, 
(Glu)], 4.31 [1 H, br, a -H  (Pro)], 4.49 [1 H, br, a -H  (Glu)], 4.85 [1 H, br, a -H  
(Asp)], 5.1 (2 H, s, PhC ft), 7.32 (5 H, s, Ph), 7.99 (1 H, br,' NH) and 8.42 (1 H, 
br, NH:); 5c(75.4 MHz; C^HCl;) 24.64 [y-CH: (Pro)], 29.53 [P-CH: (Glu)], 29.79 
[y-CH: (Glu)], 30.89 [p-CH: (Pro)], 36.47 [P-CH: (Asp)], 47.86 [0-CH,(Pro)],
49.04 [a -C  (Asp)], 52.86 [a -C  (Glu)], 53.07 [CH: (Asp)], 53.66 [CH: (Glu)], 
60.83 [a -C  (Pro)], 66.88 (PhCH:), 128.39, 128.43, 128.43 and 128.66 (Ar-CH), 
135.75 (Ar-C quaternary) and 169.88, 170.96, 171.13, 171.6 and 172.13 (CO, 
esters, amides and acid); m/z (Cl) 478 (14%, [M + H -  HCl]*), 460 (100, [M -  2 H
-  Me -  HCl]' and 287 (96, CnH uN :0:').
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Benzyl (2iS)-iV-(?er/-butoxycarbonyI)phenylalanyI-j3-alaninate ester 71
.0 .
o
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using A^-(/err-butoxycarbonyl)-(25)-phenylalanine 69 (2.65 g, 
10 mmol) and benzyl (3-alaninate p-toluenesulfbnate salt 70 (3.51 g, 10 mmol) to 
give a white solid. Recystallisation from ethyl acetate/hexane gave the required 
pure dipeptide as a white crystalline solid (3.64 g, 85%), mp 92-93 °C (Found; C, 
67.3; H, 7.1; N, 6.6. C24H30N2O5 requires: C, 67.6; H, 7.1; N, 6.6%) (HRMS: 
found [M + H]% 427.2227. C24H31N2O5 requires 427.2233); [a]o+0.63 (c 0.71 in
1 .4 5  MeOH); u„„(CH2Cl2)/cm'‘ 3325 (NH), 2984 (CH). 1746 (CO. urethane) and 
1673 (CO, ester and amide); 5h(300 MHz; C^HCI;) 1.40 [9 H. s. (CH;);]. 2.40-2.48 
[2 H. m, a-C H ; (3-Ala)], 2.99 [2 H. br. p-CH; (Phe)]. 3.38-3.50 [2 H. m, p-CH; 
(P-Ala)], 4.26 [1 H. m, a - H  (Phe)], 5.08 (2 H. s. PhC%), 6.28 [1 H. br. NH 
(urethane)] and 7.16-7.39 (10 H. m, Ph); 5c(75.4 MHz; C^HCI;) 28.41 [(CH;);]. 
33.96 [a-C H ; (P-AJa)], 34.83 [P-CH; (Phe)], 38.97 [p-CH; (p-Ala)], 56.13 
[a -C  (Phe)], 66.64 (PhCH;). 80.27 [C(CH;);], 127.03, 128.39, 128.55 128.77 and
129.39 (Ar-CH), 135.71 (Ar-C quaternary), 155.4 (CO, urethane) and 171.24 and
172.11 (CO, amide and ester); m/z (Cl) 427 (100%, [M + H]"). 371 (63, [M + H -  
C4H, + H ]1 and 327 (21, [M 4 H -  C ;H ,0; + H]-).
E x p e r im e n t .al Page  146
(25)-A^-(/erf-Butoxycarbonyl)phenylalanyl-P-alanine 72
This compound was prepared in a manner identical to a-methyl 
(2i?)-A^-(/m-butoxycarbonyl) glutamate (37), using (71) (2.13 g, 5 mmol) to give 
the required compound as a white crystalline solid in quantitative yield, which was 
not purified further, mp 89-90 °C [a]o +1 (c 0.65 in MeOH); Omax(CH2Cl2)/cm'  ^
3316 (NH), 3004 br (OH), 1727 (CO, urethane) and 1669 (CO, amide); 0h(200 
MHz; C^HCls) 1.39 [9 H, s, (CH;);]. 2.31-2.49 [2 H, m, a-C H ;, (p-Ala)], 
2.91-3.12 [2 H. m, p-CH; (Phe)], 3.32-3.55 [2 H, m, p-CH; (p-Ala)], 4.28 [1 H, 
br, a -H  (Phe)], 5.09 [1 H. d, J  7.6, NH (urethane)], 6.28 [1 H. br, NH (amide)] 
and 7.12-7.37 (5 H, m, Ph); 5c(75.4 MHz; C^HCI;) 28.35 [(CH;);], 33.61 [a-C H ; 
(P-Ala)], 34.65 [p-CH; (Phe)], 39.24 [p-CH; (p-Ala)], 55.73 [a -C  (Phe)], 80.72 
[C(CH;);], 127.04, 128.65 and 129.58 (Ar-CH), 136.71 (Ar-C quaternary), 156.02 
(CO, urethane), 171.94 (CO. amide) and 175.58 (CO, acid); m/z (Cl) 337 (30%, 
[M + H]"X 281 (100, [M + H - C 4H» + H ]')and 237 (39, [M + H -C ;H ,0 ;+ H ]1 .
(3-Benzyl (25)-A'^(^er^-butoxycarbonyl)phenylalanyl-|3-aIanyl-[a-methyl 
(2i?)-glutamyl]-Y-(2iS)-prolyI-[a-methyl (2jR)-aspartate] triester 68A
\ O f
NH
OMe
This compound was prepared in a manner identical to that described for the 
glutamyl-sarcosyl diester 39, using the phenylalanyl-p-alanyl dipeptide 72 (246 mg,
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0.73 mmol) and tripeptide 67A (376 mg, 0.73 mmol) to give the required 
compound as a colourless oil which was recrystallised using ethyl acetate,Tiexane 
(390 mg, 62%), mp 118-119 °C (Found: C, 59.7; H, 6.7; N 8.4. C40H 53N 5O 12. 0.5 
H2O requires: C, 59.7; H, 6.6; N, 8.7%); [a]o +31.67 (c 1.2 in MeOH); 
Um.x(CH;CI;)/cm ' 3307 (NH), 2955 (CH), 1740 (CO, urethane) and 1655 (CO, 
esters and amides); 5h (500 MHz; CMClj) 1.34 [9 H, s, (CH;);], 1.81-2.42 [10 H, 
m, y-CH; and p-CH; (Pro and Glu) and a -C H ; (P-.Ala)], 2.92-3.13 [4 H, m, 
P-CH; (Asp) and p-CH; (Phe)], 3.37-3.43 [4 H, m, 5-CH; (Pro) and p-CH; 
(P-Ala)], 3.64, 3.69 and 3.71 (c and l, 6 H, s, 2 x CH;), 4.28-4.41 [2 H, m, a -H  
(Phe and Pro)], 4.59-4.63 [1 H, m, a -H , (Glu)], 4.86 [1 H, q, J5 .4 , a -H  (Asp)], 
5.14 (2 H, s, PhC%), 5.22 [1 H. d J5 .6 , NH (urethane)], 6.88 [2 H, br, 2 x NH 
(amide)], 7.18-7.38 (10 H, m, Ph) and 7.76 (1 H, d J  5.4, NH); 5c(75.4 MHz; 
CMCl;) 22.76 [c, y-CH; (Pro)], 24.71 [t, y-C H ; (Pro)], 27.08 [p-CH; (Glu)],
28.36 [(CH;);], 28.87 [y-CH; (Glu)], 30.48 [1. p-CH; (Pro)], 31.63 [c, p-CH; 
(Pro)], 32.18 [a-C H ; (P-Ala)], 35.48 [c, p-CH; (Asp)], 35.88 [c, P-CH; (Asp)],
36.49 [P-CH; (P-Ala)], 39.18 [P-CH; (Phe)], 46.97 [r, 6-CH; (Pro)], 47.51 [c, 
5-CH; (Pro)], 48.84 [c. a -C  (Asp)], 49.31 [1, a -C  (Asp)], 52.02 [a -C  (Glu)], 
52.63 [CH; (Asp)], 52.82 [CH; (Glu)], 55.82 [a-C  (Phe)], 60.11 [t, a -C  (Pro)],
61.37 [c, a -C  (Pro)], 66.89 (PhCH;), 80.03 [C(CH;);], 126.83, 128.44, 128.55,
128.67, 128,73 and 129.52 (Ar-C), 135.46, 135.63 and 135.75 (Ar-C quaternary),
155.45 (CO, urethane) and 170.53, 170.82, 171.02, 171.51, 171.65, 171.78, 
171.85, 172.15 and 172.62 (c and t, CO esters and amides); m/z (FAB) 818 (72%, 
[M + Na]*), 718 (54, [M -  CsH;]*, 696 (73, [M + H -  C ;H ,0; + H]") and 133 
(100).
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P-Benzyl (2*S)-N-(tert-butoxycarbonyl)phenyiaIanyl-p-alanyl-[a-methyl 
(2i?)-glutamyl]-y-(2jR)-prolyl-[a-methyl (2i?)-aspartate] triester 68B
This compound was prepared in a manner identical to that described for the 
glutamyl-sarcosyl diester 39, using the phenylalanyl-P-alanyl dipeptide 72 (246 mg, 
0.73 mmol) and the tripeptide 67B (376 mg, 0.73 mmol) to give the required 
compound a colourless oil which was recrystallised using ethyl acetate/hexane 
(400 mg, 68%), mp 118-119 °C (Found; C, 60.6; H, 6.8; N 8.5. QoHfiNjO.z 
requires: C, 60.4; H, 6.7; N. 8.8%); [aJo+lS.O (c 0.9 in MeOH); u„,^,(CH2C y/cm '‘ 
3325 (NH). 1751 (CO. ester) and 1668 (CO, esters and amides); 5h(300 MHz; 
CMCls) 1.34 [9 H, s, (CH;);], 1.81-2.42 [10 H, m, y-CH;, (3-CH; (Pro and Glu) 
and a -C H ; (P-Ala)], 2.92-3.17 [4 H, m, P-CH; (.Asp) and p-CH; (Phe)], 
3.33-3.59 [4 H, m, 5-CH;(Pro) and p-CH; (P-Ala)], 3.63, 3.65, 3.67 and 3.69 (c 
a M  q 6 H, s, 2 X CH;), 4.28 [1 H, br, a -H  (Pro)], 4.42-4.59 [2 H, m, a -H , (Glu 
and Pro)], 4.82 [1 H, br, a -C H  (Asp)], 5.14 (2 H, s, PhC%), 5.22 [1 H, br, NH 
(urethane)], 6.68 (1 H, br, NH), 3.92 (1 H, br, NH) and 7.18-7.39 (10 H, m, Ph); 
5c(75.4 MHz; C^HCl;) 22.37 [c. y-CH; (Pro)], 24.59 [q y-CH; (Pro)], 25.46 [q 
p-CH; (Glu)], 25.74 [c, p-CH; (Glu)], 28.09 [(CH;);], 30.16 [y-CH; (Glu)], 30.51 
[q p-CH ; (Pro)], 31.86 [c, p-CH; (Pro)], 35.38 [a-CH ; (P-AJa)], 35.48 [q 
P-CH; (Asp)], 35.74 [c, p-CH; (Asp)], 36.06 [P-CH; (P-Ala)], 38.71 [P-CH; 
(Phe)], 46.88 [q 5-CH; (Pro)], 47.26 [c. 5-CH; (Pro)], 48.58 [a -C  (Asp)], 52.12 
[a -C  (Glu)], 52.31 [CH; (Asp)], 52.55 [CH; (Glu)], 55.64 [a -C  (Phe)], 59.86 
[a -C  (Pro)], 66.69 (PhCH;), 79.62 [C(CH;);], 126.58, 128.11, 128.26, 128.31, 
128.43 and 129.24 (Ar-CH), 135.21 and 135.8 (Ar-C quaternary), 155.12 (CO, 
urethane) and 170.5, 170.83, 171.1, 171.25, 171.36, 171.6, 171.85 and 172.29 
(CO, esters and amides); m/z (Cl) 796 (7%, [M + H]*), 696 (77, [M + H -  C A O ; 
+ H]" and 625 (100, [M -  C7H9NO4]*).
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(2A)-A'’-(^e7i‘"Butoxycarbonyl)phenylalanyl-p-aIanyl~[a-methyî (2i?)-glutamyl] 
-y-(26)-prolyl-[a-methyl (2i^)-aspartateJ diester 73A
This compound was prepared in a manner identical to 
a-methyl-(2i^)-//-(/er/-butoxycarbonyl)glutamate 37, using the triester 68A 
(130 mg, 0.165 mmol) to give the required compound as a white crystalline solid in 
quantitative >âeld, which was not purified further, mp 86-87 °C (Found: C, 54.7;
H, 6.5; N 9.3. C33HU7N5O12.H2O requires: C, 54.8; H, 6.8; N, 9.6%); [a]o+31.67 (c
I.2 in MeOH); Um»(CH;Cl;)/cm'' 3324 (NH). 2958 (CH), 1736 (CO, urethane) and 
1653 (CO, esters and amides); 5h(300 MHz; CMClj) 1.29 [9 H, s, (CH;);], 
1.78-2.48 [10 H, m, y-CH; and p-CH; (Pro and Glu) and a-C H ; (p-Ala)], 
2.65-3.17 [4 H, m, p-CH; (Asp) and p-CH; (Phe)], 3.32-3.58 [4 H, m, 6-CH; 
(Pro) and p-CH; (p-Ala)], 3.63, 3.65 and 3.68 (c m idt, 6 H, s, 2 x CH;), 4.21-4.4 
[2 H, m, a -H  (Phe and Pro)], 4.42-4.58 [1 H, m, a -H , (Glu)], 4.78 [1 H, br. a -H  
(Asp)], 5.22 [2H , br, NH (urethane) and OH], 7.08-7.28 (5 H, m, Ph) and
7.35-7.79 (2 H, m, NH); 5c(75.4 MHz; C^HCl;) 22.66 [c, y-CH; (Pro)], 24.65 [1. 
y-CH; (Pro)], 26.64 [P-CH; (Glu)], 28.30 [(CH;);], 28.99 [y-CH; (Glu)], 30.06 [/, 
P-CH; (Pro)], 31.41 [c, p-CH; (Pro)], 32.16 [a-C H ; (P-Ala)], 35.65 [p-CH; 
(Asp)], 35.97 [P-CH; (P-Ala)], 38.85 [P-CH; (Phe)], 47,18 [q 6-CH; (Pro)],
47.50 [c, 5-CH; (Pro)], 48.69 [c, a -C  (Asp)], 49.10 [q a -C  (Asp)], 52.06 [a-C  
(Glu)], 52.62 [CH; (Asp)], 52.74 [CH; (Glu)], 55,91 [a-C  (Phe)], 60.41 [q a -C  
(Pro)], 61.39 [c, a -C  (Pro)], 80.04 [C(CH;);], 126.82, 128.54 and 129.44 
(Ar-CH), 137.01 (Ar-C quaternary), 155.78 (CO, urethane) and 171.19, 171.58,
171.67, 171.95, 172.17, 172.34, 172.56, 172.72, 173.17 and 173.55 (cand i, CO); 
m/z (ES) 728 (5%, [M + Na]*), 706 (6, [M + H ]i, 157 (95, C,Hi,NO0 and 140 
(100, C7H 11NO;").
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(2A)-A^-(tert-Butoxycarbonyl)phenylalanyl-(3-aIanyl-[a-methyl (2i?)-glutamyl| 
-y-(22?)-prolyl-[a-methyl (2i?)-aspartate] diester 73A
This compound was prepared in a manner identical to a-methyl 
(2i?)-/7-(^ert-butoxycarbonyl)glutamate 37, using the triester 68B (130 mg, 0.165 
mmol) to give the required compound as a white crystalline solid in quantitative 
yield, which was not purified further, mp 86-87 °C (Found: C, 54.8; H, 6.8; N 9.4. 
C33H47N5O12.H2O requires: C, 54.8; H, 6.8; N, 9.6%); [a]o +31.67 (c 1.2 in 
MeOH); u„,„(CH2Cl;)/cm'‘ 3322 (NH), 2954 (CH), 1739 (CO, urethane) and 1655 
(CO, esters and amides); 5h(300 MHz; CMCl;) 1.30 [9 H, s, (CH;);], 1.82-2.38 
[10 H, m, y-CH; and p-CH; (Pro and Glu) and a-C H ; (p-Ala)], 2.74-3.05 [4 H, 
m, p-CH ; (Asp) and p-CH; (Phe)], 3.37-3.62 [4 H, m, 5-CH; (Pro) and P-CH; 
(P-Ala)], 3.64 and 3.67 (6 H, s, 2 x CH;), 4.35-4.39 [2 H, m, a -H  (Phe and Pro)], 
4.52 [1 H, br, a -H , (Glu)], 4.77 [1 H, br, a -H  (Asp)], 5.42 [2 H, br, NH 
(urethane)], 7.15-7.22 (5 H, m, Ph) and 7.24-7.74 (3 H, m, NH); 5c(75.4 MHz; 
C^HCl;) 22.71 [c, y-CH; (Pro)], 24.91 [t, y-CH; (Pro)], 25.93 [q p-CH; (Glu)],
26.36 [c. P-CH; (Glu)], 28.31 [(CH;);], 30.84 [y-CH; (Glu)], 31.64 [q p-CH; 
(Pro)], 32.21 [c, P-CH; (Pro)], 35.56 [a-C H ; (p-Ala)], 36.01 [p-CH; (Asp)], 
36.27 [P-CH; (p-Ala)] 38.74 [p-CH; (Phe)] 47.27 [5-CH; (Pro)] 47.64 [q 5-CH; 
(Pro)], 48.81 [q a -C  (Asp)], 49.16 [c, a -C  (Asp)], 52.43 [a-C (Glu)], 52.73 [CH; 
(Asp)], 52.9 [CH; (Glu)], 55,96 [a -C  (Phe)], 59.95 [q a -C  (Pro)], 60.65 [c, a -C  
(Pro)], 79.94 [C(CH;);], 126.81, 128.53 and 129.45 (Ar-CH), 137.05 (Ar-C 
quaternary), 155.7 (CO, urethane) and 171.5, 171.82, 172.08, 172,44, 172.61 and
173.39 (c and I, CO, esters and amides), m/z (ES) 744 (2%, [M + K]”), 728 (8, [M 
+ Na]*), 706 (38, [M + H]% 606 (15, [M + H -  C A O ; + H]3, 157 (95, 
C7H 11NO3*) and 140 (100, C;Hi,NO;*).
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p-Pentafluorophenyl (2tS)-N-(2’er2'-butoxycarbonyl)phenylalanyl-p alanyl 
-[a-m ethyl (2i?)-glutamyl]-y-(2A)-proIyl-[a-methyl (2i?)-aspartate] triester 
74A
To a stirred solution of the pentapeptide carboxylic acid diester 73A (130 mg, 
0.18 mmol) in CH2CI2 (20 cm^) at 0 °C was added pentafluorophenol (102 mg, 0.55 
mmol) followed by EDCI (82 mg, 0.28 mmol). The reaction mixture was allowed 
to warm to room temperature and stirred over night. The solution was 
concentrated under reduced pressure to yield a colourless oil which was purified by 
flash chromatography, on silica eluting with 95% CH2Cl2/MeOH to give triester 
74A as a white crystalline solid (100 mg, 62%), mp 79-81 °C (HRMS: found [M + 
H + Na]X 894.2978. CjsH^NsOnFsNa requires 894.2961); u^xCCHsCy/cm'' 3311 
(NH). 2957 (CH), 1742 (CO, urethane) and 1655 (CO, esters and amides); 6 h ( 3 0 0  
MHz; C^HCh) 1.33 [9 H, s, (CH;);]. 1.80-2.44 [10 H, m. y-CH; and p-CH; (Pro 
and Glu) and a-C H ; (p-Ala)], 2.84-3.57 [8 H, m, p-CH; (Asp), p-CH; (Phe), 
5-CH;(Pro) and p-CH; (P-Ala)], 3.69 and 3.72 (6 H, s, 2 x CH;), 4.27-4.38 [2 H, 
m, a -H  (Phe and Pro)], 4.62 [1 H, br, a - H  (Glu)], 4.99 [1 H, q. J  5.7, a-C H  
(Asp)], 5.27 [1 H, d. y  8,1, NH (urethane)], 6.82-6.96 (2 H, m 2 x NH), 7.12-7.26 
(5 H, m, Ph) and 7.88 (1 H, d, 77.8, NH); 5c(75.4 MHz; CMCI;) 22.73 [c, y-CH; 
(Pro)], 24.71 [r, y-CH; (Pro)], 27.21 [p-CH; (Glu)], 28.30 [(CH;);]. 28.97 [y-CH; 
(Glu)], 30.36 [q p-CH; (Pro)], 31,67 [c. p-CH; (Pro)], 32.17 [a-C H ; (P-Ala)],
35.50 [P-CH; (Asp)], 35.59 [P-CH; (p-Ala)], 39.04 [p-CH; (Phe)], 46.90 [c, 
5-CH; (Pro)], 47.54 [q 5-CH;(Pro)], 48.82 [q a -C  (Asp)], 49.48 [e, a -C  (Asp)],
51.82 [a -C  (Glu)], 52.63 [CH; (Asp)], 53.08 [CH; (Glu)], 55.89 [a -C  (Phe)], 
60.10 [q a -C  (Pro)], 61.35 [c, a -C  (Pro)], 79.95 [C(CH;);], 126.84, 128.54, 
128.90 and 129.44 (Ar-CH). 137.04 (Ar-C quaternary), 136.40, 138.10, 139.57,
141.60 and 142.8 (C-F, p ^ ), 155.51 (CO, urethane), 166.69 (CO, pfp) and 170.78, 
171.74, 171.79, 172.88 and 172.60 (c and q CO, esters and amides), m/z (ES) 895 
(34%, [M + Na]"), 873 (41, [M + H]q 196 (27, C,H.oNO;l, 158 (36. CsHsNOq) 
and 101 (100, C A O ;").
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P-Pentafluorophenyl (2A)-A'-(z‘e/t-butoxycarbonyl)phenylalanyl-p-alanyl- 
[a-methyl (2i?)-glutamyl]-y-(2i?)-prolyl-[a-methyl (2i?)-aspartate] triester 74B
To a stirred solution of the pentapeptide carboxylic acid diester 73B (120 mg, 0.17 
mmol) in CH2CI2 (20 cm^) at 0 °C was added pentafluorophenol (94 mg, 0.51 
mmol) followed by EDCI (76 mg, 0.26 mmol). The reaction mixture was allowed 
to warm to room temperature and stirred over night. The solution was 
concentrated under reduced pressure to yield a colourless oil which was purified by 
flash chromatography on silica eluting with 95% CH2Cl2/MeOH to give triester 74B 
as a white crystalline solid (100 mg, 67%), mp 80-81 °C (HRMS: found [M + H + 
Na]'. 894,2934. CsAaNsOnFjNa requires 894.2961); Um«(CH2Cl;)/cm' 3300 
(NH). 2956 (CH), 1743 (CO, urethane) and 1652 (CO, esters and amides); 5h(300 
MHz; C^HCl;) 1.35 [9 H, s, (CH;);], 1.86-2.44 [10 H, m, y-CH; and p-CH; (Pro 
and Glu) and a -C H ; (P-Ala)], 2.84-3.62 [8 H, m, p-CH; (Asp), p-CH; (Phe), 
5-CH;(Pro) and p-CH; (p-Ala)], 3.73 and 3.77 (6 H, s, 2 x CH;), 4.20-4.58 [3 H, 
m, a -H  (Phe, Pro and Glu)], 4.92 [1 H, br, a -H  (Asp)], 5.18 [1 H, br, NH 
(urethane)], 6.84-6.99 (2 H, m, 2 x NH). 7.04-7.38 (5 H, m, Ph) and 7.45 (1 H, br, 
NH); 5c(75.4 MHz; C^HCl;) 24.44 [y-CH; (Pro)], 27.00 [P-CH; (Glu)], 30.74 
[(CH;);], 30.84 [y-CH; (Glu)], 31.23 [p-CH; (Pro)], 32.74 [a-C H ; (P-.Ala)],
34.19 [p-CH; (Asp)], 35.65 [p-CH; (P-Ala)], 37.83 [p-CH; (Phe)], 49.65 
[5-CH; (Pro)], 48.82 [/, a -C  (Asp)], 50.97 [c, a -C  (Asp)], 52.64 [a -C  (Glu)],
52.82 [CH; (.Asp)], 53.23 [CH; (Glu)], 56.84 [a-C  (Phe)], 62.10 [a -C  (Pro)], 
82.17 [C(CH;);]. 125.22, 129.05, 130.69 and 131.57 (Ar-CH), 137.77 (Ar-C 
quaternary), 139.17 (C-F, pfp), 157.61 (urethane. CO) and 171.71, 171.82, 172.93 
and 173.71 ( c and t, CO, esters and amides); m/z (ES) 895 (11%, [M + Na]*), 873 
(32, [M + H]‘. 212 (100) and 196 (47, C;Hi«NO/).
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Cycl0“[p“AIa-(2jR)-GIU“CX“OîVIe-Y-(2»S)-Pr0“(2jR)-Asp-ct-ONIe“(3-(2»S)-Phe-] 52A
O H COglVIe
H o  H COzlVIe
To a stirred solution of the N-(/e7-/-butoxycarbonyl)-protected pentafluorophenyl 
ester 74A (78 mg, 0.09 mmol) in CH2CI2 (10 cm"*) was added trifluoroacetic acid 
(10 cm^). The reaction mixture was stirred for 1 h when the reaction was judged to 
be complete by TLC. The solution was concentrated under reduced pressure, 
tritrated with diethyl ether (10 cm"*), and the precipitate was collected and 
thoroughly dried under high vacuum for 6h. The residue was dissolved in CH2CI2 
(500 cm^), treated with DIPEA (316 mm^) and then left to stir under Ar for eight 
days. The reaction mixture was concentrated under reduced pressure and 
immediately purified by flash chromatography on silica eluting with 94% 
CH2Cl2-MeOH to give a white crystalline solid which was recrystallised from 
acetone/diethyl ether (28 mg, 52%) mp >220 °C (decomp.) (Found: C, 55.8; H, 
6.4; N 11.3. C2SH37N5O9.H2O requires: C, 55.8; H, 6.1; N, 11.6%) (HRMS: found 
[M + 588.2685. CisHsgNgOg requires 588.2683); Umax (Nujol)/cm*‘ 3360 (NH)
and 1719 (CO, esters and amides); 0h[500 MHz; (C% )2S0] 1.79-1.90 [5 H, m, 1 
H of P-CH2 (c, Glu), P-CH2 {t, Glu) and y-CH2 (/, Pro)], 1.92-2.07 [6 H, m, 1 H 
of P-CH2 {c, Glu), y-CH2 (c, Pro), P-CH2 (r, Pro) and 1 H of P-CH2 (c. Pro)],
2.11-2.27 [6 H, m, 1 H of P-CH2 (c. Pro), 1 H ofy-CHz (c, Glu), y-CH: (4 Pro) 
and 1 H of a-C H : (c and t, a-Ala)], 2.34-2.61 [5 H, m, 1 H of y-CH: (c, Glu), 1 
H of P-CH2 (c andt, P-Ala) and 1 H of p-CH: (c and t. Asp)], 2.68-2.82 [3 H, m.
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1 H of P-CH; (c and t, Asp), 1 H of P-CH; (t, Phe)], 2.90-3,03 [2 H, m, 1 H of 
P-CH; (c and t, Phe)], 3.08-3.25 [3 H, m, 1 H of p-CH; (c, Phe) and 1 H of 
a -C H ; (c and t, p-Ala)], 3.40-3.59 [6 H, m, 6-CH; (c and t. Pro) and 1 H of 
p-CH; (c and t, p-Ala)], 3.62, 3.64, 3.66, and 3.71 (12 H, s, 2 x CH-, c and t), 
4.13-4.25 [3 H, m, a -H  (c, Phe), a -H  ((, Glu) and a -H  (c. Asp)], 4.28 [1 H, dd, /  
8.3 and 2.7, a -H  (c. Pro)], 4.38-4.44 [2 H, m, a -H  (c, Glu) and a -H  (q Pro)],
4.47 [1 H, sep, J  3.1, a -H , (q Asp)], 4.56 [1 H, q, sep, J  5.5, a -H , (q Phe)],
7.21-7.34 (10 H, m, c andt, Ph), 7.78 [1 H, t, 75.5, NH (c, p-Ala)], 7.88 [1 H, t, 
J  5.5, NH (q P-Ala)], 8.11 [1 H, d, J  6.7, NH (c. Asp)], 8.20 [1 H, d, J9 .2 , NH (q 
Phe)], 8.21 [1 H, d, J7 .9 , N H (q Glu)], 8.30 [1 H, d, V 7.3, NH (c, Phe)], 8.32 [1 
H, d, 77 .9 , NH (c, Glu)], and 8.38 [1 H, d, 7  7.3, NH (q Asp)]; 5c[125.8 MHz; 
(C^H3);S0 ] 21.88 [c, y-CH; (Pro)], 23.92 [q y-CH; (Pro)], 26.02 [c, p-CH; 
(Glu)], 26.66 [q p-CH; (Glu)], 28.87 [q y-CH; (Glu)], 29.31 [c, y-CH; (Glu)],
30.53 [q P-CH; (Pro)], 31.46 [c, P-CH; (Pro)], 34.49 [a-C H ; (P-Ala)], 34.78 [c, 
P-CH; (Asp)], 34.93 [c, p-CH; (Asp)], 35.57 [p-CH; (p-Ala)], 37.77 [c, p-CH; 
(Phe)], 39.18 [q p-CH; (Phe)], 46.31 [q 6-CH ; (Pro)], 46.84 [c, 5-CH; (Pro)],
49.4 [c, a -C  (Asp)], 50.1 [q a -C  (Asp)], 50.8 [a-C  (Glu)], 51.79, 51.9, 52.05 and 
52.14 (c 4- q CH;), 53.71 [q a -C  (Phe)], 55.52 [c, a -C  (Phe)], 59.65 [q a -C  
(Pro)], 59.71 [c, a -C  (Pro)], 126.12, 127.91, 128.03, 128.92 and 129.03 (Ar-CH),
137.82 and 137.86 (Ar-C quaternary) and 168.88, 170.13, 170.98, 171.08, 171.14,
171.3, 171.42, 171.96, 172.18 and 172.6 (CO, ester and amides); m/z (Cl) 588 
(8%, M*). 556 (25, [M -  C H ;]i and 391 (100, [M -  CzHisNjO;]*).
Cydo-[p-Ala-(2.R)-Glu-a-OMe-y-(2i?)-Pro-(2q?)-Asp-a-OMc-p-(25)-Phe-] 52B
This compound was prepared in a manner identical to that described for the 
macrocycle 52A using the A'-(/er/-butoxycarbonyl)-protected pentafluorophenyl 
ester 74B (89 mg, 0.1 mmol) to give the required compound as a colourless oil, 
which was immediately purified by flash chromatography on silica eluting with 94% 
CH2Cl2/MeOH. This gave a crystalline solid which was recrystallised from
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acetone/diethyl ether to yield a white crystalline solid, mp >222 “C (decomp.) 
(Found: C, 55.9; H, 6.2; N 11.3. C2SH37N5O9-H2O requires: C, 55.8; H, 6.1 
N, 11.6%) (HRMS: found [M + H]', 588.2654. CzgHssNaOp requires 588.2670) 
Unia.x(CH2Cl2)/cm'^ 3395 (NH), 1743, 1724 and 1660 (CO, esters and amides) 
5h(500 MHz; (C % );SO ) 1.76-2.03 [12 H, m, 1 H of g-CH; (c and l. Pro), 1 H of 
p-CH; (c. Pro), y-CH; (c and I, Pro), P-CH; (c and t, Glu) and 1 H of y-CH; 
(/, Glu)], 2.18-2.67 [12 H, m, I H of y-CH; (c, Glu), 1 H of y-CH; {c and i, Glu), 
1 H of p-CH; (q Pro), a -C H ; (c and t, PAla) and p-CH; (c and /, Asp)],
2.77-3.15 [6 H, m, 1 H of p-CH; (c and I, p-Ala) and p-CH; (c and q Phe)], 3.38-
3.48 [5 H, m, 1 H of p-CH; (c andt, p-Ala) and 5-CH ;(c andt. Pro)], 3.68, 3.72, 
3.74, and 3.78 [12 H, s, 2 x CH;, c and (], 4.29-4.5 [8 H, m, a -H  (c and l. Phe), 
a -H  (c and t, Glu), a -H  (c and I, Asp) and a -H  (c and t. Pro)], 7.23-7.42 (10 H, 
m, c andt, Ph), 7.9-7.93 [2 H, m, NH (c, p-Ala), NH (q Glu)], 7.99-8.03 [2 H, m, 
(c. Asp), NH (q P-Ala)] and 8.2-8.29 [4 H, m, NH (c and t, Phe) NH (c, Glu) and 
NH (q Asp)]; 5c(75.4 MHz; (C^H;);SO) 22.62 [c, y-CH; (Pro)], 25.06 [q y-CH; 
(Pro)], 25.73 [q p-CH; (Glu)], 26.04 [c, p-CH; (Glu)], 28.98 [c and t, y-CH; 
(Glu)], 30.23 [q p-CH; (Pro)], 31.97 [c, p-CH; (Pro)], 35.46 [a-CH ; (P-Ala)],
35.71 [q P-CH; (Asp)], 36.09 [c, p-CH; (Asp)], 36.60 [c, P-CH; (p-Ala)], 37.03 
[q P-CH; (P-Ala)], 38.03 [c, p-CH; (Phe)], 38.74 [q p-CH; (Phe)], 47.01 
[c, 5-CH; (Pro)], 47.77 [q 5-CH; (Pro)], 50.05 [a -C  (Asp)], 51.58 [a -C  (Glu)],
52.69, 53.13 and 53.23 [c andt, CH;)], 54.61 [a-C  (Phe)], 60.47 [q a -C  (Pro)],
61.41 [c, a -C  (Pro)], 126.89, 127.16, 128.68, 129.16 and 129.3 (Ar-CH), 136.22 
and 137.32 (Ar-C quaternary) and 170.35, 171.45, 171.52, 172.04 and 172.68 
(CO, esters and amides); m/z 588 (9%, M ^, 556 (27, [M -  CH;]") and 391 ( 100, 
[M -C l;H i6N ;0;]").
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y-Benzyl (2/?)-iY-(9-fluorenylmethoxycarbonyi)glutamate 79
H COgH
To an ice-cold stirred suspension ofy-benzyl (2i?)-glutamate 78 (1 g, 4.22 mmol) in 
water (30 cm"") was added potassium carbonate (945 mg, 6.75 mmol). A pre­
stirred solution of 9-fluorenylmethoxycarbonyl chloride (1.21 g, 4.64 mmol) in 
dioxane (30 cm’) was added. The resulting solution was warmed to room 
temperature and stirred for 4 hours, then poured into water (20 cm"") and the 
dioxane was removed under reduced pressure. The resulting solution was washed 
with diethyl ether (2 x 50 cm"’) and acidified to pH 2 at 0 °C with 6 mol dm' HCl. 
The resulting solution was then extracted with diethyl ether (3 x 50 cm''). The 
ethereal solutions were combined, dried (MgS04) and the solvent removed under 
reduced pressure to yield a colourless oil. Crystallisation with ether/light petroleum 
gave a white solid (1.24 g, 72%) mp 137-8 °C (lit.™  136-8 °C (for the i'-isomer)} 
(Found: C. 70.3; H, 5.4; N 3. Calc. C, 70.6; H, 5.5; N. 3%) (HRMS:
found [M + Hj", 460.1766. Cz^HzeNO; requires 460.1760); [a]c -12.9 (c 1.51 in 
MeOH) {lit., '^* [a]u+13.8 {c 1.5 in MeOH (for the 5-isomer)}; ^^«(CHzCl:)/cm'' 
3365 (NH), 2965 (CH), 1741 (CO, urethane) and 1702 (CO, ester); Ôh(300 MHz; 
C^HCl;) 1.95-2,53 (4 H, m, y-CHi and p-CHj), 4.09-4.61 (6 H, m, fluorenyl 
CH2O, fluorenyl CH and a -H ), 5.12 (2 H, s, PhC%), 5.48 [1 H, d, J  8.1, NH 
(urethane)] and 7.26-7.76 (13 H, m, Ph); 5c(75.4 MHz; C^HCb) 27.39 (p-CHi),
30.48 (Y-CH2). 47.26 (fluorenyl CH), 53.32 (a-C), 66.88 and 67.38 (2 x CH2O), 
120.13, 125.17, 127.23, 127.89, 128.44, 128.51 and 127.83 (Ar-CH), 141.46, and
143.73 (Ar-C quaternary) 156.13 (CO, urethane) and 172.5 (CO, ester); m r  (Cl) 
460 (8%, [M-i-H]*), 179 (100, C14H 11*) and 130 (64, CsHjNOs'*).
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a-M ethyl y-benzyl (2i?)-N-(9-fluorenylmethoxycarbonyl)glutamate 80
This compound was prepared in a manner identical to a-methyl y-benzyl 
(2i^)-//-(^er/-butoxycarbonyl)gIutamate diester 36, using ester 79 (1.04 g, 
2.54 mmol) to give the required compound as a white crystalline solid in 
quantitative yield, which did not require further purification, mp 97-98 °C (Found: 
C, 71.0; H, 5.7; N, 3.0. requires: C, 71.0; H, 5.8; N, 3.0%) (HRMS:
found [M + H ]\ 474.1913. CsAgNOg requires 474.1917); [alo+16.7 (c 0.45 in 
MeOH); o„„(CH2Cl2)/cm-‘ 3375 (NH). 2955 (CH), 1736 (CO, urethane) and 1536 
(CO, esters); 5h(300 MHz; C^HCb) 1.95-2.58 (4 H, m, y-CHz and P-CH2), 3.75 (3 
H, s, CH3), 4.09-4.58 (4 H, m, flourenyl CH2O, fluorenyl CH and a-H ), 5.13 (2 H, 
s. PhCHz), 5.57 [1 H, d, J7 .5  NH (urethane)] and 7.23-7.83 (13 H, m. Ph); 5c(50.3 
MHz; C^HCb) 27.69 (p-CHj), 30.37 (y-CH;), 47.32 (fluorenyl CH), 52.69 (CH),
53.48 (a-C ), 66.71 and 67.19 (2 x CH;0), 120.16, 125.24, 127.26, 127.89, 128.45 
and 128.76 (Ar-CH), 135.91, 141.48, 143.89 and 144.07 (Ar-C quaternary) 156.15 
(CO, urethane) and 172.50 and 172.66 (CO, esters); m/z (Cl) 474 (32%, [M 4- H ]l, 
252 (100, CijHisNO/), 179 (91, CsHwNOs") and 144 (57, C«HwNO;l.
y-Allyl (2i?)-glutamate hydrochloride 82
HO2C H
cr H3N"
To a stirred suspension of (27^)-glutamic acid 81 (2.21 g, 15 mmol) in dry allyl 
alcohol (70 cm^) under N^, was added dropwise chlorotrimethylsilane (4.75 cm', 
47.5 mmol) dropwise. The resulting solution was stirred at RT for 18 h., after 
which diethyl ether (200 cm^) was added at 0 °C to give a white precipitate which 
was collected by filtration, washed with diethyl ether and dried under vacuum (2.18
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g, 65%) mp 131-132 °C {lit., '^* 130-132 °C (for the (25)-isomer)}, [ctjo - 22.1 (c 
1.1 in MeOH) {lit.^*, [a]o 4-22.5 (c 1 in MeOH), (for the (25) isomer)}; 
u„..(CH2Cl2)/cm'' 2863 br (OH) and 1729 (CO, ester); 5h(300 MHz; ^H;0)
2.08-2.21 (2 H, sep, J 7.2, P-CHz), 2.55 (2 H, t, 7 6.0, y-CHz), 3.98 (1 H, t, J6.9, 
a-H ), 4.52 (2 H, d, J5.7 , CH2O), 5.21 (2 H. dd, J  15.9, 1.5 C%=CH) and 5.84 (1 
H, m, CH2=C/7); 5c(75.4 MHz; % 0 )  25.00 (P-CH2), 29.75 (-/-CHi), 52.31 
(a-C ), 66.28 (CH2O), 171.79 (CO, ester) and 174.23 (CO, acid); m/z (Cl) 188 
(84%, [ M - C in  and 130 (100, CsHsNOj').
y-AlIyl (2/?)-A-(9-fluorenylmethoxycarbonyl)glutamate 83
This compound was prepared in a manner identical to y-benzyl {2R)~N- 
(9-fluorenylmethoxycarbonyl)glutamate 79, using y-allyl (IR)-glutamate 
hydrochloride 82, (943 mg, 4.22 mmol) to give the required compound as a white 
crystalline solid in quantitative recovery, which was not purified further, mp 113-4 
°C (HRMS: found [M + H]", 410.1595. C23H24NO6 requires 410.1603); [a jo -30.4  
(c 1.3 in MeOH); u„„„(CH2Cl2)/cm'‘ 3364 (NH), 2965 (CH) and 1746 (CO, 
urethane); 5h(300 MHz; C^HCh) 2.01-2.58 (4 H, m, y -C H  and P-CH,), 4.18-4.62 
(6 H, m, 2 X  CH2O, fluorenyl CH and a-H ), 5.21-5.58 (2 H  m, CH;=CH), 5.58 [1 
H, d, y  7.8, NH (urethane)], 5.82-5.98 (1 H, m, CHz^CTT) and 7.23-7.79 (8 H, m, 
Ph); 5c(75.4 MHz; C^HCls) 27.42 (P-CH2), 30.40 (y-CHz), 47.24 (fluorenyl CH), 
53.39 (a-C ), 65.67 and 67.34 (2 x CH,0). 118.68 (CH:=CH), 120.13, 125.23,
127.25 and 127.89 (Ar-CH), 132.03 (CH,=CH), 141.46, 143.76 and 143.97 (.Ar-C 
quaternary) 156.42 (CO, urethane) and 172.5 and 175.66 (CO, ester and acid); m/z 
(Cl) 424 (17%, [M + 2 H + Na]"), 410 (64, [M -  CO2Ü , 181 (100, C14H 1D  and 
130 (48, CjHsNOs").
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a-M ethyl Y-allyI(2i?)-A'-(9-fluorenyImethoxycarbonyl)glutamate 84
This compound was prepared in a manner identical to diester 36, using ester 83 
(1.04 g, 2.54 mmol) to give the required compound as a white crystalline solid in 
quantitative )ield, which did not require further purification mp 84-85 °C (Found; 
C, 67.9; H, 5.8; N 3.5. CzÆsNOg requires: C, 68.1; H, 5.9; N, 3.3%) (HRMS: 
found [M + FI]', 424.1766. C24H26NO6 requires 424.1760); [a]o+22.14 (c 0.56 in 
MeOH); u.^,(CH2Cl2)/cm ' 3364 (NH), 2965 (CH) and 1751 (CO. urethane); 
5h(300 MHz; C^HCb) 1.95-2.53 (4 H. m, y-CHj and g-CHz), 3.75 (3 H, s, CHs), 
4.09-4.61 (5 H, m, 2 X CHjO, fluorenyl CH and a-H ), 5.21-5.38 (2 H, m, 
C%=CH), 5.56 [1 H, d, y  8.1, NH (urethane)], 5.84-5.97 (1 H, m, CH:=CH) and 
7.26-7.77 (8 H, m, Ph); 5c(75.4 MHz; C^HCI,) 27.04 (g-CHz), 30.29 (y-CHi),
47.29 (fluorenyl CH), 52.70 (CH,), 53.48 (a-C ), 65.54 and 67,21 (2 x CH;0), 
118.61 (CHr=CH), 120.14, 125.22, 127.23 and 127.87 (Ar-CH), 132.14 
(CH2=CH), 141,46, 143.85 and 144.03 (Ar-C quaternary) 156.13 (CO, urethane) 
and 172.50 (CO. ester); m/z (Cl) 424 (45%, [M + H ]l. 179 (94, C14H ,,’), 144 (78, 
CsHioNO,") and 57 ( 100, C4H9’).
a-M ethyl (2i?)-iV-(9-fluorenylmethoxycarbonyl)glutamate ester 77
OA OH
To a stirred solution of diester 84 (423 mg, 1 mmol) and phenylsilane (247 mm% 2 
mmol) in dry DCM (30 cm'’) under Ar, was added tetrakis (triphenylphosphine) Pd 
(0) (23 mg, 0.02 mmol). The reaction mixture was allowed to stir at room
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temperature for 2 h (after which time no starting material was observed by TLC) 
and then concentrated under reduced pressure. The crude material was purified 
using silica chromatography (60% ethyl acetate/hexane) to give a white solid (310 
mg, 81%) mp 130-131 °C (Found: C, 64.6; H, 5.4; N 3.7. C21H21NO6 requires: 
C, 64.8; H, 5.5; N, 3.7%) (HRiMS: found [M + H]% 384.1443. C21H22NO6 requires 
384.1447); [a]o +19.5 (c 0.63 in MeOH); Um.,(CHiCl:)/cm-' 3355 (NH), 2965
(CH) and 1732 (CO, urethane); 5h(300 MHz; C’HCI,) 1.92-2.57 (4 H, m, y-CH, 
and P-CHî), 3.75 (3 H, s, CH,), 4.18-4.56 (4 H, m, CH2O, fluorenyl CH and 
a-H ), 5.45 [1 H, d, J  7.2, NH (urethane)] and 7.25-7.77 (8 H, m, Ph); 6c(75.4 
MHz; C^HCI,) 27.57 (P-CH2), 29.89 (y-CH;), 47.28 (fluorenyl CH), 52.74 (CH,),
53.29 (a-C ), 67.24 (CH2O), 120.14, 125.19, 127.23 and 127.88 (Ar-CH), 141.47 
and 143.81 (Ar-C quaternary), 156.15 (CO, urethane) and 177.54 (CO, acid); m/z
(CI) 384 (7%, [M + H ]l, 179 (31, C i M n )  and 144 (100, CsHioNOs").
P-Allyl (2i?)-aspartate hydrochloride 87
This compound was prepared in a manner identical to y-allyl (2/^)-glutamate 
hydrochloride 82, using (2i?)-aspartic acid, (5.33 g, 40 mmol) to give the required 
compound as a white crystalline solid, which did not require further purification 
(7.3 g, 87%), mp 184-185 °C {lit.,“ '' 185-6 °C (for the (25)-isomer)}; [a]n +7.7 
(cS.O in AcOH) (lit.,^'* -9.5 (c 8.0 in AcOH) (for the (25)-isomer)} ; 
u„a.,(CH2Cl2)/cm'’ 3364 (NH), 2965 (CH), 1751 (CO, ester) and 1536 (anüde); 
6h(300 MHz; % 0 )  3.03-3.05 (2 H, m, p-CH,), 4.27 (1 H, t, J  4.8, a -H ), 4.60 
(2H, d, y  6, CH2O), 4.65 (3 H, s, NH,^, 5.15-5.27 (2 H, m, C%=CH) and
5.77-5.90 (1 H, m, CR2=CH); 5c(75.4 MHz; ^HiO) 34.05 (P-CH2), 49.37 (a-C ), 
66.78 (CH2O), 119.00 (CH2=CH), 131.47 (CH2=CH), 170.94 (CO, ester) and
171.19 (CO, add); m.'z (Cl) 174 (100%, [M + H -  HCl]').
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P-Allyl (2i?)-.A/-(9-fluorenyImethoxycarbonyl)aspartate 88
This compound was prepared in a manner identical to y-benzyl {2R)~N- 
(9-fiuorenylmethoxycarbonyl)glutamate 83, using y-aliyl (2i?)-aspartate 
hydrochloride 87, (530 mg, 2.5 mmol) to give the required compound as a white 
crystalline solid in quantitative yield, which was not purified further (930 mg, 94%), 
mp 110-111 °C; (Found: C, 66.3; H, 5.4; N 3.6. C22H22NO6 requires: C, 66.1; H, 
5.4; N, 3.5%) (HRMS: found [M + H]‘, 396.1450. C22H22NO6 requires 396.1453); 
[a]D+3.04 (c 0.46 in MeOH); Um«(CH2Cl2)/cm-' 3363 (NH), 2956 (CH) and 1741 
(CO, urethane); 5h(300 MHz; C^HClj) 2.94 (1 H. dd, 7-18 and 3.4, IH  of 
3-CH 2), 3.13 (1 H, dd. J  18 and 3.45, 1 H of g-CH;), 4.20-4.79 (6 H, m. 
2 X CH2O, fluorenyl CH and a-H ), 5.21-5.38 (2 H, m, C%=CH), 5.82-6.21 [2 H, 
m. CH2=CH and NH (urethane)], 7.25-7.82 (8 H, m, Ph) and 9.01 (1 H, hr, OH); 
Sc(75,4 MHz; C^HCU) 36.54 (p-CHj), 47.20 (fluorenyl CH), 50.51 (a-C ), 66.07 
and 67.60 (2 x CH2O), 119.05 (CH2=CH), 120.510, 125.28, 127.26, 127.53,
127.90 and 128.41 (Ar-CH), 131.98 (CHz^CH), 141.44, 143.78 and 143.92 (Ar-C 
quaternary) 156.35 (CO, urethane), 170.96 (CO, ester) and 175.46 (CO, acid); m/z
(Cl) 396 (12%, [M + H]") and 179 (100, C,Æiii*).
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P-Aliyl (2i?)-A-(9-fluorenylmethoxycarbonyl)aspart>i-W ang resin 85
Allyiq
A suspension of Wang resin (500 mg, 0.84 mmol g’  ^ OH substitution) and 3-allyl 
(2i?)-A-(9-fluorenyimethoxycarbonyi)aspartate 88 (660 mg, 1.67 mmol) were 
stirred in dry DMF (2.5 cm^) at RT under N] for 15 min. Pyridine (100 mm ,^ 
2.77 mmol) and 2,6-dichlorobenzoyl chloride (105 mm^, 1.67 mmol) were added 
and the suspension stirred at room temperature for 20 h, then filtered and washed 
with DMF (25 cm''), DCM (25 cm") and methanol (25 cm"). The percentage 
loading was checked determined to be 70% (see Appendix 4). The remaining 
hydroxyl groups of the resin were benzoylated with benzoyl chloride and pyridine in 
DCM for 2 h., washed with DMF (25 cm"), DCM (25 cm") and methanol (25 cm"), 
and dried wider vacuum and checked once again for percentage loading (772 mg, 
70% loading).
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p-Allyl (2A)-iV-(9-fluorenylmethoxycarbonyl)phenylaIanyI-P-aIanYl-[a-methyI 
(2i?)-glutamyl]-y-(2/^)-prolyI-[(2/^)-aspartate] diester 76Â
NH
OH
p-AJlyl (25)-A'’-(9-fluorenylmethoxycarbonyl)phenylalanyl-P-aIanyl-[(2jR)"a-
methyl-gIutamyl]-y-(2i?)-prolyl-[(2i?)-aspartate-Wang resin] diester 76 (2.1 g, 
426 mg petidyl content, 0.05 mmol) was synthesised on the peptide synthesiser and 
treated with cleavage mixture TFA/TES/H2O/DCM (40:2:5:53) at room 
temperature for 1 h. The resin was filtered off and the solvent concentrated under 
reduced pressure (4-5 cm"). The peptide was then precipitated with excess diethyl 
ether to give a white solid in quantitative yield (426 mg), mp 115-116 °C (Found: 
C, 59.6; H, 6.6; N 7.9. C45H51N5O12 requires: 3 H2O: C, 59.5; H, 6.9; N, 7.7%); 
[a]D-13,0 (c 1,3 in MeOH); u^,(C H 2Cl2)/cm'‘ 3276 (NH), 2977 (CH) and 1727 br 
(CO, esters and amides); 5 h(300 MHz; C^HClj) 1.76-2.54 [10 H, m, y-CHa and 
p-CHa (Pro and Glu) and a-CHa (p-Ala)], 2.82-3.14 [4 H, m, p-CHa (Asp) and 
p-CHa (Phe)], 3.32-3.47 [4 H, m, 5-CHa(Pro) and p-CHa (p-Ala)], 3.77 (3 H, s, 
CHs), 4.16-4.88 [9 H, m, 4 x a -H , 2 x CHaO and fluorenyl CH], 4.97 [1 H, br, NH 
(urethane)], 5.14-5.36 (2 H, m, CA=CH), 5.76-5.94 (1 H, m. CHa=C7ï). 6.18 
(2 H. br, NH) and 7.00-7.23 (15 H, m. Ph. 2 x NH); 5c(75.4 MHz; C^HCb) 24.53 
[y-CHa (Pro)], 26,86 [P-CHa (Glu)]. 28.84 [y-CHa (Glu)], 29.77 [p-CHa (Pro)],
34.97 [a-CHa (P-Ala)], 35.36 [p-CHa (Asp)], 36.34 [p-CHa (P-Ala)], 38.71 
[P-CHa (Phe)], 46.90 [6-CHa (Pro)], 47.42 [a-C  (Asp)], 51.55 [a-C  (Glu)],
52.51 [CHa (Asp)], 56.02 [a -C  (Phe)], 60.00 [a-C  (Pro)], 65.56 and 67.31 (2 x
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CH2O), 118.45 (CH2=CH), 119.96, 125.14, 126.87, 127.1, 127.75, 128.49, 128.64, 
129.41, 130.13, 131.83 and 133.37 (Ar-CH), 136.67 (CH2=CH), 141.29 and
141.74 (Ar-C quaternary), 156.55 (CO, urethane) and 170.61, 171.94 and 172.7 
(CO esters and amides); (ES) 892 (20%, [M + K]'), (42, [M 4- Na]"), 855 (28, 
[M + 2H]0, 718 (49, [M + H -  C15H 11O2]" and 102 (100).
(2 ^-Pheny laIany l-P-a lanyl-[a-m ethy l (2 i?)-glutamyl]-y-(2 i?)-prolyl-[(2 i?}- 
aspartate] ester 92A
NH
HO OH
To a stirred solution of resin 76 (495 mg, 0.3 mmol) in a stirred mixture of 
DMSO/THF/0.5 M HCl/NMM (2:2:1:0.1), (25 cm )^ under Ar, was added tetrakis 
(triphenyl phosphine) Pd (0) (104 mg, 9 x 10'  ^ mol). The resin was stirred slowly at 
room temperature for 3 h, after which time the resin was filtered and washed with 
THF (25 cm^), DCM (25 cm^), and methanol (25 cm^).
The resin was then treated with 20% piperidine/DMF (10 cm^) for 30 min [reaction 
monitored by the Ninhydrin Test (see Appendix 4)], after which time the resin was 
filtered and washed with DMF, DCM and methanol respectively. This was then 
treated with cleavage mixture TFA/TES/HiO/DCM (40:2:5:53) at room 
temperature for 1 h. The resin was filtered off and the solvent concentrated under 
reduced pressure (4-5 cm'"). The peptide was then precipitated with excess diethyl 
ether to give a white solid in quantitative yield (177 mg), Uina.x(CH2Cl2)/cm'* 3200 br 
(NH and OH) and 1729 br (CO, esters and amides); 0h(300 MHz; 'H 2O) 1.44-2.39
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[10 H, m, y-CHj, P-CHj (Pro and Glu) and a-C H j (P-A la)], 2.64-3.04 [4 H, m, 
P-CH 2  (Asp) and P-CH 2  (Phe)], 3.17-3.4 [4 H, m, 6 -C H 2  (Pro) and P-CH. 
(P-A la)]. 3.57 {t, 3 H. s. CH;). 3.59 (c, 3 H. s, CH;). 4 (1 H. t, /  7.4 a -H ),
4.08-4.38 (2 H, m. 2 X a -H ), 4.58-4.61 (1 H, m. a -H ) and 7.02-7.38 (5 H. m. Ph); 
5c(75.4 MHz; C^HCl;) 22.13 [c, y-CH ; (Pro)], 24.05 [1, y-C H . (Pro)], 25.71 
[P-CHz (Glu)], 29.66 [y-CH; (Glu)], 29.77 [t, P-CH 2  (Pro)], 31.74 [r, P-CH, 
(Pro)], 34.23 [a -C H 2  (P-A la)], 35.26 [p-CH; (Asp)], 35.45 [P-CH 2  (p -A la )] , 
36.88 [p-C H ; (Phe)], 47.93 [c, 6 -C H 2  (Pro)], 47.86 [1, 6 -C H 2  (Pro)], 48.98 [/, 
a -C  (Asp)], 49.19 [c, a - C  (Asp)], 52.15 [a -C  (Glu)], 52.94 [CH; (Asp)], 54.44 
[a -C  (Phe)], 60.25 [1, a - C  (Pro)], 60.8 [c, a -C  (Pro)], 128.06, 129.23, 129.44, 
130.63, 133.75 and 133.9 (Ar-CH), 135.89 (Ar-C quaternary) and 173.43, 173.64, 
173.72, 173.89, 173.97, 174.27 and 174.4 (CO esters and amides); m/z (ES) 620 
(5%, [M + K]*), 614 (10, [M + N a]3 and 592 (100, [M + H ] i .
Cyclo-[|3-Ala-(2ii!)-Glu-a-OM e-Y-(2i?)-Pro-(2i?)-Asp-P-(2^-Phe-] 93A
O o
NH NH
To a stirred suspension o f  resin 92 (100 mg, 0.06 mmol) in DMF (5 cm^) and 
DIPEA (102 mm", 0.6 mmol) under Ar, was added PyBOP (157 mg, 0.3 mmol) and 
HOBt (41 mg, 0.3 mmol). The resin was stirred slowly at room temperature for 7 
days, (reaction monitored by the Ninhydrin Test), filtered and washed with THF (25 
cm"), DCM  (25 cm") and methanol (25 cm^). The resulting resin was treated with 
cleavage mixture TFA/TES7 H2 O/DCM (40:2:5:53) at room temperature for 1 h.
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The resin was filtered off and the filtrate concentrated under reduced pressure (4-5 
cm"). The peptide was then precipitated with excess diethyl ether to give a white 
solid which was purified by reverse phase HPLC (10 mg, 30%) mp >180 °C 
(decomp.) (HRMS; found [M + H  -  H 2 O]", 556.2420. C27H:uN30s requires 
556.2407); Unu.x(CH2 Cl2)/cm '‘ 3302 (NH) and 1735 and 1670 (CO, esters and 
amides); 5h [500 MHz; (C % )2S0 ] 1.72-2.02 [11 H. m. 1 H of p-CHj (c and t. 
Pro), 1 H of P-CH2 (c. Pro), y-CH2 (c and I, Pro) and P-CH2 (c and t, Glu)],
2.12-2.55 [15 H, m, y-CH2 (c and r, Glu), 1 H of y-CHi (c and i, Glu), I H of 
P-CH2 (f. Pro), 1 H of P-CH2 (c and /, Asp) and a-C H : (c and t, p.AJa)], 2.66-3.2 
[8 H, m, 1 H of p-CHa (c and t, p-Ala), P-CH2 (c and I, Phe) and 1 H of P-CH2 
(c and t. Asp)], 3.4-3.49 [6 H, m, 1 H of p-CH; (c and t, p-Ala) and 6-CH: (c and 
t. Pro)], 3.55, 3.67, 3.78, and 3.79 [12 H, s, 2 x  CH;, c and t], 4.08-4.48 [S H, m, 
a -H  (c and /, Phe), a -H  (c and t, Glu), a -H  (c and t. Asp) and a -H  (c and /, 
Pro)], 7.21-7.39 (10 H, m. Ph. c and /). 7.75-7.97 [3 H, m, NH (cand t, p-Ala), 
NH (c. Asp)], 8.14-8.29 [5 H, m, NH (/, Asp), NH (c and i, Phe) and NH (c and t, 
Glu)]; 5c(75.4MHz; C ^ O ^ H ) 23.89 [y-CHa (Pro)], 25.18 [P-CH; (Glu)], 29.25 
[y-CHa (Glu)], 31.61 [p-CHa (Pro)], 34.39 [a-CHa (P-Ala)], 35.11 [p-CHa 
(Asp)], 37.03 [p-CHa (p-Ala)], 38.76 [P-CHa (Phe)], 46.68 [6-CHa (Pro)], 46.91 
[a -C  (Asp)], 51,53 [a -C  (Glu)],. 51.73 (CH;), 56.53 [a -C  (Phe)], 59.5 [a -C  
(Pro)], 126.11, 127.93, 128.45, 128.96 and 129.34 (Ar-CH). 135.25 (Ar-C 
quaternary) and 169.12, 170.28, 170.71, 171.18 and 172.28 (CO ester, amides and 
acid); m/z (ES) 596 (4, [M + Na]"), 574 (16, [M + H]") and 212 (100).
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P-Aliyl (2vS)-iV-(9-fluorenylmethoxycarbonyl)phenylalanyl-j3“aianyl-[a- methyl 
(2i?)-gIutamyl]-y-(2jR)-prolyI-[a-methyl (2i?)-aspartate] triester 97
NH
OMe
This compound was prepared in a manner identical to diester 36, using diester 76, 
(853 mg, 1 mmol) to give the required compound as a white crystalline solid in 
quantitative yield, which did not require further purification mp 120-121 °C 
(Found: C, 61.9; H, 6.3; N 7.7. C46H53N5O12 requires: 1.5 H2O: C, 61.7; H, 6.3; N, 
7.8%); [a]o -17.8 (c 0.25 in MeOH); u„:<(CH2Cy/cm-‘ 3301 (NH), 2953 (CH), 
and 1739 and 1652 (CO, esters and amides); Sh(300 MHz; C^HCls) 1.82-2.52 [10 
H, m, y-CHj, p-CH; (Pro and Glu) and a-C H , (p-Ala)], 2.79-3.19 [4 H, m, 
P-CHz (Asp) and p-CHz (Phe)], 3.25-3.8 [4 H. m, S-CHj (Pro) and P-CH; 
(P-Ala)], 3.51, 3.6, 3.68 and 3.72 {candt, 6 H, 4 x s, CH;), 4.08-4.97 [9 H, m, 4 x 
a -H , 2 X CH,0 and fluorenyl CH], 5.09-5.37 (2 H, m, C JfrC H ), 5.68 [1 H. d, /  
7.9, NH, (urethane)], 5.79-5.86 (1 H, m, CHrCTT), 6.90 (1 H, d, / 7.7, NH), 7.03 
(1 H, br, NH) and 7.18-7.76 (15 H, m, Ph, 2 x NH); 5c(75.4 MHz; C^HClj) 24.63 
[Y-CH2 (Pro)], 27.07 [p-CHz (Glu)], 29.14 [y-CHz (Glu)], 30.36 [P-CHa (Pro)], 
35.28 [a-C H , (p-Ala)], 35.73 [P-CH2 (Asp)], 35.33 [P-CH2 (P-Ala)], 39.07 
[P-CH2 (Phe)], 47.14 [6-C H 2 (Pro)], 47.5 [a -C  (Asp)], 51.90 [a -C  (Glu)], 52.59 
[CH; (Asp)], 52.86 [CH; (Glu)], 56.10 [a -C  (Phe)], 60.09 [a -C  (Pro)], 65.73 and 
67.00 (2 X  CH2O), 118.60 (CH2=CH), 120.05, 125.19, 126.90, 127.15, 127.79, 
128.55, 129.48 and 131.86 (Ar-CH), 136.97 (CH2=CH), 141.33 and 143.93 (Ar-C 
quaternary), 156.12 (CO, urethane) and 170.41, 171.71, 171.87 and 172.66 (CO,
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esters and amides); m/z (ES) 891 ( 12%. [M + Na]"), 869 (50. [M + H]*), 646 (28, 
[M + H -C i< Jiu 02]‘ and 111 ( 100).
(25)-/7-{Fluorenylmethoxycarbonyl)phenylalanyl-p-alanyl-[a-methyl 
(2i?)-glutamyl]-Y-(27?)-prolyl-[a-methyl (2i?)-aspartic acid] 98
This compound was prepared in a manner identical to ester 77, using the triester 97, 
(220 mg, 0.25 mmol) to give the required compound as a white crystalline solid 
(150 mg, 72%) mp >124 °C (decomp.); [a]o -13.5 (c 1 in MeOH); 
Um«(CH2Cl2)/cm ' 3300 (NH), 3229 br (OH), and 1801 and 1721 (CO, esters and 
amides); 5h(300 MHz; C^HsO’H) 1.87-2.45 [8 H, m, y-CH,, p-CH; (Pro and Glu) 
and a -C H ; (p-Ala)], 2.74-3.14 [4 H, m ,. p-CH; (Asp) and p-CH; (Phe)], 
3.28-3.52 [4H, m, 6-CH 2 (Pro) and P-CHz (p-Ala)], 3.58, 3.59, 3.65 and 3.66 (c 
and t, 6 H, 4 X s, CH;), 4.09-4.85 [7 H, m, 4 x a -H , CH2O, fluorenyl CH], and 
7.18-7.77 (13 H, m, Ph); 5c(75.4 MHz; C % 0"H ) 24.12 [y-CH; (Pro)], 26.53 
[P-CH2 (Glu)], 29.5 [Y-CH2 (Glu)], 31.85 [P-CHj (Pro)], 34.84 [a-C H ; (P-Ala)],
35.53 [P-CH; (Asp)], 37.63 [p-CH; (p-Ala)], 37.92 [p-CH; (Phe)], 47.23 
[6-CH 2 (Pro)], 47.67 [a -C  (Asp)], 49.60 [a -C  (Glu)], 51.97 [CH; (Asp)], 52.05 
[CH; (Glu)], 56.74 [a -C  (Phe)], 60.41 [a -C  (Pro)], 66.72 (CH2O), 119.66,
124.92, 125.07, 126.5, 126.92, 127.54, 128.21 and 129.13 (Ar-CH), 137.39,
141.25 and 143.90 (Ar-C quaternary), 156.87 (CO, urethane) and 171.98, 172.32, 
172.66, 172.94, 173.12 and 176.14 (CO, esters, amides and acid); m/z (ES) 839 
(l% ,M * )an d ll3  (100).
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(2 6 )-Phenylalanyl-P-alanyl-[a-m ethyl (2i?)-glutamyl]-y~(2i?)-proIyl-[a- methyl 
(2 i?)-aspartate] diester 99
NH
HO OMe
To a stirred solution of the diester 98 (100 mg, 0.12 mmol) in diy^  DIVIF (3 cm"), 
was added piperidine (17 mm", 0.18 mmol). The reaction mixture was allowed to 
stir at room temperature for 45 min, and then concentrated under reduced pressure 
and redissolved in water (10 cm") and acidified with TFA. The resulting solution 
was washed with DCM and the acidic layer concentrated under reduced pressure to 
yield the required compound as a white hydroscopic solid (60 mg, 83%) mp 67-69 
°C (HRMS: found [M + H f, 793.3748. C22H24NO3 requires 793.3772); [a]D+14.5 
(c 1.1 in MeOH); u.«(C H 2Cl2)/cm'' 3286 (NH), 2955 br (OH), and 1746 and 1670 
(CO, esters and amides); 5h(300 MHz; % 0 )  1.45-2.18 [10 H, m, y-CH;, P-CHz 
(Pro and Glu) and a-C H j (P-Ala)], 2.64-3.04 [4 H, m, p-CH; (Asp) and P-CHj 
(Phe)], 3.15-3.36 [4H. m, 6 - 0 % (Pro) and p-C %  (p-Ala)], 3.57 and 3.60 (6 H, 2 
X s, 2 X CHj), 3.97-4.59 [4 H, m, 4 x a-H ] and 7.07-7.38 (5 H, m, Ph); Sc(75.4 
MHz; C % 0 -H ) 24.07 [y-C%  (Pro)], 26.20 [P-C%  (Glu)], 29.48 [y-C% (Glu)],
31.41 [p-CH, (Pro)], 34.88 [a-CHz (P-Ala)], 35.34 [P-C %  (Asp)], 36.42 
[p-CHz (P-Ala)], 40.15 [p-C %  (Phe)], 46.84 [5-C%  (Pro)], 46,90 [a -C  (.Asp)], 
49.86 [a -C  (Glu)], 51.58 and 52.40 (2 x CHs), 56.06 [a-C  (Phe)], 60.53 [a-C  
(Pro)], 125.11, 126.73, 126.92, 128.42, 128.59 and 129.19 (Ar-CH), 136.02 (Ar-C 
quaternary) and 170.55 and 172.39 (CO ester, amides and acid); m/s (FAB) 793 
(4%, [M + H]1 and 115 (100, CiHjOjI-
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C yclo-[P-A la-(2i?)-G lu-a-O M e-y-(26)-Pro-(2i?)-A sp-a-O M e-p-(2^-Phe-] 52A
O H C02Me
H o  H COjMe
To a stirred solution of the pentapeptide 99, (60 mg, 9.92 x 10'  ^ mol) in DiVlF 
(80 cm^), was added PyBOP (28.4 mg, 0.11 mmol) and DIPEA (102 mm\ 
0.99 mmol). The resulting solution was stirred at room temperature for 7 days and 
then concentrated under reduced pressure and immediately purified by flash 
chromatography on silica eluting with 94% CHiCb/MeOH to give a white solid 
which contained PyBOP as a contaminant. Further purification by preparative 
HDPLC on a Poros 10 R2 reverse-phase column [using isocratic reverse-phased 
conditions, eluting with 18% acetonitrile-82% water as eluent at a flow rate of 2 
cm  ^ min'\ with the detector set at 220 nm] gave the required compound which 
possessed identical analytical data to the compound prepared previously from the 
pentafluorophenyl ester (see page 152).
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a-M ethy l y-allyl (2jR)-A-(9-fluorenylmethoxycarbonyl)aspartate 102
0
^  JL
Y
H
This compound was prepared in a manner identical to diester 36, using y-allyl 
(2i?)-(9-fluorenylmethoxycarbonyl)aspartate 88, (1.00 g, 2.54 mmol) to give the 
required compound as a white crystalline solid in quantitative recovery, which did 
not require further purification (1.04 g) mp 96-97 °C (Found: C, 67.4; H, 5.7; 
N, 3.5. C23H23NO6 requires: C, 67.5; H, 5.6; N, 3.4%) (HRMS: found [M 4- E ] \  
410.1609 C23H24NO6 requires 410.1603); [ajo -15 (c 0.3 in MeOH); 
Urn«(CH2Cl2)/cm ' 3374 (NH), 2965 (CH) and 1751 (CO. urethane); 5h(300 MHz; 
C^HCy 2.91 (1 H, dd, J  17.4 and 4.1, 1 H of p-CHj), 3.09 (I H. dd, J  16.8 and
4.5, 1 H of 3-CH2), 3.77 (3 H. s, CH;), 4.20-4.74 (6 H, m, 2 x CHjO, fluorenyl CH 
and a-H ), 5.21-5.38 (2H , m, 5.82-6.21 [2 H. m, CH:=C77 and NH
(urethane)] and 7.23-7.79 (8 H, m. Ph); 5c(75.4 MHz; C^HCb) 36.75 (3-CH2), 
47.23 (fluorenyl CH), 50.53 (a-C ), 53.01 (CH;). 65.89 and 67.4 (2 x CH2O).
118.92 (CH2=CH), 120,15, 125.28, 127.23 and 127.89, 127.9 (Ar-CH), 131.76 
(CH2=CH), 141.44, 143.86 and 143.98 (Ar-C quaternary) 156.12 (CO, urethane) 
and 170.76 and 171.32 (CO, esters); m/z (Cl) 410 (57%, [M + H ] l  and 179 (100,
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a-M ethyl (2i?)-A/-(9-fIuorenyimethoxycarbonyl)aspartate 103
O C 02M e o
This compound was prepared in a manner identical to a-methyl (2K)-M-(_9- 
fluorenylmethoxycarbonyl)glutamate 77, using diester 102 (242 mg, 0.50 mmol) to 
give the required compound as a white crystalline solid (134 mg, 60%) 
mp 124-125 ’C, (Found: C, 64.8; H, 5.2; N 3.6. QoHigNOg requires: C, 65.0; 
H, 5.2; N, 3.8%); (HRMS: found [M + H]', 370.1298. CioHjoNOs requires 
370.1291); [a]o+19.05 (c 0.21 in MeOH); u„„(CH2Cl2)/cm'' 3335 (NH), 3100 br 
(OH) and 1727 (CO, ester); 0h(300 MHz; C%O^H) 2.82 (1 H, m, p-CH;), 3.71 
(3 H, s, CH;), 4.08-4.62 (4 H, m, CH2O, fluorenyl CH and a -H ) and 7.24-7.82 (13 
H, m, Ph); 5c(75.4 MHz; C^HCl;) 35.76 (p-CH;), 47.03 (fluorenyl CH), 50.69 
(a-C ), 51.71 (CH;), 66.85 (CH2O), 119.64, 124.96, 126.88 and 127.50 (Ar-CH), 
134.33, 141.28, 143.88 and 143.93 (Ar-C quaternary) 157.06 (CO, urethane),
171.91 (CO, ester) and 172.57 (CO, acid); m/z (Cl) 370 (99%, [M + H]*), 192 (64, 
[M + 2 H -C iJH „ ]T  179 (100, CiJH,,') and 148 (85, C;H,oNO/).
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a-M ethyl (2i?)-A'^(9-fluorenylmethoxycarbonyl)aspart\l-W ang resin 104
This was prepared in a manner identical to that described for p-ally I (2i )^-ifY-(9- 
fluorenylmethoxycarbonyl)aspartyI-Wang resin 85, using ester 103, (1 g,
2.71 mmol) and the loading was determined to be 84% (see Appendix 4).
p-Allyl (2jR)-iV-(9-fluorenylmethoxycarbonyl)-4-hydro5y'-l-butyrate 112
OH
To a stirred solution of p-allyl (2i?)-iV-(9-fluorenylmethoxycarbonyI)aspanate 88 
(530 mg, L34 mmol) in dry THF (15 cm^) at -30 °C, was added 
A’-methylmorpholine (147 mm'', 1.34 mmol). Isobutylchloroformate (182 mm'’, 
1.34 mmol) was added and the suspension was stirred at -30 °C for 30 min, and 
then filtered directly into a stirred solution of sodium borohydride (31 mg, 
0.80 mmol) in dry THF (10 cm*'). The reaction mixture was stirred at -30 °C for 15 
mins and was then allowed to warm up to room temperature. After 3 h, water (10 
cm") was carefully added and the resulting solution was concentrated under reduced 
pressure until the THF had been removed. The remaining aqueous solution was 
extracted with ethyl acetate (3 x 25 cm") and the combined organic extracts were
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washed with brine (20 cm"), then dried (MgSOa) and then concentrated under 
reduced pressure. The crude crystalline material was recrystallised from ethyl 
acetate/hexane to yield a white solid (430 mg, 84%) mp 124-125 °C (Found; C, 
69.3; H, 6.2; N 3.7. C22H23NO5 requires: C, 69.3; H, 6.1; N, 3.7%) (HRMS: found 
[M-r H]^ 382.1662. C22H24NO5 requires 382.1658); [a]o-^8.14 (c 0.43 in MeOH); 
Unu.x(CH2Cl2)/cm ' 3335 (NH), 1746 (CO. urethane) and 1707 (CO, ester); 5h(300 
MHz; C^HCl:,) 2.47 (1 H, br, OH), 2.68 (2 H, d, 74.48, p-CHj), 3.73 (2 H, d, J  2, 
C%OH), 4.06-4.60 (6 H, m, 2 x CHjO, fluorenyl CH and a -H ), 5.22-5.41 (2 H, 
m, C%=CH), 5.59 [1 H, d, 75.7, NH, (urethane)], 5.22-5.97 (1 H, m, CH rC H ) 
and 7.26-7.78 (8 H, m, Ph); 5c(75.4 MHz; C^HCb) 35.95 (p-CH;), 47.33 
(fluorenyl CH), 49.87 (a-C ), 64.35 (CH^OH), 65.7 and 67.02 (2 x CHjO), 118.89 
(CH2=CH), 120.13, 125.18, 127.21 and 127.86 (Ar-CH), 131.86 (CH:=CH). 
141.45 and 143.93 (Ar-C quaternary) 156.37 (CO, urethane) and 171.55 (CO, 
ester); /wÆ (Cl) 382 (6%, [M + H ]l, 179 (100, Ci4H ii^  and 102 (74, C5H 10O:").
a-B enzy l P-allyl (2i?)-A-(9-fluorenylmethoxycarbonyl)aspartate 
diester 115
p-Allyl (2i^)-7V-(9-fluorenylmethoxycarbonyl)aspartate 88 (395 mg, 1 mmol) was 
dissolved in MeOH (20 cm") and the pH adjusted to 7 with 20% CsCO?. The 
solvent was then removed under reduced pressure, redissolved in DlvfF (20 cm") 
and benzyl bromide (131 mm", 1.1 mmol) added. The resulting mixture was stirred 
at I t  for 6  h and then the solvent removed under reduced pressure to give a white 
solid which was taken up in ethyl acetate (30 cm") and washed with water ( 2 x 3 0
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cm"). The organic extracts were dried (MgSO^) and concentrated under reduced 
pressure to give a colourless oil which was crystallised using ethyl acetate/hexane to 
yield a white solid (418 mg, 86%) mp 82-83 ”C (Found: C, 70.8; H, 5.6; N 3.0. 
C29H27NO6 requires: 0.25 H2O: C, 71.1; H, 5.6; N, 2.9%); (HRMS: found [M + 
2H]*, 487.2002. C29H29NO6 requires 487.1995); [ajo +8.7 (c 0.5 in MeOH); 
u™x(CH2Cl2)/cm‘‘ 3351 (NH) and 1739 (CO, urethane); 5h(300 MHz; C^HCh) 2.9 
(1 H, dd, J  12.6 and 4.4, 1 H of p-CHz), 3.1 (1 H, dd, J  12.6 and 4.5, 1 H of 
P-CHz), 4.19-4.76 (6 H, m, 2 x CH2O, fluorenyl CH and a-H ), 5.13-5.36 [5 H, m, 
Cft=CH, PhC% and NH (urethane)], 5.78-5.98 (1 H, m, CHz^CH) and 7.26-7.82 
(13 H, m, Ph); 5c(75.4 MHz; C^HCb) 36.75 (P-CH2), 47.23 (fluorenyl CH), 50.64 
(a-C ), 65.87, 67.44 and 67.77 (3 x CH2O), 118.97 (CH2=CH), 120.13, 125.27, 
127.23, 127.87, 128.43, 128.64, 128.75, 128.94, and 129.17 (Ar-CH), 131.73 
(CH2=CH), 135.28, 141.43, 143.84 and 143.99 (Ar-C quaternary), 156.11 (CO, 
urethane) and 170.66 (CO, ester); m/z (Cl) 487 (41%, [M + 2H]*), 179 (47, 
Ci4H„*) and 57 (100, C4H9").
a-Benzyl (2i?)-A^-(9-fluorenyImethox>carbonyl)aspartate 116
This, compound was prepared in a manner identical to a-methyl {2R)-N-(9- 
fluorenylmethoxycarbonyl)glutamate 77, using diester 115 (242 mg, 0.50 mmol) to 
give the required compound as a white crystalline solid (134 mg, 60%), mp 
96-97 °C (Found: C, 69.7; H, 5.1; N 3.0. CzeHn^NOe requires. 0.20 HiO: C, 69.6; 
H, 5.2; N, 3.1%) (HRMS: found [M + H]‘, 446.1596. C26H24NO6 requires 
446.1604); [a]o-9.17 (c 0.3 in MeOH); ^.«(CHrCW/cm-' 2993 br (OH) and 1719 
(CO, ester); 5h(300 MHz; C^HCb) 2.92 (1 H, dd, J  12.6 and 4.4, 1 H of P-CH;), 
3.11 (1 H, dd, J  12.6 and 4.5, 1 H ofp-CHz), 4.18-4.78 (4 H, m, CH2O, fluorenyl 
CH and a-H ), 5,21 (2 H, m, PhC%), 5.81 [1 H, s, NH (urethane)] and 7.26-7.77 
(13 H, m, Ph); 5c(75.4 MHz; C^HCl;) 36.42 (p-CHz), 47.20 (fluorenyl CH), 50.41 
(a-C ), 67.52 and 67.9 (2 X  CH2O), 120.15, 125.24, 127.25, 127.9, 128.42, 128.69 
and 128.77 (Ar-CH), 135.14, 141.44 and 143.77 (Ar-C quaternary) 156.15 (CO,
E x p e r im e n t a l Page 176
urethane), 170.54 (CO, ester) and 175.39 (CO, acid); m/z (Cl) 446 (7%, [M -r H]'), 
224 (27, Ci^HioCOzi, 179 ( 100, C14H 11") and 91 (5, PhCH,').
P-Allyl (26)-iV-(9-FIuorenylmethoxycarbonyI)phenylalanyi-[a-benzyi 
(2/?)-aspart>dj-[a-methyl (2i?)-gIutamyl]-Y-(2/?)-prolyi-(2i?)-aspartic acid 117
N H
OH
This compound was prepared in a manner identical to that for the diester 76A 
starting from P-allyl (2/?)-77-(9-fluorenylmethoxycarbonyl)aspartyl-Wang resin 85 
to give the required pentapeptide as a white solid in quantitative yield (296 mg, 0.3 
mmol), which did not require further purification, mp 102-104 °C (Found: C, 64.6; 
H, 5.7; N 6.9. C53H57N5O14 requires: C, 64.4; H, 5.8; N, 7.1%); 17.8 (c 0.2
in MeOH); Omnx(CH2Cl2)/cm'^ 3311 (NH), 2950 (CH), and 1733 (CO, esters and 
amides); 0h(300 MHz; C^HCb) 1.81-2.58 [10 H, m, y-CH] and P-CH2 (Pro and 
Glu) and a-CHz (p-Ala)], 2.84-3.37 [6 H, m, 2 x P-CH. (Asp) and P-CH. (Phe)], 
3.42-3.71 [4 H, m, 5-CH2(Pro) and P-CH2 (p-Ala)], 3.72 (c, 3 H, s, CH3), 3.8 (/, 
3 H, s, CH3), 4.09-5.00 [10 H, m, 5 x a -H , 2 x CH2O and fluorenyl CH], 5.01-5.37 
(4 H, m, C772=CH, CH2Ph), 5.65 [, 1 H, d, J  8.8, urethane)], 5.75 [c, 1 H, d, J  8.4, 
NH (urethane)], 5.83-5.94 (1 H, m, CH2=C77), 6.31 (c, 1 H, d, J  7.9, NH), 6.39 (/, 
1 H, d, 77.8, NH) and 7.11-7.77 (21 H, m, Ph and 2 xNH); 5c(75.4 MHz; C^HCb)
24.51 [y-CHz (Pro)], 25.53 [p-CHz (Glu)], 28.71 [y-CH, (Glu)], 29.66 [p-CHz 
(Pro)], 35.34 [a-C H 2 (P-Ala)], 35.43 and 35.67 [P-CH2 (Asp)], 36.67 [p-CH.
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(P-Ala)], 39.28 [P-CH2 (Phe)], 43.48 [Ô-CH2 (Pro)], 46.9 and 47.17 [a-C  (Asp)],
51.04 [a -C  (Glu)], 52.81 [CH3 (Asp)], 55.69 [a-C  (Phe)], 60.68 [a-C  (Pro)], 
65.54, 66.95 and 67.75 (3 x CH2O), 118.46 (CHz=CH), 120.13, 123.71, 125.22,
127.05, 127.26, 127.57, 127.93, 128.36, 128.57, 128.88, 129.62 and 132.12 
(Ar-CH), 136.44 (CH2=CH), 135.22, 136.43, 138.24, 141.41, 142.24 and 141.74 
(Ar-C quaternary), 156.65 (CO, urethane) and 170.45, 170.95, 171.38, 171.84 and 
173.33 (CO, esters; amides and acid); m/z (ES) 1011 (1%, [M + Na]‘), 989 (2, [M 
+ 2H f), 211 (100), 195 (57, C14H 11O3  and 157 (78, C7H9O /).
(26)-PhenylalanyI-[a-benzyl (2i?)-aspartyl]-[a-methyl (27?)-gIutamyI]-y-(2i?}- 
prolyl-[(2i?)-aspartic acid] 118
NH
HO OH
This compound was prepared in a manner identical to ester 92 to give the required 
pentapeptide in quantitative yield, which did not require further purification, 
Urn«(CH2Cl2)/cm'^ 3311 br (OH), 2936 (CH), and 1751 (CO, esters and amides); 
5h(300 MHz; "H2O) 1.54-2.88 [10 H, m, y-CHz, p-CHz (Pro and Glu) and g-CHz 
(P-Ala)], 2.88-3.12 [6 H, m, 2 x P-CH2 (Asp) and P-CH2 (Phe)], 3.29-3.62 [4 H, 
m, 5-C H 2(Pro) and a-CHz (p-Ala)], 3.59 (c, 3 H, s, CH;), 3.61 (?, 3 H, s, CH;),
4.08-4.75 [5 H, m, 5 X a -H ], 5.02-5.05 (2 H, m, C ^P h) and 7.01-7.79 (10 H, m, 
Ph); 6c(75.4 MHz; C^HCl;) 24.00 [y-CHz (Pro)], 26.20 [P-CH2 (Glu)], 29.64 
[y-CH2 (Glu)], 31.75 [p-CHz (Pro)], 34.32 [P-CH2 (P-Ala)], 35.08 and 35.46
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[P-CH2 (Asp)], 36.66 [a-C H , (P-Ala)], 39.27 [p-CH, (Phe)], 44.49 [6-CH, 
(Pro)], 47.31 and 47.84 [a -C  (Asp)], 50.02 [a-C  (Glu)], 52.96 [CH3 (Asp)],
56.02 [a -C  (Phe)], 60.37 [a -C  (Pro)], 66.12 (CH2O), 127.77, 128.13, 128.82, 
129.19, 129.69, 130.35, 130.61, 133.75 and 133.9 (Ar-CH), 134.47 and 135.9 
(Ar-C quaternary) and 169.41, 169.86, 170.78, 173.72, 174.32, 174.62 and 176.57 
(CO, esters, amides and acids); m/z (ES) 711 (4, [M + 2H]~) and 277 (100).
(2/?)-A-(9-FIuorenylmethoxycarbonyi)aspartyl a-4-benzylpiperidinamide 121
OH
To a stirred solution of ester 88, (1 g, 2.53 mmol) in dry THF (25 cm^) at - 15 °C 
was added A-methylmorpholine (276 mm^, 2.53 mmol). Isobutylchloroformate 
(343 mm^, 2.53 mmol) was added and the suspension was stirred at - 15 °C for a 
further 5 min. A solution of 4-benzylpiperidine (356 mg, 2.53 mmol) and 
ÿV-methylmorpholine (276 mm^, 2.53 mmol) in THF (25 cm^) was added and the 
mixture left to stir overnight. The hydrochloride salts were removed by filtration 
and the filtrate concentrated under reduced pressure to give a pale yellow oil which 
was redissolved in ethyl acetate (15 cm'’), washed successively with water (10 cm^), 
5% aqueous NaHCOs solution (15 cm’), 10% citric acid solution (15 cm") and then 
brine (15 cm"). The organic phase was dried (MgSO^) and concentrated under 
reduced pressure to give the required diester 120 which was immediately used in 
the next reaction.
To a stirred solution of the above diester and phenylsilane (624 mm", 5.06 mmol) in 
dry DCM (30 cm") under Ar, was added tetrakis (triphenylphosphine) Pd (0) (58
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mg, 0.05 mmol). The reaction was allowed to stir at room temperature for 18 h, 
and then concentrated under reduced pressure. The crude material was immediately 
purified using silica chromatography (60% ethyl acetate/hexane) to give a white 
solid (700 mg, 54%) mp 79-81 T  (Found: C, 71.3; H, 6.2; N 5.1. 0.5
H2O requires: C, 71.4; H, 6.3; N, 5.4%); [ah  +27.3 (c 0.3 in MeOH); 
Um«(CH2Cl2)/cm'’ 3279 (NH). 3100 br (OH) and 1718 (CO, ester); 5h(300 MHz; 
C^HCls) 1.13-1.28 (5 H, m, CT/CHiPh and 2 x Cft-CHzNH). 1.70 (4H, br, 2 x 
CH.-CTT'jNH,), 2.46-3.04 [4 H, m, PhC% and pCH, (Asp)], 3.98-4.59 (4 H, m, 
CH2O, fluorenyl CH and a-H ), 5.09 (1 H, br, OH), 6.18 [1 H, dd J  21 and 9, NH 
(urethane)] and 7.04-7.77 (13 H, m, Ph); 5c(75.4 MHz; C^HCb) 31.42 (2 x 
CH2-CH2NH), 37.47 (pCHj), 37.95 (2 x CHCHjPh), 42.94 (CH2-CH2NH), 46.19 
(PhCHz), 46.94 (a-C ), 47.49 (fluorenyl CH), 67.09 (CH2O), 119.84, 125.03,
125.93, 125.96, 127.58, 128.16 and 128.60 (Ar-CH), 139.59, 141.13, 143.53 and 
143.59 (Ar-C quaternary) 155.68 (CO, urethane), 169.88 (CO, ester) and 173.66 
(CO, acid); m,4r (Cl) 513 (1%, [M + H]') and 179 (100, C,JHn").
P-Allyl (2iî)-.N-(9-fluorenyImethoïycarbonyl)aspartyl a-benzylamide 122
This compound was prepared in a maimer identical to that described for glutamyl- 
sarcosyl diester 39, using the ester 88, (790 mg, 2 mmol) and benzylamine 
(218 mm^, 2 mmol) to give the required compound as a white crystalline solid 
(715 mg, 74%) mp 141-142 °C. (Found; C, 71.3; H, 5.9; N 6.0. C2 9 H 2 8 N 5 O5 . 0.25 
H 2 O requires C. 71.2; H, 5.8; N, 5.7%) (HRMS: found [M + 2 H ]\ 486.2169. 
C2 9 H 3 0 N 2 O 5 requires 486.2155); [a]o+13.84 (c 0.43 in MeOH); u„,,(CH 2 Cl2 )/cm'‘
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3296 (NH) and 1756 and 1742 (CO, esters and amide); 5h(300 MHz; C^HCb) 1.91 
(2 H, s, PhCTfz), 2.59 (1 H, dd, J  10.4 and 6.4, 1 H of P-CHz), 2.72 (1 H, dd, J
10.4 and 6.2, 1 H of P-CH2), 4.16-4.78 (4 H, m, CH?0, fluorenyl CH and a-H ),
5.21-5.38 (2 H, m, C7f2=CH), 5.82-5.91 [2 H, m, CHz^CTf, NH (urethane)], 6.81 
(1 H, br, NH) and 7.22-7.81 (13 H, m, Ph); 5c(75.4 MHz; C^HCh) 36.21 (g-CHz),
43.71 (PhCH,), 47.23 (fluorenyl CH). 51.19 (a-C), 65.91 and 67.28 (2 x CHzO),
118.97 (CH rCH ), 120.18, 125.08, 127.22, 127.65, 127.93 and 128.83 (Ar-CH), 
131,66 (CH rCH ), 141.46 and 143.74 (Ar-C quaternary) 152.89 (CO, urethane)
168.02 (CO, amide) and 170.25 (CO, ester); m/z (Cl) 486 (92%, [M + 2H]'), 263 
(100, [M + 2H -  CiiHiiCOj") and 179 (60, CijH,,').
(27?)-A'-(9-Fluorenylmethoxycarbonyl)aspartyl a-benzylam ide 124
This compound was prepared in a maimer identical to ester 77, using the diester 
122 (575 mg, 1.19 mmol) to give the required compound as a white crystalline solid 
(462 mg, 87%), mp 118-119 °C (HRMS: found [M + H]‘, 445.1769. CzsHnNzO; 
requires 445.1763); [a]n+5.88 (c 0.32 in MeOH); (Nujol)/cm‘' 3335 (NH) and 
1742 and 1712 (CO, esters and amide); 5h(300 MHz; C^HsO^H) 1.98 (2 H, s, 
PhC%), 2.77 (1 H, dd, /  11.1 and 6.5, 1 H o fp -C H j, 2.91 (1 H, dd, J  10.7 and
6.3, 1 H o f P-CH2), 4.07-4.68 (4 H, m, CH2O, fluorenyl CH and a-H ), 4.99 (1 H, 
br, OH) and 7.18-7.86 (13 H, m, Ph); 6c(75.4 MHz; C%O^H) 35.87 (P-CHi), 
42.84 (PhCH,), 47.03 (fluorenyl CH), 51.85 (a-C), 65.62 and 66.89 (2 x CH2O),
119.69, 125.0, 126.93, 127.09, 127.55 and 128.23 (Ar-CH), 138.46, 141.28 and
143.93 (Ar-C quaternary) 157.07 (CO, urethane) and 170.15 and 172.81 (CO, 
amide and acid); m/z (Cl) 445 (6%, [M + H]*) and 179 (100, C14H 11’).
E x p e r im e n t .al Page  181
p-Allyl (2i?)-iY-(9-fluorenylmethoxycarbonyl)aspartyl a-benzylpiperizinamide 
123
This compound was prepared in a manner identical to that described for glutamyl- 
sarcosyl diester 39, using of ester 88, (790 mg, 2 mmol) and benzylpiperizine (348 
mm", 2 mmol) to give the required compound as a white waxy solid (763 mg, 
81%), (HRiMS; found [M + H]~, 554.2667. C33H36N3O6 requires 554.2655); [a]o 
+4.19 (c 0.31 in MeOH); «^«(CHzCy/cm’' 3290 (NH), 2963 (CH) and 1732 and 
1647 (CO, esters and amide); 5h(300 MHz; C^HClj) 2.43 (2 H, br, PhC%), 2.67 (1 
H, dd, J  16.2 and 5.7, 1 H of p-CHz), 2.87 (1 H, dd, J  15.9 and 6.6, 1 H of 
P-CHz), 3.43-3.76 [8 H, m, 4 x 0 %  (Piz)], 4.17-4.64 (3 H, m, CH2O and fluorenyl 
CH), 5.09 (1 H, q, J 6.6, a -H ). 5.21-5.35 (2 H, m, C7Ï2=CH), 5.84-5.97 (1 H, m, 
CH2=C77), 6.06 [1 H, d, J  9.6, NH (urethane)] and 7.26-7.77 (13 H, m, Ph); 
5c(75.4 MHz; C^HCb) 37.70 (p-CHj), 42.45 (PhCH:), 47.23 (fluorenyl CH),
47.54 (Piz CH:), 52.62 (a-C ), 65.7 and 67.23 (2 x CH2O), 118.67 (CH2=CH), 
120.15, 125.26, 127.23, 127.53, 127.127.9, 128.5 and 129.31 (Ar-CH), 132.03 
(CH2=CH), 137.43, 141.44 and 143.86 (Ar-C quaternary) 155.74 (CO, urethane) 
and 168.86 and 170.46 (CO, amide and ester); m/z (Cl) 554 (100%, [M + H]'), 358 
(14, [M -  C.JHuO]!, 332 (15, [M -  C nH uO :]!, 179 (24, C uH iO  and 57 (57, 
C3H5O*).
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(2i?)-A^-(9-Fluorenylmethoxycarbonyl)aspartyi a-benz>ipiperizinam ide 125
This compound was prepared in a manner identical to a-methyl {2R)-N-{9- 
fluorenylmethoxycarbonyl)glutamate 39, using a-benzylpiperizido y-allyl-(2^)- 
A^-(9-fluorenylmethoxycarbonyI)aspartamide 123, (575 mg, 1.04 mmol) to give the 
required compound as a white hydroscopic solid which still showed signs of 
impurity (763 mg, 69%) mp 74-75 "C. u..,(C H 2Cl2)/cm'' 3314 (NH). 3064 br (OH) 
and 1718 and 1635 (CO. esters and amide); 5h(300 MHz; C H O ^H ) 2.01 (2 H. s. 
PhC%). 2.57-3.98 (10 H, m. p-CHj, CH; x 4 Piz). 4.04-4.73 (3 H, m, CH2O. 
fluorenyl CH). 4.98-5.04 (1 H. m, a -H ) and 6.83-7.99 (13 H. m, Ph); 5c(75.4 
MHz; C^HCl;) 37.47 (P-CH2). 37.95 (PhCH2), 42.01 (Piz CH2). 46.94 (fluorenyl 
CH). 47.49 (a-C ), 67.24 (2 x CH2O), 119.84, 124.59, 125.03, 125.93, 127.58, 
128.16 and 128.60 (Ar-CH). 139.59, 141.13, 143.53 and 143.59 (Ar-C quaternary) 
155.68 (CO, urethane) and 168.88 and 173.66 (CO, amide and ester); m/z (Cl) 511 
(1%, [M + H]") and 179 (100, CijHiO.
A^-(9-FIuorenylmethoxycarbonyl)(2*S)-phenylaIanyl
-[a-4-benz)dpiperidinyiam ido (2i?)-aspartyl]-[a-methyl (2i?)-glutamyl]-y-(2i?)- 
prolyl~p-alIyl-(2/?)-aspartic acid 127
NH
OH
This compound was prepared in a manner identical to diester 76 to give the 
required pentapeptide as a white solid in quantitative yield, which did not require
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further purification, mp 134-136 °C (HEMS: found [M + H + Na]~, 1077.4556. 
Ci&HggNgOnNa requires 1077.4586); [a]o+30 (c 1 in MeOH); Uma.\(CH2Cl2)/crn'^ 
3302 (NH), 2952 (CH), and 1739 (CO, esters and amides); 5h(300 MHz; C^HCb) 
1.18-1.43 (4 H. m, 2 X CH2-CH2NH), 1.7 (4 H, br, CH2-CH2NH), 2.46-3.04 [5 H, 
m, C^7CH2Ph, CHCifjPh and PCH2 (Asp)], 1.81-2.58 [10 H, m, Y-CH2. P-CH2 
(Pro and Glu) and a-C H 2 (P-Ala)], 2.84-3.37 [6 H, m, 2 x p -C H  (Asp) and 
P-CH2 (Phe)], 3.42-3.71 [4 H, m, 6-CH 2 (Pro) and P-CH2 (P-Ala)], 3.72 (c, 3 H, 
s, CH3), 3.8 (1, 3 H, s, CH;), 4.09-5.00 [10 H, m. 5 x a -H . 2 x CH2O and fluorenyl 
CH], 5.01-5.37 (4 H, m, C%=CH and CH2Ph), 5.65 [1, 1 H. d, J  8.8, NH 
(urethane)], 5.75 [c, 1 H. d, J  8.4, NH (urethane)], 5.83-5.94 (1 H. m. CH2=C77). 
6.31 (c, 1 H .d ,J7 .9 . NH), 6.39 (r, 1 H. d, J7 .8 . NH) and 7.11-7.77 (21 H, m, Ph 
and 2 x NH); 5c(75.4 MHz; C^HClj) 24.51 [y-CHj (Pro)], 25.53 [P-CH2 (Glu)],
28.71 [Y-CH2 (Glu)], 29.66 [P-CH, (Pro)], 35.34 [a-C H ; (p-Ala)]. 35.43 and 
35.67 [P-CH2 (Asp)], 36.67 [p-CHz (p-Ala)], 39.28 [P-CH2 (Phe)], 43.48 
[5-CH 2 (Pro)], 46.90 and 47.17 [a -C  (Asp)], 51.04 [a -C  (Glu)], 52.81 [CH3 
(Asp)], 55.69 [a -C  (Phe)], 60.68 [a -C  (Pro)], 65.54, 66.95 and 67.75 (3 x CH2O), 
118.46 (CH2=CH), 120.13, 123.71, 125.22, 127.05, 127.26, 127.57. 127.93, 
128.36, 128.57, 128.88. 129.62 and 132.12 (Ar-CH), 136.44 (CH^CH), 135.22, 
136.43, 138.24, 141.41, 142.24 and 141.74 (Ar-C quaternary), 156.65 (CO, 
urethane) and 170.45, 170.95. 171.38, 171.84 and 173.33 (CO esters, amides and 
acid); m/z (ES) 1011 (1%, [M + Na]*). 989 (2. [M + 2H]1, 211 (100), 195 (57. 
[CiiHiiO]*) and 157 (78, [C7H9O4]*).
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Cydo{(2»S)-Phe-[(2/^)-a-4-benzylpiperidinylam ido-Asp]-(2i?)-a- 
OMe-Gïu-y-(25)-Pro-{3-(2J?)-Asp} 126
O o
NH NH
This compound was prepared in a manner identical to 93 using the diester, 127, 
(316 mg, 0.3 mmol) which was selectively deprotected [see 92] and cyclised to give 
the required compound after purification using preparative HPLC on a C-18 
column [using isocratic reverse-phased conditions, eluting with 35% 
acetonitrile-65% water as eluent at a flow rate of 4.5 cm’' min'\ with the detector 
set at 220 nm] (40 mg, 17%) mp>167°C (decomp.), Um=x(CH2Cl2)/cm'' 3301 
(NH), 2939 (CH), and 1732 and 1672 (CO, esters and amides); 5h(300 iVlHz; 
C^HCb) ) 1.18-1.43 (4 H, m. 2 X 1.7 (4 H, br. 2 x CH,-C%KH),
2.46-3.04 [5 H, m, œ C H îP h. CHC%Ph and pCHj (Asp)]. 1.81-2.58 [10 H, m, 
Y-CHz. P-CHj (Pro and Glu) and a-C H i (p-Ala)], 2.84-3.37 [6 H, m. 2 x P-CH2 
(Asp) and p-CH^ (Phe)], 3.42-3.71 [4 H. m. 5-C %  (Pro) and p-CHj (P-.AJa)], 
3.72 (c, 3 H, s. CH3). 3.80 (1, 3 H, s. CH3), 4.09-5.00 [10 H, m, 5 x a-H . 2 x 
CH2O and fluorenyl CH], 5.01-5.37 (4 H, m, C%=CH and CHzPh), 5.83-5.94 (1 
H. m, CRi=CH ), 6.31 (c. 1 H. d, J  7.9, NH), 6.39 (t, 1 H. d, J  7.8, NH) and 
7.11-7.77 (13 H, m. Ph, 3 X NH); m/z (ES) 1011 (1%, [^I + N a]l, 989 (2, [M + 
2H]-), 211 (100), 195 (57, CiÆnO*) and 157 (78, CtHsOO.
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General Hydrolysis Procedure for the Cyclo-Esters to Yield the Bioactive 
Materials
To a stirred solution of the cyclic pentapeptide (0.03 mmol) in methanol (2 cm") 
and water (2 cm") was added NaOH (0.065 mmol). The reaction was allowed to 
stir at room temperature for 2 h, after which time the methanol then was removed 
under reduced pressure. The aqueous layer was acidified using trifluoroacetic acid 
and the cyclic peptide extracted using DCM (2 cm"). The organic phase was dried 
(MgSO;) and the solvent removed under reduced pressure.
Cyclo-[p-AIa-(2i?)-Glu-Y-(25)-Pro-(2i?)-Asp-p-(2Y)-Phe-] 94A
This compound was prepared as the described general procedure above, m/z (ES) 
582 (3%, [M 4- Na]0, 561 (7, [M+ 2H]"); >95% HPLC purity on a Poros 10 R2/H 
reverse phase column [using isocratic reverse-phased conditions eluting with 24% 
acetonitrile-76% water as eluent at a flow rate of 5 cm  ^ min^ with the detector set 
at 220 nm].
Cyclo-[P-Ala-(2i?)-Glu-y-(2i?)-Pro-(2i?)-Asp-(3-(2iS)-Phe-] 94B
This compound was prepared as the described general procedure above, m 'z 
(MALDITOF) 582 ( 10%, [M + Na]"), 560 (5, [M+ H]"); >95% HPLC purity on a 
Poros 10 R2/H reverse phase column [using isocratic reverse-phased conditions 
eluting with 24% acetonitrile-76% water as eluent at a flow rate of 5 cm  ^min^ with 
the detector set at 220 nm].
Cyclo{(25)-Phe-[(2i?)-a-4-benzylpiperidinyIamido-Asp]-(2i?)-Glu-y- 
(26)-Pro-P-(2i?)-Asp} 130
This compound was prepared as the described general procedure above, m/z 
(MALDITOF) 784 (8%, [M + H + Na]3, 762 (3, [M+ 2H]"); >95% HPLC purity 
on a C-18 reverse phase column [using isocratic reverse-phased conditions eluting 
with 51% acetonitrile-49% water as eluent at a flow rate of 1 cm" min'^ with the 
detector set at 220 nm].
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3.1 Enzymic Studies
3.1.1 Materials
The Escherichia coli expression vector plasmid pET21a, together with the HIS« 
bind resin, were purchased from Novagen and used according to the manufacturers 
instructions. Native PPl, isolated from rabbit muscle, was purchased from TCS 
Biologicals Ltd. The phosphoiylated peptides RRATpVA and KRTpIRR were 
purchased from Immune Systems (Bristol, UK). All other reagents were purchased 
from Sigma unless otherwise indicated.
3.1.2 Expression of P P l
The gene which encodes for PPl was cloned into a pET21a''‘^ ‘ expression vector by 
Mrs J Sullivan (Zeneca Pharmaceuticals). Single colonies were selected and stored 
as glycerol stock.
5 cm" L-amp broth was inoculated using the glycerol stock and grown up at 37 °C 
overnight. This was then used to inoculate 120 cm" fresh L-amp broth and the cells 
grown to an OD of 0.4 ( ~3 h) in the presence of 1 mM MnC^. IPTG was then 
added to a final concentration of 0.1 mM and the culture grown at 25 °C overnight. 
The cells were harvested by centrifugation and sonicated in 4 cm" culture of the ice 
cold binding buffer (5 mM imidazole, 200 mM NaCl, 20 mM Tris-HCl pH 7.9). 
The particulate matter was removed by centrifugation at 1300 rpm for 5 min and 
the supernatant purified on a Novagen His®Bind column.
The protein was eluted off the column in the standard elution buffer (1 M 
imidazole, 0.5 mM NaCl, 20 mlvl Tris-HCl, 2 mM MnCl], 5% glycerol and 0.03% 
Brij 35 pH 7.9). The sample was then dialysed at 4 °C for 3 h against 25 mM 
triethanolamine-HCl pH 7,5, 1 mM MnCh, 0.1 mM EGTA, 0.2 M NaCl, 0.03% 
Brij 35, 0.1% 2-mercatoethanol and 50% glycerol. The dialysis was repeated 
overnight and the enzyme stored at - 20 °C.
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3.1.3 Assays of P P l
PPl was diluted prior to use with 50 mlVI Tris (pH 7.4), 0.01 mM EDTA 1% 
|3-mercatoethanol and BSA (1 mg/cm^) at 4 °C. All kinetic constants were 
calculated using Grafit analysis under steady state conditions.
3 .1 .3 .1  /?NPP as a su b stra te
The activity of PP1 with /?NPP as substrate was assayed at room temperature and 
25 ®C. Reaction mixtures contained 80 mM Tris/HCl, 40 mAI KCl, 60 mM MgCb, 
lOrmVI dithiothreitol and 2 M MnCb (pH 8.1), To start the pNPP phosphatase 
activities, reaction was started by addition of enzyme and the initial rate of 
liberation of p-nitrophenol was measured by recording the change in absorbance at 
405 nm on a 96 well-plate.
A standard curve was constructed using a nitrophenol standard, and the specific 
activity was calculated using a nitrophenol standard.
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Graph 3.1: pN PP Standard Curve
where the gradient of the graph is 0.465.
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3.1,3.2 R ecom binant P P l
The assay was performed over 60 min at 25 °C, under steady state conditions, using 
19 nM enzyme concentration and varying the substrate concentration (0.06-80 
mM). The results were plotted using the unweighted non-linear regression fit in 
Grafit.
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Graph 3.2: pNPPwith Recombinant PPl after 60 min
The assay at 21 °C gave very similar results. Using the/?NPP calibration curve (see 
Graph 3.1) and the specificity constant were calculated (see Table 3.7)
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Table 3.7: pNPP Kinetic Measurements with Recombinant PPl
TEMPERATURE Km
(mM)
kcat
(s ')
kcat/Km
(M 's ')
21 °C 37.56 1.68 45.33
25 °C 53.04 2.78 52.41
3.1.3.3 Phosphopeptides as substrates
The activity of PPl with peptide substrates was assayed at room temperature and 
25 °C in a reaction containing 50 mM Tris (pH 7.5), 0.1 mM EDTA and 0.5 mM 
dithiothreitol.
Phosphate released was detected by addition of malachite green reagent (25 mm^) 
to a sample (100 cm^) containing phosphate which formed a green solution. After 
the colour had been allowed to develop for 20 min, the adsorption in the visible 
spectrum at 660 nm was measured in a 96 well plate.
A standard curve was set up by measuring the adsorption of known concentrations 
of phosphate, and then plotting the absorption as a function of phosphate 
concentration. This was expressed over a region of 0-8 nmol phosphate (see Graph 
3.3).
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Graph 3.3: Malachite Green Standard Curve
This curve fits the following equation :
b M
-0 .1 2 9 2 9
Equation 1
where y = OD reading 
Colour Reagent
Concentrated sulfuric acid (60 cm ,^ d=  1.84 g/1) was slowly added to 300 cm'’ of 
water. The solution was then cooled to room temperature and 440 mg of malachite 
green added. The resulting orange solution was stable for at least a year at rt. On 
the day of use (-20 min before use), 2.5 cm" of 7.5% ammonium molybdate was 
added to 10 cm" of the dye solution, followed by 0.2 cm" of 11% Tween 20.
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3.1.3.4 RRATpVA as S ubstra te  
Recombinant P P l
In order to check that we were using steady state conditions, the first experiment 
varied the enzyme concentration at a fixed substrate concentration (0.2 mM).
0.18
□  19 nM
0.16 9.5 nM
0.14 O 4.7 nM
2.4 nM0.12
O
D
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Time (min)
Graph 3.4: Varying concentrations o f  enzyme over time period at fixed  substrate
concentration
From the graph it was evident that either 4.7 nM or 9.5 nM enzyme concentration 
was suitable for assays. Because the OD change was quite significant with 9.5 nM 
after 20 min, this was chosen for all enzyme assays using recombinant enzyme.
The equilibrium constant {Kf), the catalytic constant (^ car) and the specificity 
constant {kcJKf) were determined by varying the substrate concentration, assuming 
the enzyme is 100% pure and 100% active (assumed from Gel and Protein 
Determination Assay). The reaction was performed at 21 °C and 25 °C. As the
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substrate concentration required was varied (0.005 mM -  4.7 miVI), and the results 
were fitted by unweighted non-linear regression using Grafit.
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Graph 3.5: RRATpVA with Recombinant Enzyme
From the graph above (see Graph 3.5) and the malachite green standard curv'e (see 
Graph 3.3), kcat, Km and the specificity constant were calculated. The results are 
tabulated below:
Table 3.8: RRATpVA  Kinetic Measurements with Recombinant P P l
TEMPERATURE Km
(mM)
lOat
(s ')
kcal/Km
(M-^s'^)
21 °C 1.04 6.58 6 299
25 °C 0.42 6.97 16 787
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Native P P l Enzyme
From initial assays with the native enzyme, it was obvious that RRATpVA was a 
very poor substrate with the native enzyme. Thus, obtaining an accurate and 
Km value would use up too much of the valuable Native PP 1 enzyme, we decided to 
only determine the specificity constant.
For this experiment only very low concentrations of substrate (> are used, so 
that we are still on the linear part of Graph 3.2. This was checked at a variety of 
substrate concentrations (0.065 mM -  0.8 mM), at a fixed enzyme concentration 
(6.75 nM), (see Graph 3.5) and at 25 °C. The results are plotted below :
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Graph 3.5: Vaty Substrate Concentration with Native Enzyme
Because the line is linear, a time course was taken when the substrate concentration 
was at 0.153 mM.
E x p e r im e n t a l P a ge  194
0.035
0.03
0.025
0.02O
D 0.015
0.01
0.005
0 3 6 9 12 18 21 2415
Time (min)
Graph 3.6: Time Course RRATpVA at 0.153 m M
The rate of the above line gave the specificity constant {kcJKn^, only. This is 
because at low substrate concentrations v = [Et][S]kcJKm, where k^JKm is the 
apparent second order rate constant.
Hence, using the equation;
V = [Et][S]kçJKn^
The rate, v, was determined using the slope of Graph 3.6, which correlates to 1.14 
nM P04."''/s'\ Therefore, the specificity constant, k t^/Km is 1 102 M"^s'\
This implies that RRATpVA is a lO-fold better substrate for the recombinant 
enzN-me, than for the native enz^mte.
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3.1.3.5 K R TpIR R  (129) as Substrate 
Recombinant PP l
Once again, assays were performed over 20 min at 21 °C and 25 °C, under steady 
state conditions.
Having established, once again, that 9.5 nM was a suitable enzyme concentration, 
the substrate concentration was varied (0.002 -  2 miVI). The results plotted using 
the unweighted non-linear regression fit in Grafit are shown below.
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Graph 3.7: KRTpIRR as Substrate with Recombinant PPl
From the graph above and the malachite green standard curve, k-st, K,n and the 
specificity constant were determined, see Table 3.9.
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Table 3.9: KRTpIRR Kinetic Measurements with Recombinant PPl
TEMPERATURE Km
(mM)
heat
(s')
hcat/Km
(2vr's^)
21 °C 0.17 3.87 23 081
25 °C 0.09 4.12 45 382
Native P P l Enzyme
The assay was performed over 20 min at 25 °C, under steady state conditions, using
3.2 nM enzyme concentration and varying the substrate concentration (0.002 -  
2 miVl). The results plotted using the unweighted non-linear regression fit in Grafit 
are shown in Graph 3.8.
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Graph 3.8: KRTpIRR with Native Enzyme
From the above graph Km 0.55 mM, hat 8.18 s'* and the specificity constant is 14 
871 M'*s'*. This implies that KRTpIRR 129 is a 2-fold better substrate for the 
recombinant enzyme. It is, however, 75-/o/<i better than RRATpVA 128.
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A ppendix  1 : M icrocystin A nalogues
NHOMe
HN
NH
M icrocystin-LR (2)
Am in o  A c id  Re s id u e  :
Cyclic-M icro cy stin 
Analogues
1 2 ( X ) 3 4 |Y ) 5  • 6 7 !
M icrocystin-LR ''*^ R-Ala S-Leu M asp S-Arg Adda R-Glu H-M dha j
M ic ro c y s tin -R R '^ ’ R-Ala S-Arg M asp S-Arg Adda R-Glu N-Mdha
M icrocystin-YR'*® R-Ala S-Tyr M asp S-Arg Adda R-Glu N-M dha
M ic ro c y s tin -F R '” R-Ala S-Pha M asp S-Arg Adda R-Glu N-M dha
M icrocystin -A R ’'*' R-Ata S-Ala M asp S-Arg Adda R-Glu N-Mdha
M icro cy s tin -W R '^ ' R-Ala S-Trp M asp S-Arg Adda R-Glu N-Mdha
M icrocystin-LA '^® R-Ala S-Leu M asp S-Ala A dda R-Glu N-Mdha
M ic ro c y s tin -Y A ''^ R-Ala S-Tyr M asp S-Ala A dda R-Glu N-Mdha
M icfo cy stin -Y M '* ' R-Ala S-Tyr M asp S-M et Adda R-Glu N-Mdha
M icrocystin -L Y '^ ' R-Ala S-Leu M asp S-Tyr Adda R-Glu N-M dha
M ic ro c y s tin -L L " ' R-Ala S-Leu M asp S-Leu A dda R-Glu N-M dha
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M icrocystin-LV ''* ' R-Ala S-Lsu M asp S-Val Adda R-Glu N-M dha 1
M icfocystin -L M '* ' R-Ala S-Lsu M asp S-M et Adda R-Glu N-M dha '
M icrocystin-L F ''* ' R-Ala S-Leu M asp S-Phe A dda R-Glu N-M dha
M ic ro c y s tin -M (0 )R ''’ R-Ala S-M etiO l M asp S-Arg Adda R-Glu N-M dha
M icrocystin-YM (O)''** R-Ala S-Tyr M asp S-M atIO) A dda R-Glu N-Mdha
M icrocystin-LA ba^* ' R-Ala S-Lsu M asp Aba A dda R-Glu N-Mdha
M ic ro c y s tin -H ty R ''* ' R-Ala S-H ty M asp S-Arg Adda R-Glu N-M dha
M icrocystin-H ilR '^^ R-Ala S-Hil M asp S-Arg Adda R-Glu N-Mdha
[S-Ser) M ic rocystin -L R "^ R-Ala S-Leu M asp S-Arg Adda R-Glu S-Ser
[S-Sar] M icrocystin -R R ” ® R-Ala S-Arg M asp S-Arg A dda R-Glu S-Sar
[S -Sar] M icrocystin -H tyR '^^ R-Ala S-Hty M asp S-Arg A dda R-Glu S-Ser
[S -M aSar] M icrocystin-L R ” ^ R-Ala S-Lsu M asp S-Arg A dda R-Glu S-M aS ar
[(BZ)-Adda] M icrocystin-LR'® '*’ R-Ala S-Lsu M asp S-Arg (BZ)-Adda R-Glu N-Mdha
((6Z1-Addal M icrocystin -R R ” ® R-Ala S-Arg M asp S-Arg (GZ)-Adda R-Glu N-Mdha
[DM Addal M icrocystin -L R "" R-Ala S-Lsu M asp S-Arg DM Adda R-Glu N-M dha
(AOM Addal M icrocystin-LR'®"* R-Ala S-Leu M asp S-Arg AOM Adda R-Glu N-Mdha
[AOM Adda] M icrocystin-LH ar'® '* R-Ala S-Lsu M asp S-Har AOM Adda R-Glu N-Mdha
[R-Asp, A O M A dda] Microcystin-LR'®® R-Ala S-Leu R-Asp S-Arg AOM Adda R-Glu N-M dha
[R -Ssr, A O M A dda) Microcystin-LR'®® R -Ssr S-Leu R-Asp S-Arg AOM Adda R-Glu N-Mdha
[AOM Adda, M ser] Microcystin-LR'®® R-Ala S-Lsu M asp S-Arg AOM Adda R-Glu N-M ser
(R-Asp, A O M A dda] M icrocystin-LHar'®® R-Ala S-Lsu R-Asp S-Har AOM Adda R-Glu N-Mdha
(R-GIulOCjH,)] M icrocystin-LR '® ' R-Ala S-Lsu M asp S-Arg A dda lOC-H,)
e s te r
N-M dha
[R-GiulOCjHjlCHjlOH]] M icrocystin-L R "® R-Ala S-Lsu M asp S-Arg A dda (OCjH-ICHjI 
OH) a s te r
N-M dha
[R-GlulOCHj)] Microcystin-LR®"® R-Ala S-Leu M asp S-Arg A dda (OCH3)
e s te r
N-M dha
[R-Asp] M icrocystin-LR'®® R-Ala S-Leu R-Asp S-Arg A dda R-Glu N-Mdha
[R-Asp] M icrocystin-R R '® '" R-Ala S-Arg R-Asp S-Arg A dda R-Glu N-Mdha
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[R-Asp] M icrocystin-Y R "® R-Ala S-Tyr R-Asp S-Arg Adda R-Glu N-Mdha
[R-Asp] M icrocystin -H tyR "® R-Ala S-H ty R-Asp S-Arg A dda R-Glu N-M dha ;
[R-Asp, R-Glu(OCHj)j M icrocystin -L R ” ® R-Ala S-Lsu R-Asp S-Arg Adda [OCHjl
e s te r
N-M dha i
[R-Asp, M ser] M icrocystin-LR®"' R-Ala S-Lau R-Asp S-Arg Adda R-Glu N-M ser
[R-Asp, S -S er] Microcystin-LR®®® R-Ala S-Lsu R-Asp S-Arg Adda R-Glu S -Ser i
[R-Asp, Oha] M icrocystin-L R '® '’ R-Ala S-Lau R-Asp S-Arg Adda R-Glu Oha
[R-Asp, Dha] M icrocystin-RR®"" R-Ala S-Arg R-Asp S-Arg Adda R-Glu Oha
[R-Asp, Dha] M icrocystin-HtyR'®® R-Ala S-H ty R-Asp S-Arg Adda R-Glu Dha
[Dha] M icrocystin-LR®"' R-Ala S-Leu M asp S-Arg Adda R-Glu Oha
[Dha] Microcystin-RR®"® R-Ala S-Arg M asp S-Arg A dda R-Glu Oha
[Dha] Microcystin-YR'®® R-Ala S-Tyr M asp S-Arg Adda R-Glu Dha
[Dha] Microcystin-HtyR®"® R-Ala S-Hty M asp S-Arg Adda R-Glu Oha
[Dha] Microcystin-HphR®"® R-Ala S-Hph M asp S-Arg Adda R-Glu Oha
[Ohb] M icrocystin-RR '"® R-Ala S-Arg M asp S-Arg Adda R-Glu Ohb
[S-M sLan] M icrocystin-LR '"® R-Ala S-Leu M asp S-Arg Adda R-Glu S-M eLan
[M ser] M icrocystin-LR '® ' R-Ala S-Leu M asp S-Arg Adda R-Glu N-M ser
Nodularin'"® M asp S-Arg Adda R-Glu N-Mdhb
Motuporin®"" M asp S-Val Adda R-Glu N-Mdhb
[DM Adda] N odularin"® M asp S-Arg DM Adda R-Glu N-Mdhb
[[6Z)-Adda] Nodularin® " M asp S-Arg (6Z]-Adda R-Glu N-Mdhb
[R-Asp] N odularin® " R-Asp S-Arg Adda R-Glu N-Mdhb j
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A ppendix  2 : ROE Interactions in M ajor  Isomer of 
Cyclic P eptide ( 5 2 A )
(2« )-G lu  
O CO 2 H
I  H O o = j  (2S ;-P rc
NH H .ijH
(2 S )-P h e o  C O 2 H 
(2R)-Asp
Analogue 52A
ROE INTERACTIONS*
AspHN ; Asp Ha Strong
Asp HN : Asp H|3 Weak
Asp HN : Asp H3' Weak
AspHN : Pro Ha Medium
AspHN : Pro H3 Weak
Asp HN : Pro H5 Medium
PheHN : Asp H0 Strong
PheHN : Asp HP' Strong
Ala H|3 : Glu HN Wealc
PheHN : Phe Ha Strong
PheHN : Phe HP' Weak
PheHN : Phe HP Medium
PheHN : Phe He Weak
‘ Restraints applied as symmetrical energ>- well, with force constant 30 kcal/À" and a 
maximum potential of 1000 kcal/mol per constant. No energ}' penalty was applied when H- 
H distances lay outside tlie range 1 .8-2.7 Â (strong), 1.8-3.3 À (medium) and 1 .8 - 5  A 
(weak), respectively.
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PheHN : Phe H6 Medium
PheHN : AlaHN Medium
Phe Ha : Phe Hs Weak
Phe Ha : Phe H5 Medium
Phe Ha : AlaHN Strong
Phe HP' : Phe Hs Weak
Phe HP : Phe HÔ Medium
Phe HP' : AlaHN Medium
Phe HP' ; Phe Hs Weak
Phe HP : Phe HÔ Medium
Phe HP : AlaHN Weak
AlaHN : Ala Ha Medium
AlaHN : Ala Ha' Medium
AlaHN : Ala HP Weak
AlaHN : Ala HP' Weak
Ala Ha : Glu HN Weak
Ala Ha' : GluHN Weak
Ala HP : Glu HN Weak
GluHN : Glu Ha Medium
GluHN : Glu Hy Weak
GluHN : Glu HP' Medium
Glu Ha : Glu Hy Weak
Glu Ha ; Glu Hy' Weak
Glu Hy : Pro HÔ Medium
GluHy : Pro H5 Medium
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A ppendix  3 : Reco m binant  P P l  (B old)  a n d  N ative 
D N A  Sequences
Martinez/Needleman-Wunsch DNA Alignment
Minimum Match: 9; Gap Penalty: 1.10; Gap Length Penalty: 0.33
v l O  v 2 0  v 3 0  v 4 0  v 5 0  v 5 0  v 7 0
ATGTCCGACAGCGAGAAGCTCAA.CCTGGACTCGATCATCGGGCGCCTGCTGGAAGTGCAGGGCTCGCGGC
i l l i l l M M n i l M I I U l l M i n i l M n i i l i M M I I I M M I I I I t i l U l l t i l l i l l l i l l
ATGTCCGACAGCGAGAAGCTCAACCTGGACTCGATCATCGGGCGCCTGCTGGAAGTGCAGGGCTCGCGGC  
■"10 " 2 0  " 3 0  " 4 0  " 5 0  " 6 0  " 7 0
V 8 0  v 9 0  v lO O  v l l O  V 1 2 0  v l 3 0  V 1 4 0
CTGGCAAGAATGTACAGCTGACAGAGAACGAGATCCGCGGTCTGTGCCTGAAATCCCGGGAGATTTTTCT
l l l i i l l l l l l l l l l M I I I M I I I I I M I I I I M I I I I M i l M l l l l l l l i i l l M l i M l l i i M I I
CTGGCAAGAATGTACAGCTGACAGAGAACGAGATCCGCGGTCTGTGCCTGAAATCCCGGGAGATTTTTCT  
^ 8 0  " 9 0  " 1 0 0  " 1 1 0  " 1 2 0  " 1 3 0  " 1 4 0
V 1 5 0  V 150  V1 70  v i a o  v l 9 0  v 2 Q 0  v 2 1 0
GAGCCAGCCCATTCTTCTGGAGCTGGAGGCACCCCTCAAGATCTGCGGTGACATACACGGCCAGTACTAC
i l M M I I I I I i l l l l l l l t l l l l t l l l i l l l t l l l l l l l l t l l i l l M l l l l i l l l l l l i i M i l l l l l
GAGCCAGCCCATTCTTCTGGAGCTGGAGGCACCCCTCAAGATCTGCGGTGACATACACGGCCAGTACTAC  
" 1 5 0  " 1 6 0  " 1 7 0  " 1 8 0  " 1 9 0  " 2 0 0  " 2 1 0
V 2 2 0  V 2 3 0  V 2 4 0  v 2 5 0  v 2 6 0  v 2 7 0  v 2 8 0
GACCTTCTGCGACTATTTGAGTATGGCGGTTTCCCTCCCGAGAGCAACTACCTCTTTCTGGGGGACTATG
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
GACCTTCTGCGACTATTTGAGTATGGCGGTTTCCCTCCCGAGAGCAACTACCTCTTTCTGGGGGACTATG  
" 2 2 0  " 2 3 0  " 2 4 0  " 2 5 0  " 2 6 0  " 2 7 0  " 2 8 0
V 2 9 0  v 3 0 0  v 3 i 0  v 3 2 0  v 3 3 Q  v 3 4 0  v 3 5 0
TGGACAGGGGCAAGCAGTCCTTGGAGACCATCTGCCTGCTGCTGGCCTATAAGATCAAGTACCCCGAGAA
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
TGGACAGGGGCAAGCAGTCCTTGGAGACCATCTGCCTGCTGCTGGCCTATAAGATCAAGTACCCCGAGAA  
" 2 9 0  " 3 0 0  " 3 1 0  " 3 2 0  " 3 3 0  " 3 4 0  " 3 5 0
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v 3 6 0  V37 0 v 3 3 0  v 3 9 0  v 4 0 C  v 4 1 0  v 4 2 0
CTTCTTCCTGCTCCGTGGGAACCACGAGTGTGCCAGCATCAACCGCATCTATGGTTTCTACGATGAGTGC
I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I
CTTCTTCCTGCTCCGTGGGÀACCACGAGTGTGCCAGCATCAACCGCATCTATGGTTTCTACÜATGÀGTGC  
" 3 6 0  " 3 7 0  " 3 8 0  " 3 9 0  " 4 0 0  " 4 1 0  "4 20
V 4 3 0  V4 40  V45 0 v 4 6 0  v 4 7 0  v 4 3 0  v 4 9 0
AAGAGACGCTACAACATCAAACTGTGGAAAACCTTCACTGACTGCTTCAACTGCCTGCCCATCGCGGCCA
111i M It I M 11111 i II111111111 M 11111 i 111111 M 11111 [ I ! [ 11111111 M 11 M 11 !
AAGAGACGCTACÀÀCATCAÀACTGTGGAAAACCTTCÀCTGACTGCTTCAACTGCCTGCCCATCGCGGCCA  
" 4 3 0  " 4 4 0  " 4 5 0  " 4 6 0  " 4 7 0  " 4 8 0  "4 90
vSO O  v S l O  v 5 2 0  v 5 3  0 v 5 4 0  v 5 5 0  v 5 S 0
TAGTGGACGAAAAGATCTTCTGCTGCCACGGAGGCCTGTCCCCGGACCTGCAGTCTATGGAGCAGATTCG
l l l l l l l l l l l l i l l l l l l l l l l l l l l Ml l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l
TAGTGGACGAAAAGATCTTCTGCTGCCACGGAGGCCTGTCCCCGGACCTGCAGTCTATGGAGCAGATTCG  
" 5 0 0  " 5 1 0  " 5 2 0  " 5 3 0  " 5 4 0  " 5 5 0  "5 60
v 5 7 0  v S S O  v 5 9 0  v 6 0 0  v 6 l 0  v 5 2 0  Vo30
GCGGATCATGCGGCCCACAGATGTGCCTGACCAGGQCCTGCTGTGTGACCTGCTGTGGTCTGACCCTGAC
1111111 ! 11111111111111111 ! 11 ! 111111111111111111111111 ni  11111111111111
GCGGATCATGCGGCCCACAGATGTGCCTGACCAGGGCCTGCTGTGTGACCTGCTGTGGTCTGACCCTGAC  
" 5 7 0  " 5 8 0  " 5 9 0  " 6 0 0  " 6 1 0  " 6 2 0  " 530
v 6 4 0  V5 50  v 5 5 0  v 6 7 0  v 6 8 D  v 5 9 Q  v 7 Q 0
AAGGACGTGCAGGGCTGGGGCGAGAACGACCGTGGCGTCTCTTTTACCTTTG-GAGCCGAGGTGGTGGCCA
111111111111111111111111111111111111111111111111111 ! 111111111111111111
AAGGACGTGCAGGGCTGGGGCGAGAACGACCGTGGCGTCTCTTTTACCTTTGGAGCCGAGGTGGTGGCCA  
" 6 4 0  " 6 5 0  " 6 6 0  " 6 7 0  " 6 8 0  " 6 9 0  " 7 0 0
v 7 1 0  v 7 2 0  v 7 3 0  v 7 4 0  v 7 5 0  v 7 6 0  v 7 7 0
AGTTCCTCCACAAGCACGACTTGGACCTCATCTGCCGAGCACACCAGGTGGTAGAAGACGGCTACaAGTT
i i i n i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i n i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
AGTTCCTCCACAAGCACGACTTGGACCTCATCTGCCGAGCACACCAGGTGGTAGAAGACGGCTACGAGTT  
" 7 1 0  " 7 2 0  " 7 3 0  " 7 4 0  " 7 5 0  " 7 6 0  "7 70
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V 78 0 V7 90  V3 0 0 v S l O  v 8 2 0  v 8 3 0  v 3 4 0
CTTTGCCAAGCGGCAGCTGGTGACACTTTTCTCAGCTCCCAACTACTGTGGCGAGTTTGACAATGCTGGC
I I I M I I I I M I i l l M I I M I I M M I I I I i l l l i l l l l l l l l l l i l l l l l l i l M i i i l l M M I i l l
CTTTGCCAAGCGGCAGCTGGTGACACTTTTCTCAGCTCCCAACTACTGTGGCGAGTTTGACAATGCTGGC  
" 7 8 0  " 7 9 0  " 8 0 0  " 8 1 0  " 8 2 0  " 8 3 0  " 8 4 0
v 8 5 0  V8 60  V8 7 0 v 8 8 0  v S 9 0  v 9 0 0  v 9 1 0
GCCATGATGAGTGTGGACGAGACCCTCATGTGCTCTTTCCAGA'rCCTCAAGCCCGCCGACAAGAACAAGG
I I I M I I I I I I I M I I I I I I I I I i l l i M l l l l i l l l l l i l l l l l l M M I i l l l l l l l l l l l l l l l l l !
GCCATGATGAGTGTGGACGAGACCCTCATGTGCTCTTTCCAGATCCTCAAGCCCGCCGACAAGAACAAGG  
" 8 5 0  " 8 6 0  " 8 7 0  " 8 8 0  " 8 9 0  " 9 0 0  " 9 1 0
v 9 2 D  V9 3 0  v 9 4 0  v 9 5 0  v 9 6 0  v 9 7 0  v 9 S 0
GGAAGTACGGGCAGTTCAGTGGCCTGAACCCTGGAGGCCGACCCATCACCCCACCCCGCAATTCCGCCAA
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l
GGAAGTACGGGCAGTTCAGTGGCCTGAACCCTGGAGGCCGACCCATCACCCCACCCCGCAATTCCGCCAA  
" 9 2 0  " 9 3 0  " 9 4 0  " 9 5 0  " 9 6 0  " 9 7 0  " 9 8 0
V990
AGCCAAGAAA-------------------------------------------TAG
I M I i M M I  I
AGCCAAGAAACACCACCACCACCACCACTGA
" 9 9 0  " 1 0 0 0  " 1 0 1 0
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A ppendix  4 ; Estim ation  of Level of First Residue 
A ttachment - from N o v a bio ch em ’ 
Catalogue
Dry Fmoc amino acid-resin (2 mg) was placed into two x 10 mm matched silica 
UV cells, to this was added 20% piperidine in DMF (3 cm’'), and the resin agitated 
with the aid of a Pasteur pipette for 2-3 min.
The cells were placed in a spectrophotometer using a third matched cell with 20% 
piperidine in DMF (3 cm"*) as a reference (no resin). Positions 2 and 3 held the 
resin samples.
The absorbance at 290 nm was read and an estimate of first residue attachment 
was taken from the correlation graph (see Graph 4.1). The average of these two 
values were used to calculate the percentage loading.
2.4
2.2
O
D
0.8
0,6
0 20 40 60 80 100
% Loading
Graph 4.1: Correlation Graph fo r  Percentage Loading fo r  First Residue 
Attachment; Based on 2 mg Resin
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K a i s e r  ( N i n h y d r i n )  T est
The most widely used qualitative test for the presence or absence of free amino 
groups was devised by Kaiser.^"^ Free amino groups show a dark blue colour.
The following solutions were prepared:
® 5 g of ninhydrin was dissolved in 100 cm'" ethanol
® 80 g of liquefied phenol was dissolved in 20 cm*' ethanol
• 2 cm" of 0.001 M Potassium Cyanide solution was added to 98 cm" pyridine
A few resin beads, which had been washed several times with ethanol, were 
transferred to a small ampule and 2 drops of each of the solutions above were 
added. This was mixed well, and heated to 120 “C for 4-6 mins. A positive test is 
indicated by blue resin beads.
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A p p e n d ix  5 :  D e t e r m in a t io n  o f  K in e t ic  P a r a m e t e r s
Introduction
For many enzymes, the rate of catalysis, v, varies with the substrate concentration, 
[5], in a manner shown in Graph 4.1.
V =
V = Vmax = kcat (E,
V
V,max
2
[substrate]
Graph 4.1: A plot o f  the reaction velocity, V, as a function o f  the substrate 
concentration, [S],for an enzyme that obeys Michaelis-Menten kinetics is 
maximal velocity and Km is the Michaelis constant
At a fixed concentration of enzyme, v is almost linearly proportional to [6] when 
[5] is small. At high [S] v is nearly independent of [5].
In 1913, Michaelis and Menten proposed a simple model to account for these 
kinetic characteristics (see Scheme 4.1).
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Scheme 4.1: Simple Michaelis-Menten Equation
The critical feature in their treatment is that a specific enzyme-substrate {ES) 
complex is a necessary intermediate in catalysis. The enzyme-substrate reaction is 
divided into two processes. First the substrate (5) binds rapidly and reversibly to 
the enzyme (£) to form an ES complex. The reaction then occurs in a slow second 
step giving the product, P, and regenerating the enzyme.
Because the breakdown of ES complex to E  and S is faster than the breakdown of 
ES  complex to E  and P, the rate, v, is defined by:
V = kcat[ES] Equation 2
[E6] can also be expressed by:
ES  = Equation 3: Rate o f  Formation
ES = {kl + :^ar)[£iS] Equation 4: Rate o f  Breakdown
Assays are carried out under steady-state conditions. In a steady state, the 
concentrations of enzyme-bound intermediates stay the same while the 
concentrations of starting materials and products are changing. This occurs when 
the rate of formation and breakdown of the ES complex are equal.
= (A'2 + A*.-=)[E5'] Equation 5
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Equation 5 can be rearranged;
i E S l =  _________)  Equation 6(A* 2 + Acof) / k I
Equation 7 can be simplified by defining a new constant, Km, called the Michaelis 
coiistant.
Æm = Equation 7
and substituting it into equation 6, which then becomes:
Equation 8
K  m
The concentration of uncombined substrate, [5], is very nearly equal to the 
concentration to the total substrate concentration, provided that the concentration 
of enzyme is much lower than that of the substrate. The concentration of 
uncombined enzyme, [E\, is equal to the total enzyme concentration, [Et], minus 
the concentration of the ES  complex.
[ E ] = [ E f ] - [ £ . S ]  Equation 9 
Substituting this expression for [£] in equation 9,
[ES] = Equation 10
Km
Solving equation for [££] gives
[ES]  = [Et ] — ^ —  Equation 11\ S ] - r K m
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By substituting this expression for [ES\ into equation 3, we get
= kca, [E, ]  -----  Equation 12 ^  ^ [ S ] + Km
The maximal rate, Vmax, is attained when the enzyme sites are saturated with 
substrate -  that is, when [5] is much greater than Km -  so that [6]/([iS] -j- Km) 
approaches 1. Thus,
V  max = kcat[Et] Equatioii 13
Substituting equation 14 into equation 13 yields the Michaelis-Menten equation;
ry ]V -  V max------------- Equation 14[ S] ~Kn ,
Significance of Michaelis-Menten Parameters 
k c a t -  Catalytic Constant
In simple Michaelis-Menten mechanisms, in which there is only one 
substrate-enzyme complex and all binding steps are very fast, kcat is simply a first 
order rate constant for the chemical conversion of the ES  complex to the EP 
complex.
Constant kcai is often called the turnover number of the enzyme because it 
represents the maximum number of substrate molecules converted to products per 
unit of time, or the number of times the enzyme ‘tums-over’ per unit time.
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K m  -  Real and Apparent Equilibrium Constants
Although it is only for the simple Michaelis-Menten mechanism or in similar cases 
that Km -  K}, the true dissociation constant of the enzyme-substrate complex. Km, 
may be treated for some purposes as an apparent dissociation constant. For 
example, the concentration of free enzyme in solution may be calculated from the 
relationship;
K m = 4 =^ -^   ^ Equation 15S  [ ES ]
Where is the sum of all the bound enzyme species.
Km is the substrate concentration at which
V ~ ILjUPl Equation 16
Specificity Constant: kcat/Km
kcaJKm determines the specificity for competing substrates, and is called the 
Specificity Constant.
It is an apparent second-order rate constant that refers to the properties and the 
reactions of the free enzyme and free substrate.
Graphical Representation of Data
The Michaelis-Menten equation is often transformed into a linear form for 
analysing data graphically and detecting deviations fi*om ideal behaviour. One of 
the best known methods is the double-reciprocal or Lineweaver-Burk plot. 
Inverting both sides of equation 15 gives the Lineweaver-Burk plot.
i= _L _-i-.—^L _ Equation 17
V F  max
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Plotting 1/v against l/[S] gives an intercept of 1/Vmax on they axis as l/[£] tends 
toward zero, and of l/[iS] = ~l/Km on the x axis. The slope of the line is
The Lineweaver-Burk plot has the disadvantage of compressing the data points at 
high substrate concentrations into a small region and emphasising the points at 
lower concentrations. Hence, data collected in our study were fitted to 
unweighted non-linear regression NIichaelis-Menten fit, using Grafit, which avoids 
the overemphasis of small values of v and S, thus yielding the parameters Km and
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